


**CUMULATIVE  
SUPPLEMENT 5  
MAY 2021**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**41st EDITION**

**Department of Health and Human Services**

Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**2021**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**41<sup>th</sup> EDITION**

**Cumulative Supplement 5  
May 2021**

**CONTENTS**

	<i>PAGE</i>
<b>Contents</b>	
1.0 INTRODUCTION.....	v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2 CUMULATIVE SUPPLEMENT CONTENT .....	vi
1.3 APPLICANT NAME CHANGES .....	vii
1.4 LEVOTHYROXINE SODIUM .....	viii
1.5 AVAILABILITY OF THE EDITION.....	ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7 CUMULATIVE SUPPLEMENT LEGEND.....	xi
 <b>DRUG PRODUCT LISTS</b>	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
 <b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**41<sup>st</sup> EDITION**

**CUMULATIVE SUPPLEMENT 5  
MAY 2021**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## **1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## **1.2 CUMULATIVE SUPPLEMENT CONTENT**

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### **1.3 APPLICANT NAME CHANGES**

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
AKORN INC (AKORN)	AKORN OPERATING CO LLC (AKORN)
AKORN INC (AKORN INC)	AKORN OPERATING CO LLC (AKORN)

## 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS
-----	-----------------------------------	-------	-------	---------	---	----

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
 Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

---

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## **1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST**

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2020</u>	<u>MAR 2021</u>	<u>JUN 2021</u>	<u>SEP 2021</u>	<u>DEC 2021</u>
DRUG PRODUCTS	20478	20726			
LISTED SINGLE SOURCE	2659 (13.0%)	2671 (12.9%)			
MULTISOURCE	17819 (87.0%)	18055 (87.1%)			
THERAPEUTICALLY EQUIVALENT	17746 (86.7%)	17990 (86.8%)			

NOT THERAPEUTICALLY EQUIVALENT	73 (0.4%)	65 (0.3%)
EXCEPTIONS <sup>4</sup>	54 (0.3%)	54 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	22	29
NUMBER OF APPLICANTS	1185	1184

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

<u><b>ABIRATERONE ACETATE</b></u>					
TABLET;ORAL ABIRATERONE ACETATE					
AB	AMNEAL PHARMS	500MG	A208327	002	Dec 23, 2020
<u><b>ACARBOSE</b></u>					
TABLET;ORAL ACARBOSE					
AB	EMCURE PHARMS LTD	25MG	A202271	001	Feb 07, 2012
AB		50MG	A202271	002	Feb 07, 2012
AB		100MG	A202271	003	Feb 07, 2012
<u><b>ACETAMINOPHEN</b></u>					
POWDER;INTRAVENOUS ACETAMINOPHEN					
+ @	MYLAN LABS LTD	1GM/VIAL	N206610	001	Jan 15, 2021
SOLUTION;INTRAVENOUS ACETAMINOPHEN					
+!	B BRAUN MEDICAL INC	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021
+!		1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021
<u><b>ACETAMINOPHEN; BUTALBITAL; CAFFEINE</b></u>					
CAPSULE;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
AA	XSPIRE PHARMA	300MG;50MG;40MG	A206615	001	Aug 04, 2017
TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
@	GRANULES	325MG;50MG;40MG	A040864	001	Dec 01, 2008
<u><b>ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE</b></u>					
CAPSULE;ORAL BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE					
AB	NOSTRUM LABS INC	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002
<u><b>ACETAMINOPHEN; CODEINE PHOSPHATE</b></u>					
TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE					
@	VINTAGE	300MG;15MG	A089990	001	Sep 30, 1988
@		300MG;30MG	A089805	001	Sep 30, 1988
@		300MG;60MG	A089828	001	Sep 30, 1988
AA		300MG;60MG	A089828	001	Sep 30, 1988
<u><b>ACETAMINOPHEN; HYDROCODONE BITARTRATE</b></u>					
TABLET;ORAL ANEXSIA 5/325					
AA	! SPECGX LLC	325MG;5MG	A040409	001	Oct 20, 2000
AA	! SPECGX LLC	325MG;7.5MG	A040405	001	Sep 08, 2000
AA	! SPECGX LLC	325MG;10MG	A040400	001	Jul 26, 2000
NORCO					
@	APIL	325MG;2.5MG	A040148	004	Jul 07, 2014
@		325MG;5MG	A040099	001	Jun 25, 1997
@		325MG;5MG	A040148	005	Jul 07, 2014
@		325MG;7.5MG	A040148	003	Sep 12, 2000
@		325MG;10MG	A040148	001	Feb 14, 1997
<u><b>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE</b></u>					
TABLET;ORAL OXYCODONE AND ACETAMINOPHEN					
AA	CHARTWELL	325MG;5MG	A207834	001	Aug 15, 2019
AA		325MG;7.5MG	A207834	002	Aug 15, 2019
AA		325MG;10MG	A207834	003	Aug 15, 2019
ROXICET					
@	HIKMA	325MG;5MG	A087003	001	Jan DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL  
ACETAZOLAMIDE

AB	ACCORD HLTHCARE	500MG	A207659	001	Oct 18, 2018	Apr CMFD
	TABLET;ORAL					
	ACETAZOLAMIDE					
AB	APPCO	125MG	A211372	001	Feb 22, 2021	Feb NEWA
AB		250MG	A211372	002	Feb 22, 2021	Feb NEWA

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS  
ACETYLCYSTEINE

AP	EXELA PHARMA	6GM/30ML (200MG/ML)	A204797	001	Apr 15, 2021	Apr NEWA
----	--------------	---------------------	---------	-----	--------------	----------

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION  
TUDORZA PRESSAIR

+!	ASTRAZENECA	0.4MG/INH	N202450	001	Jul 23, 2012	Feb CAHN
----	-------------	-----------	---------	-----	--------------	----------

ACYCLOVIR

OINTMENT;TOPICAL  
ACYCLOVIR

>A> AB	MACLEODS PHARMS LTD	5%	A212444	001	May 19, 2021	May NEWA
	SUSPENSION;ORAL					
	ACYCLOVIR					
AB	VISTAPHARM	200MG/5ML	A213951	001	Jan 11, 2021	Jan NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION  
ACYCLOVIR SODIUM

AP	ZYDUS PHARMS	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan CHRS
AP	!	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan CPOT

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL  
EPIDUO FORTE

+!	GALDERMA LABS	0.3%;2.5%	N207917	001	Jul 15, 2015	Feb CTEC
----	---------------	-----------	---------	-----	--------------	----------

ADENOSINE

SOLUTION;INTRAVENOUS  
ADENOSINE

AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Feb CMFD
AP		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Feb CMFD

ALBENDAZOLE

TABLET;ORAL  
ALBENDAZOLE

AB	DR REDDYS	200MG	A211034	001	Jan 26, 2021	Jan NEWA
	@ LUPIN LTD	200MG	A211636	001	Jun 10, 2020	Jan DISC
AB	MSN	200MG	A213435	001	Jan 21, 2021	Jan NEWA

ALBUTEROL SULFATE

AEROSOL, METERED;INHALATION  
ALBUTEROL SULFATE

>A> AB1	SANDOZ INC	EQ 0.09MG BASE/INH	A207085	001	Jun 01, 2021	May NEWA
	TABLET;ORAL					
	ALBUTEROL SULFATE					
AB	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Feb CMFD
AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Feb CMFD
	@ EYWA	EQ 2MG BASE	A213524	001	Oct 08, 2020	Apr DISC
	@	EQ 4MG BASE	A213524	002	Oct 08, 2020	Apr DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION  
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ AUROBINDO PHARMA LTD	EQ 0.083% BASE;0.017%	A206532	001	Jul 08, 2020	Jan DISC
------------------------	-----------------------	---------	-----	--------------	----------

ALENDRONATE SODIUM

TABLET;ORAL

ALENDRONATE SODIUM

>D>	@ NEOPHARMA	EQ 5MG BASE	A079049	003	Aug 04, 2008	May CAHN
>D>	@	EQ 10MG BASE	A079049	004	Aug 04, 2008	May CAHN
>D>	@	EQ 35MG BASE	A079049	001	Aug 04, 2008	May CAHN
>D>	@	EQ 70MG BASE	A079049	002	Aug 04, 2008	May CAHN
>A>	@ US ANTIBIOTICS	EQ 5MG BASE	A079049	003	Aug 04, 2008	May CAHN
>A>	@	EQ 10MG BASE	A079049	004	Aug 04, 2008	May CAHN
>A>	@	EQ 35MG BASE	A079049	001	Aug 04, 2008	May CAHN
>A>	@	EQ 70MG BASE	A079049	002	Aug 04, 2008	May CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEKURNA HCT

>D>	+ NODEN PHARMA	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008	May DISC
>A>	+ @	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008	May DISC
>D>	+ @	EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008	May DISC
>A>	+ @	EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008	May DISC

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

AB	NOVITIUM PHARMA	0.25MG	A074174	001	Oct 19, 1993	Apr CMFD
AB		0.5MG	A074174	002	Oct 19, 1993	Apr CMFD
AB		1MG	A074174	003	Oct 19, 1993	Apr CMFD
AB		2MG	A074174	004	Oct 19, 1993	Apr CMFD

ALPROSTADIL

INJECTABLE;INJECTION

CAVERJECT

	+ @ PFIZER	0.005MG/VIAL	N020379	003	Jun 27, 1996	Jan CAHN
AP	+	0.01MG/VIAL	N020379	001	Jul 06, 1995	Jan CAHN
AP	+!	0.02MG/VIAL	N020379	002	Jul 06, 1995	Jan CAHN
AP	+!	0.04MG/VIAL	N020379	004	May 19, 1997	Jan CAHN
	CAVERJECT IMPULSE					
	PFIZER	0.01MG/VIAL	N021212	001	Jun 11, 2002	Jan CAHN
		0.02MG/VIAL	N021212	002	Jun 11, 2002	Jan CAHN
	PROSTIN VR PEDIATRIC					
AP	+! PFIZER	0.5MG/ML	N018484	001		Jan CAHN

AMANTADINE HYDROCHLORIDE

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

@ WOCKHARDT BIO AG 50MG/5ML

A075060 001 Dec 24, 1998 Jan DISC

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

@ INVAGEN PHARMS 100MG

A207571 001 Jan 31, 2017 Jan DISC

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

	+ ADAMAS PHARMA	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan CAHN
	+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan CAHN
	+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan CAHN
>D>	+!	EQ 258MG BASE	N209410	003	Feb 16, 2018	May DISC
>A>	+ @	EQ 258MG BASE	N209410	003	Feb 16, 2018	May DISC
	+!	EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan CAHN
	+ ADAMAS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan CAHN
	+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan CAHN
	+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan CAHN
	+!	EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan CAHN

AMINOCAPROIC ACID

SOLUTION;ORAL

AMICAR

AA	+! AKORN	0.25GM/ML	N015230	002		Feb CPOT
AA	+!	1.25GM/5ML	N015230	002		Feb CDFR
	AMINOCAPROIC ACID					
AA	AIRIS PHARMA PVT LTD	0.25GM/ML	A213825	001	Apr 08, 2021	Apr NEWA
AA	AMNEAL	0.25GM/ML	A212780	001	Aug 23, 2019	Feb CPOT
AA		1.25GM/5ML	A212780	001	Aug 23, 2019	Feb CDFR
AA	LEADING PHARMA LLC	0.25GM/ML	A214140	001	Jan 26, 2021	Feb CPOT

SOLUTION;ORAL  
AMINOCAPROIC ACID

AA		1.25GM/5ML	A214140	001	Jan 26, 2021	Feb CDFR
AA	TULEX PHARMS INC	0.25GM/ML	A212494	001	Aug 11, 2020	Feb CPOT
AA		1.25GM/5ML	A212494	001	Aug 11, 2020	Feb CDFR
AA	VISTAPHARM	0.25GM/ML	A212814	001	Feb 26, 2020	Feb CPOT
AA		1.25GM/5ML	A212814	001	Feb 26, 2020	Feb CDFR
	SYRUP;ORAL AMINOCAPROIC ACID					
AA	LEADING PHARMA LLC	1.25GM/5ML	A214140	001	Jan 26, 2021	Jan NEWA
	TABLET;ORAL AMINOCAPROIC ACID					
AB	LEADING PHARMA LLC	500MG	A213928	001	Feb 12, 2021	Feb NEWA
AB		1GM	A213928	002	Feb 12, 2021	Feb NEWA

AMIODARONE HYDROCHLORIDE

	TABLET;ORAL AMIODARONE HYDROCHLORIDE					
AB	RUBICON	100MG	A078578	002	Feb 26, 2021	Feb NEWA
AB		400MG	A078578	003	Feb 26, 2021	Feb NEWA

AMITRIPTYLINE HYDROCHLORIDE

	TABLET;ORAL AMITRIPTYLINE HYDROCHLORIDE					
AB	MANKIND PHARMA	10MG	A213999	001	Feb 19, 2021	Feb NEWA
AB		25MG	A213999	002	Feb 19, 2021	Feb NEWA
AB		50MG	A213999	003	Feb 19, 2021	Feb NEWA
AB		75MG	A213999	004	Feb 19, 2021	Feb NEWA
AB		100MG	A213999	005	Feb 19, 2021	Feb NEWA
AB		150MG	A213999	006	Feb 19, 2021	Feb NEWA
>A> AB	UNICHEM	10MG	A214548	001	May 19, 2021	May NEWA
>A> AB		25MG	A214548	002	May 19, 2021	May NEWA
>A> AB		50MG	A214548	003	May 19, 2021	May NEWA
>A> AB		75MG	A214548	004	May 19, 2021	May NEWA
>A> AB		100MG	A214548	005	May 19, 2021	May NEWA
>A> AB		150MG	A214548	006	May 19, 2021	May NEWA

AMLODIPINE BESYLATE

	TABLET;ORAL AMLODIPINE BESYLATE					
@	WOCKHARDT	EQ 2.5MG BASE	A078500	001	Sep 06, 2007	Jan DISC
@		EQ 5MG BASE	A078500	002	Sep 06, 2007	Jan DISC
@		EQ 10MG BASE	A078500	003	Sep 06, 2007	Jan DISC

AMMONIA N-13

	INJECTABLE; INTRAVENOUS AMMONIA N 13					
AP	NUKEMED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Jan CAHN

AMOXICILLIN

	CAPSULE;ORAL AMOXIL					
>D> AB	NEOPHARMA	250MG	A062216	001		May CAHN
>D> AB		500MG	A062216	004		May CAHN
>A> AB	US ANTIBIOTICS	250MG	A062216	001		May CAHN
>A> AB		500MG	A062216	004		May CAHN
	FOR SUSPENSION;ORAL AMOXIL					
>D> AB	NEOPHARMA	50MG/ML	A062226	005		May CAHN
>D> AB		125MG/5ML	A062226	001		May CAHN
>D>	+ @	200MG/5ML	N050760	001	Apr 15, 1999	May CAHN
>D> AB		250MG/5ML	A062226	002		May CAHN
>D>	+ @	400MG/5ML	N050760	002	Apr 15, 1999	May CAHN
>A> AB	US ANTIBIOTICS	50MG/ML	A062226	005		May CAHN
>A> AB		125MG/5ML	A062226	001		May CAHN
>A>	+ @	200MG/5ML	N050760	001	Apr 15, 1999	May CAHN
>A> AB		250MG/5ML	A062226	002		May CAHN
>A>	+ @	400MG/5ML	N050760	002	Apr 15, 1999	May CAHN
	LAROTID					
>D> AB	NEOPHARMA	125MG/5ML	A062226	003		May CAHN
>D> AB		250MG/5ML	A062226	004		May CAHN
>A> AB	US ANTIBIOTICS	125MG/5ML	A062226	003		May CAHN

FOR SUSPENSION;ORAL  
LAROTID

>A> AB		250MG/5ML	A 062226	004	May CAHN
	TABLET;ORAL AMOXIL				
>D>	+ @ NEOPHARMA	500MG	N 050754	002	Jul 10, 1998
>D>	+ @	875MG	N 050754	001	Jul 10, 1998
>A>	+ @ US ANTIBIOTICS	500MG	N 050754	002	Jul 10, 1998
>A>	+ @	875MG	N 050754	001	Jul 10, 1998
	TABLET, CHEWABLE;ORAL AMOXIL				
>D>	+ @ NEOPHARMA	125MG	N 050542	002	May CAHN
>D>	@	200MG	N 050761	001	Apr 15, 1999
>D>	+ @	250MG	N 050542	001	May CAHN
>D>	@	400MG	N 050761	002	Apr 15, 1999
>A>	+ @ US ANTIBIOTICS	125MG	N 050542	002	May CAHN
>A>	@	200MG	N 050761	001	Apr 15, 1999
>A>	+ @	250MG	N 050542	001	May CAHN
>A>	@	400MG	N 050761	002	Apr 15, 1999
>D>	<u>AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE</u>				
>D>	CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL				
>D>	OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN				
>D>	+! CUMBERLAND PHARMS	500MG,N/A,N/A;N/A;N/A,500MG,N/A;N/A,N/A,20MG	N 050824	001	Feb 08, 2011
>A>	+ @	500MG,N/A,N/A;N/A;N/A,500MG,N/A;N/A,N/A,20MG	N 050824	001	Feb 08, 2011
	<u>AMOXICILLIN; CLAVULANATE POTASSIUM</u>				
	FOR SUSPENSION;ORAL				
	AMOXICILLIN AND CLAVULANATE POTASSIUM				
>A> AB	MICRO LABS LTD INDIA	200MG/5ML;EQ 28.5MG BASE/5ML	A 205187	001	May 21, 2021
>A> AB		400MG/5ML;EQ 57MG BASE/5ML	A 205187	002	May 21, 2021
	AUGMENTIN '125'				
>D> AB	+ NEOPHARMA	125MG/5ML;EQ 31.25MG BASE/5ML	N 050575	001	Aug 06, 1984
>A> AB	+ US ANTIBIOTICS	125MG/5ML;EQ 31.25MG BASE/5ML	N 050575	001	Aug 06, 1984
	AUGMENTIN '200'				
>D>	+ @ NEOPHARMA	200MG/5ML;EQ 28.5MG BASE/5ML	N 050725	001	May 31, 1996
>A>	+ @ US ANTIBIOTICS	200MG/5ML;EQ 28.5MG BASE/5ML	N 050725	001	May 31, 1996
	AUGMENTIN '250'				
>D> AB	+! NEOPHARMA	250MG/5ML;EQ 62.5MG BASE/5ML	N 050575	002	Aug 06, 1984
>A> AB	+! US ANTIBIOTICS	250MG/5ML;EQ 62.5MG BASE/5ML	N 050575	002	Aug 06, 1984
	AUGMENTIN '400'				
>D>	+ @ NEOPHARMA	400MG/5ML;EQ 57MG BASE/5ML	N 050725	002	May 31, 1996
>A>	+ @ US ANTIBIOTICS	400MG/5ML;EQ 57MG BASE/5ML	N 050725	002	May 31, 1996
	AUGMENTIN ES-600				
>D> AB	+ NEOPHARMA	600MG/5ML;EQ 42.9MG BASE/5ML	N 050755	001	Jun 22, 2001
>A> AB	+ US ANTIBIOTICS	600MG/5ML;EQ 42.9MG BASE/5ML	N 050755	001	Jun 22, 2001
	TABLET;ORAL				
	AUGMENTIN '250'				
>D>	+ @ NEOPHARMA	250MG;EQ 125MG BASE	N 050564	001	Aug 06, 1984
>A>	+ @ US ANTIBIOTICS	250MG;EQ 125MG BASE	N 050564	001	Aug 06, 1984
	AUGMENTIN '500'				
>D>	+ @ NEOPHARMA	500MG;EQ 125MG BASE	N 050564	002	Aug 06, 1984
>A>	+ @ US ANTIBIOTICS	500MG;EQ 125MG BASE	N 050564	002	Aug 06, 1984
	AUGMENTIN '875'				
>D> AB	+ NEOPHARMA	875MG;EQ 125MG BASE	N 050720	001	Feb 13, 1996
>A> AB	+ US ANTIBIOTICS	875MG;EQ 125MG BASE	N 050720	001	Feb 13, 1996
	TABLET, CHEWABLE;ORAL				
	AUGMENTIN '125'				
>D>	+ @ NEOPHARMA	125MG;EQ 31.25MG BASE	N 050597	001	Jul 22, 1985
>A>	+ @ US ANTIBIOTICS	125MG;EQ 31.25MG BASE	N 050597	001	Jul 22, 1985
	AUGMENTIN '200'				
>D>	+ @ NEOPHARMA	200MG;EQ 28.5MG BASE	N 050726	001	May 31, 1996
>A>	+ @ US ANTIBIOTICS	200MG;EQ 28.5MG BASE	N 050726	001	May 31, 1996
	AUGMENTIN '250'				
>D>	+ @ NEOPHARMA	250MG;EQ 62.5MG BASE	N 050597	002	Jul 22, 1985
>A>	+ @ US ANTIBIOTICS	250MG;EQ 62.5MG BASE	N 050597	002	Jul 22, 1985
	AUGMENTIN '400'				
>D>	+ @ NEOPHARMA	400MG;EQ 57MG BASE	N 050726	002	May 31, 1996
>A>	+ @ US ANTIBIOTICS	400MG;EQ 57MG BASE	N 050726	002	May 31, 1996

TABLET, EXTENDED RELEASE;ORAL  
AUGMENTIN XR

>D>	+ @ NEOPHARMA	1GM;EQ 62.5MG BASE	N 050785 001 Sep 25, 2002	May CAHN
>A>	+ @ US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N 050785 001 Sep 25, 2002	May CAHN

AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE TABLET;ORAL

AB	RHODES PHARMS	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE 2.5MG;2.5MG;2.5MG;2.5MG	A 213111 003 Jan 13, 2021	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A 213111 005 Jan 13, 2021	Jan NEWA
AB		5MG;5MG;5MG;5MG	A 213111 006 Jan 13, 2021	Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE TABLET;ORAL

AB	ASCENT PHARMS INC	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE 1.25MG;1.25MG;1.25MG;1.25MG	A 213709 001 Apr 22, 2021	Apr NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A 213709 002 Apr 22, 2021	Apr NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A 213709 003 Apr 22, 2021	Apr NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A 213709 004 Apr 22, 2021	Apr NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A 213709 005 Apr 22, 2021	Apr NEWA
AB		5MG;5MG;5MG;5MG	A 213709 006 Apr 22, 2021	Apr NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A 213709 007 Apr 22, 2021	Apr NEWA
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A 213111 001 Jan 13, 2021	Jan NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A 213111 002 Jan 13, 2021	Jan NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A 213111 004 Jan 13, 2021	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A 213111 007 Jan 13, 2021	Jan NEWA

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	GLENMARK PHARMS LTD	5MG	A 212186 001 Jan 27, 2021	Jan NEWA
AA		10MG	A 212186 002 Jan 27, 2021	Jan NEWA
	@ MAYNE PHARMA	5MG	A 213898 001 Jul 14, 2020	Jan DISC
	@	10MG	A 213898 002 Jul 14, 2020	Jan DISC
	@ NOVAST LABS	5MG	A 213763 001 Aug 24, 2020	Mar DISC
	@	10MG	A 213763 002 Aug 24, 2020	Mar DISC
AA	SPECGX LLC	5MG	A 213583 001 Jan 22, 2021	Jan NEWA
AA		10MG	A 213583 002 Jan 22, 2021	Jan NEWA
AA	SUN PHARM INDUS INC	5MG	A 214574 001 Jan 27, 2021	Jan NEWA
AA		10MG	A 214574 002 Jan 27, 2021	Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL  
EVEKEO ODT

+ ARBOR PHARMS LLC	2.5MG	N 209905 005 Apr 16, 2021	Apr NEWA
+!	20MG	N 209905 004 Jan 30, 2019	Apr CHRS

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

	@ HQ SPECLT PHARMA	EQ 125MG BASE/VIAL	A 062772 005 Apr 15, 1993	Mar CAHN
AP		EQ 250MG BASE/VIAL	A 062772 006 Apr 15, 1993	Mar CAHN
AP		EQ 500MG BASE/VIAL	A 062772 007 Apr 15, 1993	Mar CAHN
	@	EQ 500MG BASE/VIAL	A 062772 008 Apr 15, 1993	Mar CAHN
AP		EQ 1GM BASE/VIAL	A 062772 001 Apr 15, 1993	Mar CAHN
	@	EQ 1GM BASE/VIAL	A 062772 002 Apr 15, 1993	Mar CAHN
AP		EQ 2GM BASE/VIAL	A 062772 003 Apr 15, 1993	Mar CAHN
	@	EQ 2GM BASE/VIAL	A 062772 004 Apr 15, 1993	Mar CAHN
AP		EQ 10GM BASE/VIAL	A 063142 001 Apr 15, 1993	Mar CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP	HQ SPECLT PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 065176 001 Nov 30, 2005	Mar CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 065176 002 Nov 30, 2005	Mar CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A 065188 001 Nov 25, 2005	Mar CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

>D>	@ NEOPHARMA	1MG	A 090732 001 Jun 28, 2010	May CAHN
>A>	@ US ANTIBIOTICS	1MG	A 090732 001 Jun 28, 2010	May CAHN

APREMILAST

TABLET;ORAL

APREMILAST

AB	UNICHEM	10MG	A211819	001	Feb 17, 2021	Feb NFTG
AB		20MG	A211819	002	Feb 17, 2021	Feb NFTG
AB		30MG	A211819	003	Feb 17, 2021	Feb NFTG

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP	CAPLIN	50MG/50ML (1MG/ML)	A214235	001	Jan 21, 2021	Jan NFTG
	INJECTABLE; INTRAVENOUS					
	ARGATROBAN IN SODIUM CHLORIDE					
>D>	+! EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	May DISC

>A>	+ @	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	May DISC
-----	-----	--------------------	---------	-----	--------------	----------

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

ARSENIC TRIOXIDE

>D> AP	AMNEAL	1MG/ML	A210739	001	Jan 25, 2021	May DISC
>A>	@	1MG/ML	A210739	001	Jan 25, 2021	May DISC
AP		1MG/ML	A210739	001	Jan 25, 2021	Jan NEWA
	@ INGENUS PHARMS LLC	2MG/ML	A209315	002	Jan 14, 2021	Feb DISC
AP		2MG/ML	A209315	002	Jan 14, 2021	Jan NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	002	Jan 29, 2004	Feb CAIN
----	-------------------	---	---------	-----	--------------	----------

ASENAPINE MALEATE

TABLET;SUBLINGUAL

ASENAPINE MALEATE

AB	BRECKENRIDGE	EQ 5MG BASE	A205960	003	Mar 08, 2021	Feb NEWA
----	--------------	-------------	---------	-----	--------------	----------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

NORGESIC

>A>	+ @ BAUSCH	385MG;30MG;25MG	N013416	003	Oct 27, 1982	May CAHN
>D>	+ @ MEDICIS	385MG;30MG;25MG	N013416	003	Oct 27, 1982	May CAHN
	NORGESIC FORTE					
>A>	+ @ BAUSCH	770MG;60MG;50MG	N013416	004	Oct 27, 1982	May CAHN
>D>	+ @ MEDICIS	770MG;60MG;50MG	N013416	004	Oct 27, 1982	May CAHN

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

@ LANNETT CO INC 25MG;200MG

A204552 001 Mar 20, 2019 Apr DISC

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ASPIRIN

>A>	LGM PHARMA	500MG;5MG	A205479	001	May 28, 2021	May NEWA
-----	------------	-----------	---------	-----	--------------	----------

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB	LAURUS LABS LTD	EQ 150MG BASE	A212579	001	Apr 30, 2021	Apr NEWA
AB		EQ 200MG BASE	A212579	002	Apr 30, 2021	Apr NEWA
AB		EQ 300MG BASE	A212579	003	Apr 30, 2021	Apr NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	HETERO LABS LTD V	10MG	A202682	001	Mar 11, 2021	Mar NEWA
AB		18MG	A202682	002	Mar 11, 2021	Mar NEWA
AB		25MG	A202682	003	Mar 11, 2021	Mar NEWA
AB		40MG	A202682	004	Mar 11, 2021	Mar NEWA
AB		60MG	A202682	005	Mar 11, 2021	Mar NEWA
AB		80MG	A202682	006	Mar 11, 2021	Mar NEWA
AB		100MG	A202682	007	Mar 11, 2021	Mar NEWA
	@ MYLAN	10MG	A079021	001	Feb 18, 2021	Feb DISC
AB		10MG	A079021	001	Feb 18, 2021	Feb NEWA
	@	18MG	A079021	002	Feb 18, 2021	Feb DISC
AB		18MG	A079021	002	Feb 18, 2021	Feb NEWA
	@	25MG	A079021	003	Feb 18, 2021	Feb DISC
AB		25MG	A079021	003	Feb 18, 2021	Feb NEWA
	@	40MG	A079021	004	Feb 18, 2021	Feb DISC
AB		40MG	A079021	004	Feb 18, 2021	Feb NEWA
	@	60MG	A079021	005	Feb 18, 2021	Feb DISC
AB		60MG	A079021	005	Feb 18, 2021	Feb NEWA
	@	80MG	A079021	006	Feb 18, 2021	Feb DISC
AB		80MG	A079021	006	Feb 18, 2021	Feb NEWA
	@	100MG	A079021	007	Feb 18, 2021	Feb DISC
AB		100MG	A079021	007	Feb 18, 2021	Feb NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	ALKEM LABS LTD	EQ 10MG BASE	A209288	001	Dec 21, 2018	Jan CAHN
AB		EQ 20MG BASE	A209288	002	Dec 21, 2018	Jan CAHN
AB		EQ 40MG BASE	A209288	003	Dec 21, 2018	Jan CAHN
AB		EQ 80MG BASE	A209288	004	Dec 21, 2018	Jan CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

+ @ ORGANON	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	Feb CAHN
+ @	EQ 20MG BASE;10MG	N200153	002	May 03, 2013	Feb CAHN
+ @	EQ 40MG BASE;10MG	N200153	003	May 03, 2013	Feb CAHN
+ @	EQ 80MG BASE;10MG	N200153	004	May 03, 2013	Feb CAHN

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB	BIONPHARMA INC	750MG/5ML	A212918	001	Mar 30, 2021	Mar NEWA
----	----------------	-----------	---------	-----	--------------	----------

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

AP	+! HOSPIRA	1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Mar CTEC
AP	INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	A212461	001	Oct 05, 2020	Mar CTEC
SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL						
	ATROPINE SULFATE					
AP	ACCORD HLTHCARE	8MG/20ML (0.4MG/ML)	A213424	001	Mar 19, 2021	Mar NFTG

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	WINDER LABS LLC	0.025MG;2.5MG	A211362	001	Jan 27, 2021	Jan NEWA
----	-----------------	---------------	---------	-----	--------------	----------

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON-PLUS

+ @ MYLAN	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Jan CAHN
-----------	-------------------	---------	-----	--------------	----------

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;INTRAVENOUS

AVYCAZ

+! ALLERGAN	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Jan CDFR
-------------	------------------------	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB PERRIGO UK FINCO EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY A208111 001 Feb 18, 2021 Feb NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB TARO EQ 200MG BASE/5ML A211521 001 Dec 11, 2019 Feb CMFD

INJECTABLE;INJECTION

AZITHROMYCIN

@ MYLAN ASI

EQ 500MG BASE/VIAL

A065506 001 Mar 24, 2009 Feb DISC

TABLET;ORAL

AZITHROMYCIN

AB YUNG SHIN PHARM EQ 500MG BASE A211318 001 Mar 17, 2021 Mar NEWA

AB EQ 600MG BASE A211068 001 May 08, 2020 Feb CMFD

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP MAIA PHARMS INC 0.05MG/ML A210777 001 Jan 15, 2021 Jan NEWA

GABLOFEN

AP +! PIRAMAL CRITICAL 0.05MG/ML N022462 001 Nov 19, 2010 Mar CHRS

AP + 0.05MG/ML N022462 001 Nov 19, 2010 Mar CRLD

AP +! 0.5MG/ML N022462 002 Nov 19, 2010 Mar CHRS

AP + 0.5MG/ML N022462 002 Nov 19, 2010 Mar CRLD

AP +! 2MG/ML N022462 003 Nov 19, 2010 Mar CHRS

AP + 2MG/ML N022462 003 Nov 19, 2010 Mar CRLD

TABLET;ORAL

BACLOFEN

AB INNOGENIX 5MG A212378 003 Apr 30, 2021 Apr NEWA

AB KARTHA 5MG A214374 001 Mar 05, 2021 Feb NEWA

AB 10MG A214374 002 Mar 05, 2021 Feb NEWA

AB 20MG A214374 003 Mar 05, 2021 Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

KEMSTRO

&gt;D&gt; @ UCB INC 10MG N021589 001 Oct 30, 2003 May CRLD

&gt;A&gt; + @ 10MG N021589 001 Oct 30, 2003 May CRLD

&gt;D&gt; @ 20MG N021589 002 Oct 30, 2003 May CRLD

&gt;A&gt; + @ 20MG N021589 002 Oct 30, 2003 May CRLD

BALOXAVIR MARBOXIL

TABLET;ORAL

XOFLUZA

+ GENENTECH INC

80MG

N210854 003 Mar 18, 2021 Mar NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

LOTENSIN

AB + VALIDUS PHARMS 5MG N019851 001 Jun 25, 1991 Feb CAHN

AB + 10MG N019851 002 Jun 25, 1991 Feb CAHN

AB + 20MG N019851 003 Jun 25, 1991 Feb CAHN

AB +! 40MG N019851 004 Jun 25, 1991 Feb CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLORTHIAZIDE

TABLET;ORAL

LOTENSIN HCT

+ @ VALIDUS PHARMS

5MG;6.25MG

N020033 001 May 19, 1992 Feb CAHN

AB + 10MG;12.5MG N020033 002 May 19, 1992 Feb CAHN

AB + 20MG;12.5MG N020033 004 May 19, 1992 Feb CAHN

AB +! 20MG;25MG N020033 003 May 19, 1992 Feb CAHN

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC

FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE

&gt;D&gt; +! BAUSCH 0.4%;0.3% N211039 001 Mar 09, 2020 May CAHN

&gt;A&gt; +! BAUSCH LOMB IRELAND 0.4%;0.3% N211039 001 Mar 09, 2020 May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	ENCUBE	5%;1.2%	A212433	001	Apr 28, 2021	Apr NEWA
AB	! PERRIGO ISRAEL	5%;1.2%	A090979	001	Jun 26, 2012	Jan CHRS
	DUAC					
AB	+ STIEFEL	5%;1.2%	N050741	001	Aug 26, 2002	Jan CHRS

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

>D>	@ APOTEX	1.5%	A206066	001	Mar 05, 2019	May CMFD
>A> AT		1.5%	A206066	001	Mar 05, 2019	May CMFD
>D>	@ MYLAN	1.5%	A206220	001	Mar 18, 2019	May CMFD
>A> AT		1.5%	A206220	001	Mar 18, 2019	May CMFD
	BEPREVE					
>D>	+! BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	May CTEC
>A> AT	+!	1.5%	N022288	001	Sep 08, 2009	May CTEC

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

>D>	@ INVATECH	EQ 0.05% BASE	A070274	001	Aug 12, 1985	May CAHN
>A>	@ PHARMGEN	EQ 0.05% BASE	A070274	001	Aug 12, 1985	May CAHN
	SPRAY;TOPICAL					
	SERNIVO					
	+! PRIMUS PHARMS	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Mar CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	! TARO	EQ 0.05% BASE;1%	A076493	001	Jul 28, 2004	Feb CHRS
	LOTRISONE					
	+ @ MERCK SHARP DOHME	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb DISC

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

	@ WOCKHARDT	5MG	A040532	001	Sep 29, 2003	Jan DISC
	@	50MG	A040518	001	Sep 29, 2003	Jan DISC

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB	TEVA PHARMS USA	75MG	A209931	001	Jan 14, 2021	Jan NEWA
----	-----------------	------	---------	-----	--------------	----------

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT	@ AKORN	0.03%	A203299	001	Nov 08, 2018	Feb CAHN
AT	! ALEMBIC PHARMS LTD	0.03%	A210263	001	Apr 12, 2019	Jan CHRS
AT	LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Jan CHRS

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB	UNICHEM	5MG	A078635	001	Aug 18, 2009	Apr CAHN
AB	!	10MG	A078635	002	Aug 18, 2009	Apr CAHN

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

>A> AP	HAINAN POLY PHARM	250MG/VIAL	A213078	001	May 28, 2021	May NEWA
--------	-------------------	------------	---------	-----	--------------	----------

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

VELCADE

>D>	+! MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003	May CAHN
>A>	+! TAKEDA PHARMS USA	3.5MG/VIAL	N021602	001	May 13, 2003	May CAHN

BOSENTAN

TABLET;ORAL

BOSENTAN

>D>	@ ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020	May CMFD
>A> AB		62.5MG	A211461	001	Jan 23, 2020	May CMFD
>D>	@	125MG	A211461	002	Jan 23, 2020	May CMFD
>A> AB		125MG	A211461	002	Jan 23, 2020	May CMFD
	TRACLEER					
AB	+ ACTELION	62.5MG	N021290	001	Nov 20, 2001	Feb CAHN
AB	+!	125MG	N021290	002	Nov 20, 2001	Feb CAHN
	TABLET, FOR SUSPENSION;ORAL					
	TRACLEER					
+!	ACTELION	32MG	N209279	001	Sep 05, 2017	Feb CAHN

BRIGATINIB

TABLET;ORAL

ALUNBRIG

>D>	+ ARIAD	30MG	N208772	001	Apr 28, 2017	May CAHN
>D>	+	90MG	N208772	002	Apr 28, 2017	May CAHN
>D>	+!	180MG	N208772	003	Oct 02, 2017	May CAHN
>A>	+ TAKEDA PHARMS USA	30MG	N208772	001	Apr 28, 2017	May CAHN
>A>	+	90MG	N208772	002	Apr 28, 2017	May CAHN
>A>	+!	180MG	N208772	003	Oct 02, 2017	May CAHN

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

PARLODEL

AB	+ VALIDUS PHARMS	EQ 5MG BASE	N017962	002	Mar 01, 1982	Feb CAHN
AB	+ VALIDUS PHARMS	EQ 2.5MG BASE	N017962	001		Feb CAHN

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

	@ BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Jan DISC
	CAPSULE, DELAYED RELEASE;ORAL					
	BUDESONIDE					
AB	@ ALVOGEN	3MG	A206724	001	Nov 23, 2016	Apr CDFR
	AMNEAL PHARMS	3MG	A206200	001	Jul 31, 2017	Apr CDFR
AB	@ BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Apr CDFR
AB	MAYNE PHARMA	3MG	A206623	001	Apr 08, 2016	Apr CDFR
AB	MYLAN	3MG	A090410	001	May 16, 2011	Apr CDFR
AB	RISING	3MG	A207367	001	Apr 07, 2017	Apr CDFR
AB	SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Apr CDFR
AB	ZYDUS PHARMS	3MG	A206134	001	May 04, 2017	Apr CDFR
	ENTOCORT EC					
AB	+! PERRIGO PHARMA INTL	3MG	N021324	001	Oct 02, 2001	Apr CDFR
	SUSPENSION;INHALATION					
	BUDESONIDE					
AN	SUN PHARM	0.25MG/2ML	A211922	001	Apr 14, 2021	Apr NEWA
AN		0.5MG/2ML	A211922	002	Apr 14, 2021	Apr NEWA
AN		1MG/2ML	A211922	003	Apr 14, 2021	Apr NEWA

BUPIVACAINE

SOLUTION, EXTENDED RELEASE;INFILTRATION

POSIMIR

+ @ DURECT	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Mar DISC
+!	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Feb NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP	HIKMA PHARMS	0.25%	A205141	001	Feb 11, 2021	Feb NEWA
AP		0.5%	A205141	002	Feb 11, 2021	Feb NEWA
	BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
AP	HIKMA PHARMS	0.25%	A204842	001	Feb 11, 2021	Feb NEWA
AP		0.5%	A204842	002	Feb 11, 2021	Feb NEWA
AP		0.75%	A204842	003	Feb 11, 2021	Feb NEWA

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL  
BUPRENORPHINE

AB	MYLAN TECHNOLOGIES	5MCG/HR	A210162	001	May 03, 2021	Apr NEWA
AB		7.5MCG/HR	A210162	002	May 03, 2021	Apr NEWA
AB		10MCG/HR	A210162	003	May 03, 2021	Apr NEWA
AB		15MCG/HR	A210162	004	May 03, 2021	Apr NEWA
AB		20MCG/HR	A210162	005	May 03, 2021	Apr NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL  
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE  
@ MAYNE PHARMA INC EQ 2MG BASE;EQ 0.5MG BASE  
>D> @ EQ 8MG BASE;EQ 2MG BASE  
>A> AB @ EQ 8MG BASE;EQ 2MG BASE  
@ EQ 8MG BASE;EQ 2MG BASE

A206953	001	Jul 17, 2020	Jan DISC
A206953	002	Jul 17, 2020	May CMFD
A206953	002	Jul 17, 2020	May CMFD
A206953	002	Jul 17, 2020	Jan DISC

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL  
APLENZIN  
+ BAUSCH 174MG  
+ 348MG  
+! 522MG

N022108	001	Apr 23, 2008	Feb CAHN
N022108	002	Apr 23, 2008	Feb CAHN
N022108	003	Apr 23, 2008	Feb CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
BUPROPION HYDROCHLORIDE  
@ TORRENT 100MG  
@ 150MG  
@ 200MG  
WELLBUTRIN XL  
AB3 + BAUSCH 150MG  
AB3 +! 300MG

A203969	001	Oct 31, 2014	Jan DISC
A203969	002	Oct 31, 2014	Jan DISC
A203969	003	Oct 31, 2014	Jan DISC
N021515	001	Aug 28, 2003	Feb CAHN
N021515	002	Aug 28, 2003	Feb CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL  
BUSPIRONE HYDROCHLORIDE  
AB RUBICON 5MG  
AB 7.5MG  
AB 10MG  
AB 15MG  
AB 30MG

A075521	001	Apr 05, 2002	Feb CMFD
A075521	004	Mar 16, 2021	Mar NEWA
A075521	002	Apr 05, 2002	Feb CMFD
A075521	003	Apr 05, 2002	Feb CMFD
A075521	005	Mar 16, 2021	Mar NEWA

BUSULFAN

INJECTABLE;INJECTION  
BUSULFAN  
AP AM REGENT 6MG/ML

A202259	001	Dec 22, 2015	Feb CAHN
---------	-----	--------------	----------

CABERGOLINE

TABLET;ORAL  
DOSTINEX  
+ @ PFIZER 0.5MG

N020664	001	Dec 23, 1996	Jan CAHN
---------	-----	--------------	----------

CABOTEGRAVIR SODIUM

TABLET;ORAL  
VOCABRIA  
+! VIIV HLTHCARE EQ 30MG BASE

N212887	001	Jan 21, 2021	Jan NEWA
---------	-----	--------------	----------

CABOTEGRAVIR; RILPIVIRINE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR  
CABENUVA KIT  
+! VIIV HLTHCARE 400MG/2ML (200MG/ML);600MG/2ML  
(300MG/ML)  
+! 600MG/3ML (200MG/ML);900MG/3ML  
(300MG/ML)

N212888	001	Jan 21, 2021	Jan NEWA
N212888	002	Jan 21, 2021	Jan NEWA

CALCITONIN SALMON

INJECTABLE; INJECTION

CALCITONIN-SALMON

&gt;A&gt; AP CUSTOPHARM INC 200 IU/ML A212416 001 May 14, 2021 May NFTG

CALCIUM ACETATE

TABLET; ORAL

CALCIUM ACETATE

AB ! CHARTWELL MOLECULAR 667MG A202420 001 Feb 05, 2013 Apr CHRS

CARBAMAZEPINE

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB CSPC OUYI 100MG A213311 001 Apr 13, 2021 Apr NEWA  
AB 200MG A213311 002 Apr 13, 2021 Apr NEWA  
AB 400MG A213311 003 Apr 13, 2021 Apr NEWACARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB SCIEGEN PHARMS INC 10MG;100MG A214092 001 May 07, 2021 Apr NEWA  
AB 25MG;100MG A214092 002 May 07, 2021 Apr NEWA  
AB 25MG;250MG A214092 003 May 07, 2021 Apr NEWACARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

AP ! HOSPIRA 50MG/5ML (10MG/ML) A076517 001 Oct 14, 2004 Mar CHRS  
AP ! 150MG/15ML (10MG/ML) A076517 002 Oct 14, 2004 Mar CHRS  
AP ! 450MG/45ML (10MG/ML) A076517 003 Oct 14, 2004 Mar CHRS  
AP ! 600MG/60ML (10MG/ML) A077059 001 Nov 23, 2004 Mar CHRS  
AP PHARMACHEMIE BV 50MG/5ML (10MG/ML) A077269 001 Oct 14, 2004 Mar CHRS  
AP 150MG/15ML (10MG/ML) A077269 002 Oct 14, 2004 Mar CHRS  
AP 450MG/45ML (10MG/ML) A077269 003 Oct 14, 2004 Mar CHRS  
AP 600MG/60ML (10MG/ML) A077269 004 Dec 28, 2007 Mar CHRSCARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

AP SUNNY PHARMTECH INC EQ 0.25MG BASE/ML A213118 001 Mar 25, 2021 Mar NEWA

CARMUSTINE

INJECTABLE; INJECTION

CARMUSTINE

AP JIANGSU HENGRI MED 100MG/VIAL A211202 001 Mar 12, 2021 Mar NEWA

CASIMERSEN

SOLUTION; INTRAVENOUS

AMONDYS 45

+! SAREPTA THERAPS INC 100MG/2ML (50MG/ML)

N213026 001 Feb 25, 2021 Feb NEWA

CEFAZOLIN SODIUM

SOLUTION; INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

+! BAXTER HLTHCARE CORP EQ 1GM BASE/50ML (EQ 20MG BASE/ML) N207131 002 Feb 01, 2021 Mar NEWA  
+! EQ 2GM BASE/100ML (EQ 20MG BASE/ML) N207131 001 Aug 07, 2015 Mar CRLD  
! EQ 2GM BASE/100ML (EQ 20MG BASE/ML) N207131 001 Aug 07, 2015 Mar CHRSCEFDINIR

CAPSULE; ORAL

CEFDINIR

AB ALKEM LABS LTD 300MG A210220 001 Feb 19, 2021 Feb NEWA

FOR SUSPENSION; ORAL

CEFDINIR

AB ALKEM LABS LTD 125MG/5ML A210534 001 Feb 19, 2021 Feb NEWA  
AB 250MG/5ML A210534 002 Feb 19, 2021 Feb NEWA

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

@ ASTRAL

EQ 1GM BASE/VIAL

A212721 001 Jul 21, 2020 Mar DISC

@

EQ 2GM BASE/VIAL

A212721 002 Jul 21, 2020 Mar DISC

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

AB ALKEM LABS LTD 100MG/5ML A211775 001 Feb 19, 2021 Feb NEWA  
AB 200MG/5ML A211775 002 Feb 19, 2021 Feb NEWACEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

+ @ VALIDUS PHARMS

EQ 500MG BASE/VIAL

N050547 001 Feb CAHN

+ @

EQ 1GM BASE/VIAL

N050547 002 Feb CAHN

+ @

EQ 2GM BASE/VIAL

N050547 003 Feb CAHN

+ @

EQ 10GM BASE/VIAL

N050547 004 Dec 29, 1983 Feb CAHN

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

@ VALIDUS PHARMS

EQ 20MG BASE/ML

N050596 002 May 20, 1985 Feb CAHN

@

EQ 40MG BASE/ML

N050596 004 May 20, 1985 Feb CAHN

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ VALIDUS PHARMS

EQ 20MG BASE/ML

N050596 001 May 20, 1985 Feb CAHN

@

EQ 40MG BASE/ML

N050596 003 May 20, 1985 Feb CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

@ TELIGENT

EQ 10MG BASE/ML

N050634 001 Apr 28, 1989 Feb CAHN

+ @

EQ 20MG BASE/ML

N050634 002 Apr 28, 1989 Feb CAHN

+ @

EQ 40MG BASE/ML

N050634 003 Apr 28, 1989 Feb CAHN

CEFUROXIME SODIUM

INJECTABLE; INJECTION

ZINACEF

AP +! TELIGENT EQ 1.5GM BASE/VIAL N050558 003 Oct 19, 1983 Feb CAHN  
AP +! EQ 7.5GM BASE/VIAL N050558 004 Oct 23, 1986 Feb CAHN  
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
ZINACEF  
AB +! TELIGENT EQ 750MG BASE/VIAL N050558 002 Oct 19, 1983 Feb CAHNCELECOXIB

CAPSULE; ORAL

CELEBREX

AB + UPJOHN 50MG N020998 004 Dec 15, 2006 Apr CAHN  
AB + 100MG N020998 001 Dec 31, 1998 Apr CAHN  
AB + 200MG N020998 002 Dec 31, 1998 Apr CAHN  
AB +! 400MG N020998 003 Aug 29, 2002 Apr CAHN  
CELECOXIB  
AB UNICHEM 50MG A213301 001 Jan 12, 2021 Jan NEWA  
AB 100MG A213301 002 Jan 12, 2021 Jan NEWA  
AB 200MG A213301 003 Jan 12, 2021 Jan NEWA  
AB 400MG A213301 004 Jan 12, 2021 Jan NEWACEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

@ YUNG SHIN PHARM

EQ 250MG BASE

A065152 001 Feb 24, 2005 Mar DISC

@

EQ 500MG BASE

A065152 002 Feb 24, 2005 Mar DISC

&gt;D&gt; KEFLEX

EQ 250MG BASE

N050405 002 May DISC

&gt;D&gt; AB + PRAGMA

EQ 250MG BASE

N050405 002 May DISC

&gt;A&gt; + @

EQ 250MG BASE

N050405 003 May DISC

&gt;D&gt; AB +

EQ 500MG BASE

N050405 003 May DISC

&gt;A&gt; + @

EQ 500MG BASE

N050405 003 May DISC

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

@ CHARTWELL RX	5MG	A084678	001	Apr CAHN
@	10MG	A084041	001	Apr CAHN
@	25MG	A084679	002	Apr CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB ALKEM LABS LTD	5MG;2.5MG	A214065	001	Apr 26, 2021	Apr NEWA
AB DR REDDYS	5MG;2.5MG	A214698	001	May 10, 2021	Apr NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

AT BAJAJ	0.12%	A075561	001	Nov 14, 2000	Feb CMFD
----------	-------	---------	-----	--------------	----------

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

>A> GENUS	30MG/ML	A214542	001	Jun 02, 2021	May NEWA
>A>	100MG/ML	A214542	002	Jun 02, 2021	May NEWA

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB GLENMARK PHARMS LTD	10MG	A212144	001	Mar 23, 2021	Mar NEWA
AB	25MG	A212144	002	Mar 23, 2021	Mar NEWA
AB	50MG	A212144	003	Mar 23, 2021	Mar NEWA
AB	100MG	A212144	004	Mar 23, 2021	Mar NEWA
AB	200MG	A212144	005	Mar 23, 2021	Mar NEWA
AB LANNETT CO INC	10MG	A212996	001	Jan 22, 2021	Jan NEWA
AB	25MG	A212996	002	Jan 22, 2021	Jan NEWA
AB	50MG	A212996	003	Jan 22, 2021	Jan NEWA
AB	100MG	A212996	004	Jan 22, 2021	Jan NEWA
AB	200MG	A212996	005	Jan 22, 2021	Jan NEWA
@ MAYNE PHARMA	10MG	A213590	001	Aug 31, 2020	Mar DISC
@	25MG	A213590	002	Aug 31, 2020	Mar DISC
@	50MG	A213590	003	Aug 31, 2020	Mar DISC
@	100MG	A213590	004	Aug 31, 2020	Mar DISC
@	200MG	A213590	005	Aug 31, 2020	Mar DISC

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

@ RISING	100MG	A088725	001	Aug 31, 1984	Jan CAHN
@	250MG	A088726	001	Aug 31, 1984	Jan CAHN

CHLORTHALIDONE

TABLET;ORAL

THALITONE

>D> + @ CASPER PHARMA LLC	15MG	N019574	001	Dec 20, 1988	May CMFD
>A> +	15MG	N019574	001	Dec 20, 1988	May CMFD
>D> @	25MG	N019574	002	Feb 12, 1992	May CMFD
>A> BX +!	25MG	N019574	002	Feb 12, 1992	May CMFD

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AB PAR PHARM INC	375MG	A212743	002	Apr 29, 2021	Apr NEWA
------------------	-------	---------	-----	--------------	----------

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

AB TAGI	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Feb NEWA
AB	EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Feb NEWA
AB LOCHOLEST LIGHT					
@ CHARTWELL RX	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Apr CAHN
@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Apr CAHN

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

@ UCSF RODIOPHARM

4-33.1mCi/ML

A208444 001 Nov 20, 2017 Apr DISC

CICLESONIDE

SPRAY, METERED; NASAL

OMNARIS

>D>	+!	COVIS	0.05MG/INH	N022004	001	Oct 20, 2006	May CPOT
>A>	+!		0.05MG/SPRAY	N022004	001	Oct 20, 2006	May CPOT

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

@ AKORN

8%

A078975 001 Feb 17, 2010 Apr DISC

>D> AT		NOVAST LABS	8%	A078124	001	Sep 18, 2007	May CAHN
--------	--	-------------	----	---------	-----	--------------	----------

>A> AT		RISING	8%	A078124	001	Sep 18, 2007	May CAHN
--------	--	--------	----	---------	-----	--------------	----------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

@ EPIC PHARMA LLC

50MG

A077022 002 Mar 11, 2005

Jan CMS1

@ NOSTRUM LABS INC

50MG

A077708 001 Sep 28, 2009

Mar DISC

AB			50MG	A077708	001	Sep 28, 2009	Jan CAHN
----	--	--	------	---------	-----	--------------	----------

@

100MG

A077708 002 Sep 28, 2009

Mar DISC

AB			100MG	A077708	002	Sep 28, 2009	Jan CAHN
----	--	--	-------	---------	-----	--------------	----------

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ NOVITIUM PHARMA

300MG

A074340 001 Jun 23, 1995

Feb CAHN

@

400MG

A074340 002 Jun 23, 1995

Feb CAHN

@

800MG

A074339 001 Jun 23, 1995

Feb CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

@ ZYDUS PHARMS

EQ 2MG BASE/ML

A213527 001 Aug 31, 2020

Feb DISC

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

@ WOCKHARDT

250MG

A065266 001 May 31, 2006

Jan DISC

@

500MG

A065266 002 May 31, 2006

Jan DISC

CLASCOTERONE

CREAM; TOPICAL

WINLEVI

+ @ CASSIOPEA SPA

1%

N213433 001 Aug 26, 2020

Mar DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE

AB	+	PFIZER	EQ 75MG BASE	N050162	001		Feb CAHN
AB	+		EQ 150MG BASE	N050162	002		Feb CAHN
AB	+		EQ 300MG BASE	N050162	003	Apr 14, 1988	Feb CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

AA	!	PFIZER	EQ 75MG BASE/5ML	A062644	001	Apr 07, 1986	Feb CAHN
----	---	--------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLEOCIN

@ PFIZER

EQ 2% BASE

N050680 001 Aug 11, 1992

Feb CAHN

AB	+		EQ 2% BASE	N050680	002	Mar 02, 1998	Feb CAHN
----	---	--	------------	---------	-----	--------------	----------

GEL; TOPICAL

CLEOCIN T

AB	+	PFIZER	EQ 1% BASE	N050615	001	Jan 07, 1987	Feb CAHN
----	---	--------	------------	---------	-----	--------------	----------

<u>GEL;TOPICAL</u>					
<u>CLINDAMYCIN PHOSPHATE</u>					
AB	ENCUBE	EQ 1% BASE	A212438	001	Mar 11, 2021
AB	GLENMARK PHARMS LTD	EQ 1% BASE	A214251	001	Feb 10, 2021
AB	PERRIGO UK FINCO	EQ 1% BASE	A212104	001	Dec 31, 2020
<u>INJECTABLE; INJECTION</u>					
<u>CLEOCIN PHOSPHATE</u>					
AP	PFIZER	EQ 150MG BASE/ML	A062803	001	Oct 16, 1987
AP	+!	EQ 150MG BASE/ML	N050441	001	Feb CAHN
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
+ @ PFIZER		EQ 6MG BASE/ML	N050639	001	Aug 30, 1989
+ @		EQ 12MG BASE/ML	N050639	002	Aug 30, 1989
+ @		EQ 18MG BASE/ML	N050639	003	Apr 10, 1991
<u>CLINDAMYCIN PHOSPHATE</u>					
@ MYLAN LABS LTD		EQ 150MG BASE/ML	A204748	001	Oct 10, 2017
<u>LOTION;TOPICAL</u>					
<u>CLEOCIN T</u>					
AB	+! PFIZER	EQ 1% BASE	N050600	001	May 31, 1989
<u>CLINDAMYCIN PHOSPHATE</u>					
AB	GAGE DEVELOPMENT	EQ 1% BASE	A214604	001	Mar 08, 2021
AB	PERRIGO UK FINCO	EQ 1% BASE	A214604	001	Mar 08, 2021
<u>SOLUTION;TOPICAL</u>					
<u>CLEOCIN T</u>					
+ @ PFIZER		EQ 1% BASE	N050537	001	Feb CAHN
+ @ PHARMACIA AND UPJOHN		EQ 1% BASE	N050537	001	Jan DISC
<u>CLINDAMYCIN PHOSPHATE</u>					
AT	! PERRIGO NEW YORK	EQ 1% BASE	A064050	001	Nov 30, 1995
<u>SUPPOSITORY;VAGINAL</u>					
<u>CLEOCIN</u>					
+! PFIZER		100MG	N050767	001	Aug 13, 1999
<u>SWAB;TOPICAL</u>					
<u>CLEOCIN</u>					
+ @ PFIZER		EQ 1% BASE	N050537	002	Feb 22, 1994
AT	+!	EQ 1% BASE	N050537	002	Feb 22, 1994
<u>CLINDAMYCIN PHOSPHATE</u>					
AT	! PERRIGO NEW YORK	EQ 1% BASE	A065049	001	May 25, 2000
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN</u>					
<u>GEL;TOPICAL</u>					
<u>ZIANA</u>					
>A> AB	+! BAUSCH	1.2%;0.025%	N050802	001	Nov 07, 2006
>D> AB	+! MEDICIS	1.2%;0.025%	N050802	001	Nov 07, 2006
<u>CLOBAZAM</u>					
<u>SUSPENSION;ORAL</u>					
<u>CLOBAZAM</u>					
AB	ALKEM LABS LTD	2.5MG/ML	A213039	001	May 06, 2021
<u>TABLET;ORAL</u>					
<u>CLOBAZAM</u>					
@ LANNETT CO INC		10MG	A212092	001	Oct 30, 2019
@		20MG	A212092	002	Oct 30, 2019
AB	MSN	10MG	A213404	001	May 11, 2021
AB		20MG	A213404	002	May 11, 2021
<u>CLOBETASOL PROPIONATE</u>					
<u>CREAM;TOPICAL</u>					
<u>CLOBETASOL PROPIONATE</u>					
AB1	GLASSHOUSE PHARMS	0.05%	A211207	001	Mar 26, 2021
<u>IMPOYZ</u>					
+! PRIMUS PHARMS		0.025%	N209483	001	Nov 28, 2017
<u>OINTMENT;TOPICAL</u>					
<u>CLOBETASOL PROPIONATE</u>					
@ TORRENT		0.05%	A212926	001	Oct 25, 2019
<u>SHAMPOO;TOPICAL</u>					
<u>CLOBETASOL PROPIONATE</u>					
AB	TARO PHARMS	0.05%	A214867	001	Mar 25, 2021
<u>SOLUTION;TOPICAL</u>					
<u>CLOBETASOL PROPIONATE</u>					
AT	PRINSTON INC	0.05%	A213139	001	Feb 08, 2021
<u>PRINSTON INC</u>					

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

@ AKORN

0.05%

A207218 001 Apr 28, 2017 Apr DISC

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

AP MEITHEAL 20MG/20ML (1MG/ML)  
@ NOVAST LABS 20MG/20ML (1MG/ML)A213461 001 Oct 23, 2020 Jan CAHN  
A210270 001 Sep 14, 2018 Mar DISCCLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

>D> @ VGYAAN 25MG A213221 001 Jun 22, 2020 May CMFD  
>A> AB 25MG A213221 001 Jun 22, 2020 May CMFD  
>D> @ 50MG A213221 002 Jun 22, 2020 May CMFD  
>A> AB 50MG A213221 002 Jun 22, 2020 May CMFD  
>D> @ 75MG A213221 003 Jun 22, 2020 May CMFD  
>A> AB 75MG A213221 003 Jun 22, 2020 May CMFDCLONAZEPAM

TABLET;ORAL

CLONAZEPAM

@ WATSON LABS 0.5MG A074964 001 Dec 30, 1997 Apr DISC  
@ 1MG A074964 002 Dec 30, 1997 Apr DISC  
@ 2MG A074964 003 Dec 30, 1997 Apr DISCCLONIDINE

SYSTEM;TRANSDERMAL

CATAPRES-TTS-1

AB + LAVIPHARM 0.1MG/24HR N018891 001 Oct 10, 1984 Jan CAHN  
AB + TECHNOMED 0.1MG/24HR N018891 001 Oct 10, 1984 Jan CAHN  
CATAPRES-TTS-2  
AB + LAVIPHARM 0.2MG/24HR N018891 002 Oct 10, 1984 Jan CAHN  
AB + TECHNOMED 0.2MG/24HR N018891 002 Oct 10, 1984 Jan CAHN  
CATAPRES-TTS-3  
AB +! LAVIPHARM 0.3MG/24HR N018891 003 Oct 10, 1984 Jan CAHN  
AB +! TECHNOMED 0.3MG/24HR N018891 003 Oct 10, 1984 Jan CAHNCLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP ! HIKMA FARMACEUTICA 5MG/10ML (0.5MG/ML) A200300 002 Jan 26, 2011 Mar CHRS  
DURACLON  
+ @ MYLAN INSTITUTIONAL 5MG/10ML (0.5MG/ML) N020615 002 Apr 27, 1999 Mar DISCCLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB POLYGEN PHARMS EQ 75MG BASE A213351 001 Jul 17, 2020 Feb CMFD  
AB EQ 300MG BASE A213351 002 Jul 17, 2020 Feb CMFDCLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

TRANXENE

>D> @ RECORDATI RARE 3.75MG N017105 001 May CRLD  
>A> + @ 3.75MG N017105 001 May CRLD  
>D> @ 7.5MG N017105 002 May CRLD  
>A> + @ 7.5MG N017105 002 May CRLD  
>D> @ 15MG N017105 003 May CRLD  
>A> + @ 15MG N017105 003 May CRLD

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB AUROLIFE PHARMA LLC 3.75MG A071858 002 Jul 17, 1987 Jan CAHN  
AB 7.5MG A071858 003 Jul 17, 1987 Jan CAHN  
AB ! 15MG A071858 001 Jul 17, 1987 Jan CAHN  
TRANXENE  
>D> @ RECORDATI RARE 3.75MG N017105 006 May CRLD  
>A> + @ 3.75MG N017105 006 May CRLD  
TRANXENE SD  
>D> @ RECORDATI RARE 11.25MG N017105 005 May CRLD  
>A> + @ 11.25MG N017105 005 May CRLD

TABLET;ORAL  
TRANXENE SD

>D>	@	22.5MG	N 017105 004	May CRLD
>A>	+	22.5MG	N 017105 004	May CRLD

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA	AKORN	10MG/5ML;5MG/5ML;6.25MG/5ML	A 040674 001 Dec 23, 2014	Feb CAHN
----	-------	-----------------------------	---------------------------	----------

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

GLENMARK PHARMS LTD	1.875GM/PACKET	A 202190 001 Jul 16, 2018	Feb CTEC
@ WATSON LABS INC	1.875GM/PACKET	A 202178 001 Sep 01, 2020	Feb DISC
@	3.75GM/PACKET	A 202178 002 Sep 01, 2020	Feb DISC

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

@ WATSON LABS INC	625MG	A 200830 001 Sep 02, 2020	Feb DISC
-------------------	-------	---------------------------	----------

COlestipol HYDROCHLORIDE

GRANULE;ORAL

COlestid

AB	+	Pfizer	5GM/SCOOPFUL	N 017563 003 Sep 22, 1995	Feb CAHN
AB	+	!	5GM/PACKET	N 017563 004 Sep 22, 1995	Feb CAHN

FLAVORED COlestid

+	Pfizer	5GM/PACKET	N 017563 001	Feb CAHN
+		5GM/SCOOPFUL	N 017563 002	Feb CAHN

TABLET;ORAL

COlestid

AB	+	!	Pfizer	1GM	N 020222 001 Jul 19, 1994	Feb CAHN
----	---	---	--------	-----	---------------------------	----------

CROTAMITON

CREAM;TOPICAL

EURAX

+ @ JOURNEY	10%	N 006927 001	Jan CAHN
-------------	-----	--------------	----------

LOTION;TOPICAL

EURAX

AT	+	!	JOURNEY	10%	N 009112 003	Jan CAHN
----	---	---	---------	-----	--------------	----------

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE

SOLUTION;INTRAVENOUS

TRALEMENT

+! AM REGENT	(1ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML	N 209376 001 Jul 02, 2020	Jan CPOT
--------------	---	---------------------------	----------

+!	(5ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML	N 209376 002 Dec 02, 2020	Jan NEWA
----	---	---------------------------	----------

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

@ PLIVA	10MG	A 074421 001 Sep 29, 1995	Apr DISC
---------	------	---------------------------	----------

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	QUAGEN	4MG	A 212491 001 Feb 24, 2021	Feb NEWA
----	--------	-----	---------------------------	----------

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE;ORAL

PROCYSB

>A>	+	HORIZON	EQ 25MG BASE	N 203389 001 Apr 30, 2013	May CAHN
>A>	+	!	EQ 75MG BASE	N 203389 002 Apr 30, 2013	May CAHN
>D>	+	HORIZON PHARMA USA	EQ 25MG BASE	N 203389 001 Apr 30, 2013	May CAHN
>D>	+	!	EQ 75MG BASE	N 203389 002 Apr 30, 2013	May CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

>D> AP	MYLAN LABS LTD	20MG/ML	A200914	001	Dec 13, 2011	May DISC
>A>	@	20MG/ML	A200914	001	Dec 13, 2011	May DISC

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

AP	AUROMEDICS PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Jan CAHN
AP	MEITHEAL	0.5MG/VIAL	A213463	001	Nov 13, 2020	Feb CAHN

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPTOMYCIN

AP	HISUN PHARM HANGZHOU	500MG/VIAL	A212250	001	Apr 21, 2021	Apr NEWA
	POWDER; IV (INFUSION)					
	DAPTOMYCIN					
>D> AP	DR REDDYS	350MG/VIAL	A211403	001	Aug 31, 2020	May DISC
>A>	@	350MG/VIAL	A211403	001	Aug 31, 2020	May DISC

DASIGLUCAGON HYDROCHLORIDE

SOLUTION; SUBCUTANEOUS

ZEGALOGUE

>D>	+! ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	May CAHN
>A>	+!	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	May CAHN
	+!	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Mar NEWA
	ZEGALOGUE (AUTOINJECTOR)					
>D>	+! ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	May CAHN
>A>	+!	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	May CAHN
	+!	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Mar NEWA

DECITABINE

INJECTABLE; INTRAVENOUS

DECITABINE

>D> AP	APOTEX	50MG/VIAL	A205539	001	Nov 23, 2020	May DISC
>A>	@	50MG/VIAL	A205539	001	Nov 23, 2020	May DISC
>D> AP	CIPLA	50MG/VIAL	A208601	001	Nov 16, 2017	May DISC
>A>	@	50MG/VIAL	A208601	001	Nov 16, 2017	May DISC
AP	QILU	50MG/VIAL	A212826	001	Apr 12, 2021	Apr NEWA

DEFERASIROX

GRANULE; ORAL

DEFERASIROX

AB	AMNEAL	180MG	A214194	001	Feb 09, 2021	Jan NEWA
AB		360MG	A214194	002	Feb 09, 2021	Jan NEWA
AB	AUCTA	90MG	A214559	001	Mar 09, 2021	Feb NEWA
AB		180MG	A214559	002	Mar 09, 2021	Feb NEWA
AB		360MG	A214559	003	Mar 09, 2021	Feb NEWA
AB	MSN	180MG	A214650	001	Mar 17, 2021	Mar NEWA
AB		360MG	A214650	002	Mar 17, 2021	Mar NEWA
	TABLET; ORAL					
	DEFERASIROX					
>A> AB	ANNORA PHARMA	90MG	A214341	001	May 14, 2021	May NEWA
>A> AB		180MG	A214341	002	May 14, 2021	May NEWA
>A> AB		360MG	A214341	003	May 14, 2021	May NEWA
>A> AB	CELLTRION	90MG	A212669	001	May 27, 2021	May NEWA
>A> AB		180MG	A212669	002	May 27, 2021	May NEWA
>A> AB		360MG	A212669	003	May 27, 2021	May NEWA

DEFERIPRONE

TABLET; ORAL

DEFERIPRONE

AB	HIKMA	500MG	A213239	001	Mar 29, 2021	Mar NEWA
	FERRIPROX					
AB	+! CHIESI	500MG	N021825	001	Oct 14, 2011	Mar CTEC

DEOXYCHOLIC ACID

SOLUTION; SUBCUTANEOUS  
DEOXYCHOLIC ACID

AP SLAYBACK PHARMA LLC 20MG/2ML (10MG/ML) A212296 001 Apr 02, 2021 Mar NFTG

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL  
NORPRAMIN

AB + VALIDUS PHARMS	10MG	N014399	007	Feb 11, 1982	Feb CAHN
AB +	25MG	N014399	001	Feb 11, 1982	Feb CAHN
AB +	50MG	N014399	003	Feb 11, 1982	Feb CAHN
AB +	75MG	N014399	004	Feb 11, 1982	Feb CAHN
AB +!	100MG	N014399	005	Feb 11, 1982	Feb CAHN
AB +	150MG	N014399	006	Feb 11, 1982	Feb CAHN

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL  
NOCTIVA

+ @ ROIVANT 0.00083MG/SPRAY  
+ @ 0.00166MG/SPRAY

N201656 001 Mar 03, 2017 Feb CAHN  
N201656 002 Mar 03, 2017 Feb CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21  
ORTHO-CEPT

>D> @ JANSSEN PHARMS	0.15MG; 0.03MG	N020301	001	Dec 14, 1992	May CRLD
>A> + @	0.15MG; 0.03MG	N020301	001	Dec 14, 1992	May CRLD
TABLET; ORAL-28 ORTHO-CEPT					
>D> @ JANSSEN PHARMS	0.15MG; 0.03MG	N020301	002	Dec 14, 1992	May CRLD
>A> + @	0.15MG; 0.03MG	N020301	002	Dec 14, 1992	May CRLD

DESONIDE

GEL; TOPICAL  
DESONATE

+ @ LEO PHARMA AS 0.05%  
DESONIDE  
! CINTEX SVCS 0.05%  
0.05%

N021844 001 Oct 20, 2006 Mar DISC  
A202470 001 May 11, 2020 Mar CHRS  
A202470 001 May 11, 2020 Mar CTEC

DESOXIMETASONE

CREAM; TOPICAL  
DESOXIMETASONE

@ AKORN 0.05%  
@ 0.25%

A203787 001 Jan 06, 2017 Apr DISC  
A203234 001 Jun 12, 2015 Apr DISC

OINTMENT; TOPICAL  
DESOXIMETASONE

AB ! GLENMARK GENERICS	0.25%	A202838	001	Sep 20, 2013	Apr CHRS
TOPICORT					
@ TARO PHARM IND LTD	0.25%	A074286	001	Jun 07, 1996	Apr DISC

DEXAMETHASONE

TABLET; ORAL  
DEXAMETHASONE

BP ! HIKMA	1MG	A088306	001	Sep 15, 1983	Apr CHRS
BP !	2MG	A087916	001	Aug 26, 1982	Apr CHRS

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION  
DEXMEDETOMIDINE HYDROCHLORIDE

>A> AP GLAND	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202126	001	Aug 20, 2015	May CAHN
>D> AP SUN PHARM IND INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202126	001	Aug 20, 2015	May CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB MYLAN	25MG	A204266	005	May 04, 2021	Apr NEWA
AB	35MG	A204266	006	May 04, 2021	Apr NEWA

>A> DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

&gt;A&gt; CAPSULE;ORAL

&gt;A&gt; AZSTARYS

>A> + COMMAGE THERAP	EQ 5.2MG BASE;EQ 26.1MG BASE	N212994	001	May 07, 2021	May NEWA
>A> +	EQ 7.8MG BASE;EQ 39.2MG BASE	N212994	002	May 07, 2021	May NEWA
>A> +!	EQ 10.4MG BASE;EQ 52.3MG BASE	N212994	003	May 07, 2021	May NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP AUROMEDICS PHARMA	EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Jan CAHN
AP	EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Jan CAHN
ZINECARD					
AP +! PFIZER	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995	Mar CAHN
AP +!	EQ 500MG BASE/VIAL	N020212	002	May 26, 1995	Mar CAHN

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

>D> ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	May CTEC
>A> AA	2.5MG	A090533	001	Oct 25, 2011	May CTEC
>D>	7.5MG	A090533	003	Oct 25, 2011	May CTEC
>A> AA	7.5MG	A090533	003	Oct 25, 2011	May CTEC
>D>	15MG	A090533	005	Oct 25, 2011	May CTEC
>A> AA	15MG	A090533	005	Oct 25, 2011	May CTEC
>D>	20MG	A090533	006	Oct 25, 2011	May CTEC
>A> AA	20MG	A090533	006	Oct 25, 2011	May CTEC
>D>	30MG	A090533	007	Oct 25, 2011	May CTEC
>A> AA	30MG	A090533	007	Oct 25, 2011	May CTEC
>A> AA WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021	May NEWA
>A> AA	5MG	A212160	002	Jun 07, 2021	May NEWA
>A> AA	7.5MG	A212160	003	Jun 07, 2021	May NEWA
>A> AA	10MG	A212160	004	Jun 07, 2021	May NEWA
>A> AA	15MG	A212160	005	Jun 07, 2021	May NEWA
>A> AA	20MG	A212160	006	Jun 07, 2021	May NEWA
>A> AA	30MG	A212160	007	Jun 07, 2021	May NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%

@ FRESENIUS KABI USA	5GM/100ML;75MG/100ML	A212346	001	Sep 10, 2020	Mar DISC
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%					
@ FRESENIUS KABI USA	5GM/100ML;150MG/100ML	A212346	002	Sep 10, 2020	Mar DISC
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER					
+ BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634	003		Mar CTEC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP FRESENIUS KABI USA	5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Feb NEWA
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP FRESENIUS KABI USA	5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Feb NEWA
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP FRESENIUS KABI USA	5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Feb NFTG
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP FRESENIUS KABI USA	5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Feb NEWA
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP FRESENIUS KABI USA	5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Feb NEWA
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP FRESENIUS KABI USA	5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Feb NFTG

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D> @ FRESENIUS KABI USA	2.5GM/100ML;450MG/100ML	A211190	001	Dec 20, 2019	May CMFD
>A> AP	2.5GM/100ML;450MG/100ML	A211190	001	Dec 20, 2019	May CMFD
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
>D> @ FRESENIUS KABI USA	5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	May CMFD
>A> AP	5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	May CMFD
@ 5GM/100ML;300MG/100ML					
>D> +! ICU MEDICAL INC	5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	Feb DISC
	5GM/100ML;300MG/100ML	N017799	001		May CTEC

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

>A> AP	+!	5GM/100ML; 300MG/100ML	N 017799 001	May CTEC
	+!	5GM/100ML; 300MG/100ML	N 017799 001	Feb CTEC
	DEXTROSE 5% AND SODIUM CHLORIDE 0.45%			
>D>	@ FRESENIUS KABI USA	5GM/100ML; 450MG/100ML	A 211276 001	Sep 15, 2020
>A> AP		5GM/100ML; 450MG/100ML	A 211276 001	Sep 15, 2020
	@	5GM/100ML; 450MG/100ML	A 211276 001	Mar DISC
	DEXTROSE 5% AND SODIUM CHLORIDE 0.9%			
>D>	@ FRESENIUS KABI USA	5GM/100ML; 900MG/100ML	A 211211 001	Sep 14, 2020
>A> AP		5GM/100ML; 900MG/100ML	A 211211 001	Sep 14, 2020
	@	5GM/100ML; 900MG/100ML	A 211211 001	Mar DISC

DIAZEPAM

TABLET; ORAL

DIAZEPAM

@ BARR	2MG	A 070152 001	Nov 01, 1985	Apr DISC
@	10MG	A 070154 001	Nov 01, 1985	Apr DISC

DICLOFENAC POTASSIUM

TABLET; ORAL

>A>	CATAFLAM			
>A> AB	AMICI	50MG	A 076561 001	Mar 18, 2004
>D>	DICLOFENAC POTASSIUM			
>D> AB	AMICI	50MG	A 076561 001	Mar 18, 2004

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB	! TARO SOLARAZE	3%	A 206298 001	Apr 28, 2016	Mar CHRS
	+ @ FOUGERA PHARMS SOLUTION; TOPICAL	3%	N 021005 001	Oct 16, 2000	Mar DISC
	DICLOFENAC SODIUM				
AT	AKORN	1.5%	A 206655 001	Jan 28, 2021	Jan NEWA
>D>	@ NOVAST LABS	1.5%	A 206715 001	Aug 07, 2017	May CAHN
>A>	@ RISING	1.5%	A 206715 001	Aug 07, 2017	May CAHN
	TABLET, DELAYED RELEASE; ORAL				
	DICLOFENAC SODIUM				
	@ MICRO LABS	50MG	A 074986 001	Feb 26, 1999	Feb CAHN
	@	75MG	A 074986 002	Feb 26, 1999	Feb CAHN

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

	@ SANDOZ	EQ 125MG BASE	A 061454 002	Jan DISC
	@	EQ 250MG BASE	A 061454 001	Jan DISC
	@	EQ 500MG BASE	A 061454 003	Jan DISC
	TEVA	EQ 250MG BASE	A 062286 001	Jun 03, 1982
	!	EQ 500MG BASE	A 062286 002	Jun 03, 1982
AB	!	EQ 500MG BASE	A 062286 002	Jun 03, 1982
				Jan CHRS

DICYCLOMINE HYDROCHLORIDE

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

AA	NOVITIUM PHARMA	10MG/5ML	A 214721 001	Apr 23, 2021	Apr NEWA
----	-----------------	----------	--------------	--------------	----------

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

	@ AUROBINDO PHARMA	125MG	A 090094 001	Sep 24, 2008	Jan DISC
	@	200MG	A 090094 002	Sep 24, 2008	Jan DISC
	@	250MG	A 090094 003	Sep 24, 2008	Jan DISC
	@	400MG	A 090094 004	Sep 24, 2008	Jan DISC

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	! ANI PHARMS	0.05%	A 076263 001	Dec 20, 2002	Apr CAHN
----	--------------	-------	--------------	--------------	----------

OINTMENT;TOPICAL  
DIFLORASONE DIACETATE  
© AKORN 0.05%

A206572 001 Jul 24, 2015 Apr DISC

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION  
DIHYDROERGOTAMINE MESYLATE

AP PROVEPHARM SAS 1MG/ML

A212046 001 Jan 07, 2020 Jan CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
DILTIAZEM HYDROCHLORIDE

AB1	GLENMARK PHARMS LTD	60MG	A212317	001	Mar 22, 2021	Mar NEWA
AB1		90MG	A212317	002	Mar 22, 2021	Mar NEWA
AB1		120MG	A212317	003	Mar 22, 2021	Mar NEWA
AB1	MYLAN	60MG	A074910	001	May 02, 1997	Mar CTEC
AB1		90MG	A074910	002	May 02, 1997	Mar CTEC
AB1	!	120MG	A074910	003	May 02, 1997	Mar CTEC

INJECTABLE;INJECTION  
DILTIAZEM HYDROCHLORIDE  
© INTL MEDICATION 5MG/ML

A075749 001 Nov 21, 2001 Jan DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL  
DIMETHYL FUMARATE

AB	PHARMATHEN	120MG	A210436	001	Mar 26, 2021	Mar NEWA
AB		240MG	A210436	002	Mar 26, 2021	Mar NEWA
	© ZYDUS PHARMS	120MG	A210538	001	Sep 24, 2020	Feb DISC
	©	240MG	A210538	002	Sep 24, 2020	Feb DISC
	TECFIDERA					
AB	+ BIOGEN INC	120MG	N204063	001	Mar 27, 2013	Apr CAHN
AB	+!	240MG	N204063	002	Mar 27, 2013	Apr CAHN

DINOPROSTONE

GEL;ENDOCERVICAL  
PREPIDIL  
+! PFIZER 0.5MG/3GM  
SUPPOSITORY;VAGINAL  
PROSTIN E2  
+! PFIZER 20MG

N019617	001	Dec 09, 1992	Jan CAHN
N017810	001		Jan CAHN

DIPYRIDAMOLE

TABLET;ORAL  
DIPYRIDAMOLE

AB	OXFORD PHARMS	25MG	A040542	001	Apr 21, 2006	Jan CMFD
AB		50MG	A040542	002	Apr 21, 2006	Jan CMFD
AB		75MG	A040542	003	Apr 21, 2006	Jan CMFD

DIROXIMEI FUMARATE

CAPSULE, DELAYED RELEASE;ORAL  
VUMERTY  
+! BIOGEN INC 231MG

N211855 001 Oct 29, 2019 Apr CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL  
DISOPYRAMIDE PHOSPHATE  
© MAYNE PHARMA EQ 100MG BASE  
© EQ 150MG BASE

A070173	001	May 31, 1985	Feb DISC
A070173	002	May 31, 1985	Feb DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL  
DIVALPROEX SODIUM  
>D> AB TEVA PHARMS USA EQ 125MG VALPROIC ACID A211505 001 Nov 17, 2020 May DISC  
>A> © EQ 125MG VALPROIC ACID A211505 001 Nov 17, 2020 May DISC  
TABLET, DELAYED RELEASE;ORAL  
DIVALPROEX SODIUM  
>D> AB ANCHEN PHARMS EQ 500MG VALPROIC ACID A078411 001 Nov 03, 2008 May DISC  
>A> © EQ 500MG VALPROIC ACID A078411 001 Nov 03, 2008 May DISC  
TABLET, EXTENDED RELEASE;ORAL  
DIVALPROEX SODIUM  
AB AMTA EQ 250MG VALPROIC ACID A214462 001 Mar 15, 2021 Mar NEWA

TABLET, EXTENDED RELEASE;ORAL  
DIVALPROEX SODIUM

AB EQ 500MG VALPROIC ACID A214462 002 Mar 15, 2021 Mar NEWA

DOCETAXELINJECTABLE; INJECTION  
DOCETAXEL

>D> AP	DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20,	2017	May DISC
>A>	@	20MG/ML (20MG/ML)	A206177	001	Jan 20,	2017	May DISC
>D> AP		80MG/4ML (20MG/ML)	A206177	002	Jan 20,	2017	May DISC
>A>	@	80MG/4ML (20MG/ML)	A206177	002	Jan 20,	2017	May DISC
>D>		200MG/10ML (20MG/ML)	A206177	003	Jan 20,	2017	May DISC
>A>	@	200MG/10ML (20MG/ML)	A206177	003	Jan 20,	2017	May DISC
AP	HIKMA	20MG/ML (20MG/ML)	A204490	001	Jan 14,	2021	Jan NEWA
AP		80MG/4ML (20MG/ML)	A204490	002	Jan 14,	2021	Jan NEWA
	@ INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31,	2017	Apr DISC
AP	+! SHILPA	20MG/ML (20MG/ML)	N205934	001	Dec 22,	2015	Apr CHRS
AP	+	20MG/ML (20MG/ML)	N205934	001	Dec 22,	2015	Apr CRLD
AP		20MG/ML (20MG/ML)	N205934	001	Dec 22,	2015	Jan CAHN
AP	+!	80MG/4ML (20MG/ML)	N205934	002	Dec 22,	2015	Apr CHRS
AP	+	80MG/4ML (20MG/ML)	N205934	002	Dec 22,	2015	Apr CRLD
AP		80MG/4ML (20MG/ML)	N205934	002	Dec 22,	2015	Jan CAHN
AP	+!	160MG/8ML (20MG/ML)	N205934	003	Dec 22,	2015	Apr CHRS
AP	+	160MG/8ML (20MG/ML)	N205934	003	Dec 22,	2015	Apr CRLD
AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22,	2015	Jan CAHN

DOFETILIDECAPSULE;ORAL  
DOFETILIDE

@ RICONPHARMA LLC	0.125MG	A212410	001	Dec 27,	2019	Feb DISC
@	0.25MG	A212410	002	Dec 27,	2019	Feb DISC
@	0.5MG	A212410	003	Dec 27,	2019	Feb DISC

DOLASETRON MESYLATEINJECTABLE; INJECTION  
ANZEMET

+ @ VALIDUS PHARMS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11,	1997	Feb CAHN
+ @	100MG/5ML (20MG/ML)	N020624	001	Sep 11,	1997	Feb CAHN
@	500MG/25ML (20MG/ML)	N020624	003	Dec 11,	2001	Feb CAHN

## TABLET;ORAL

## ANZEMET

+ @ VALIDUS PHARMS	50MG	N020623	001	Sep 11,	1997	Feb CAHN
+ @	100MG	N020623	002	Sep 11,	1997	Feb CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATESOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	ALEMBIC PHARMS LTD	EQ 2% BASE;EQ 0.5% BASE	A213099	001	May 04,	2021	Apr NEWA
>A> AT	AUROBINDO PHARMA LTD	EQ 2% BASE;EQ 0.5% BASE	A207629	001	May 14,	2021	May NEWA
AT	FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13,	2019	Feb CMFD

DOXEPIN HYDROCHLORIDECAPSULE;ORAL  
DOXEPIH HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 10MG BASE	A215076	001	Apr 21,	2021	Apr NEWA
AB		EQ 25MG BASE	A215076	002	Apr 21,	2021	Apr NEWA
AB		EQ 50MG BASE	A215076	003	Apr 21,	2021	Apr NEWA
AB		EQ 75MG BASE	A215076	004	Apr 21,	2021	Apr NEWA
AB		EQ 100MG BASE	A215076	005	Apr 21,	2021	Apr NEWA
AB	APPCCO	EQ 10MG BASE	A214908	001	Apr 01,	2021	Mar NEWA
AB		EQ 25MG BASE	A214908	002	Apr 01,	2021	Mar NEWA
AB		EQ 50MG BASE	A214908	003	Apr 01,	2021	Mar NEWA
AB		EQ 75MG BASE	A214908	004	Apr 01,	2021	Mar NEWA
AB		EQ 100MG BASE	A214908	005	Apr 01,	2021	Mar NEWA
AB	LEADING PHARMA LLC	EQ 10MG BASE	A211619	001	Mar 09,	2021	Feb NEWA
AB		EQ 25MG BASE	A211619	002	Mar 09,	2021	Feb NEWA
AB		EQ 50MG BASE	A211619	003	Mar 09,	2021	Feb NEWA
AB		EQ 75MG BASE	A211619	004	Mar 09,	2021	Feb NEWA
AB		EQ 100MG BASE	A211619	005	Mar 09,	2021	Feb NEWA
AB		EQ 150MG BASE	A211618	001	Mar 01,	2021	Feb NEWA
>D>	@ UPSHER SMITH LABS	EQ 10MG BASE	A210268	001	Sep 04,	2020	May CAHN
>A>	@	EQ 10MG BASE	A210268	001	Sep 04,	2020	May CAHN
	@	EQ 10MG BASE	A210268	001	Sep 04,	2020	Feb DISC

**CAPSULE;ORAL**  
DOXEPIN HYDROCHLORIDE

>D>	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	May CAHN
>A>	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	May CAHN
	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	Feb DISC
>D>	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	May CAHN
>A>	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	May CAHN
	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	Feb DISC
>D>	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	May CAHN
>A>	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	May CAHN
	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	Feb DISC
>D>	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	May CAHN
>A>	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	May CAHN
	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	Feb DISC

**TABLET;ORAL**  
DOXEPIN HYDROCHLORIDE

	@ PAR PHARM INC	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan DISC
	@	EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan DISC
AB	RK PHARMA	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan CAHN
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan CAHN

**DOXYCYCLINE**

**CAPSULE;ORAL**  
DOXYCYCLINE

	@ MYLAN	EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan DISC
AB		EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan NEWA
	@	EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan DISC
AB		EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan NEWA
	@	EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan DISC
AB		EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan NEWA

**DOXYCYCLINE HYCLATE**

**CAPSULE, DELAYED RELEASE;ORAL**  
DOXYCYCLINE HYCLATE

>A>	@ BAUSCH	EQ 75MG BASE	A065281	001	Dec 21, 2005	May CAHN
>A>	@	EQ 100MG BASE	A065281	002	Dec 21, 2005	May CAHN
>D>	@ MEDICIS	EQ 75MG BASE	A065281	001	Dec 21, 2005	May CAHN
>D>	@	EQ 100MG BASE	A065281	002	Dec 21, 2005	May CAHN

**INJECTABLE;INJECTION**  
DOXYCYCLINE HYCLATE

>D>	@ WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989	May CMFD
>A> AP		EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989	May CMFD
>D>	@	EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989	May CMFD
>A> AP		EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989	May CMFD

**TABLET;ORAL**  
DOXYCYCLINE HYCLATE

	@ ORYZA	EQ 100MG BASE	A213475	001	Mar 10, 2021	Apr DISC
AB		EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb NEWA

**DROSPIRENONE; ESTETROL**

**TABLET;ORAL**  
NEXTSTELLIS

+!	MAYNE PHARMA	3MG;14.2MG	N214154	001	Apr 15, 2021	Apr NEWA
----	--------------	------------	---------	-----	--------------	----------

**DROXIDOPA**

**CAPSULE;ORAL**  
DROXIDOPA

AB	AJANTA PHARMA LTD	100MG	A214391	001	Feb 18, 2021	Feb NFTG
AB		200MG	A214391	002	Feb 18, 2021	Feb NFTG
AB		300MG	A214391	003	Feb 18, 2021	Feb NFTG
AB	ALKEM LABS LTD	100MG	A213911	001	Feb 18, 2021	Feb NFTG
AB		200MG	A213911	002	Feb 18, 2021	Feb NFTG
AB		300MG	A213911	003	Feb 18, 2021	Feb NFTG
AB	ANNORA	300MG	A211726	001	Feb 18, 2021	Feb NFTG
AB	AUROBINDO PHARMA LTD	100MG	A214387	001	Feb 18, 2021	Feb NFTG
AB		200MG	A214387	002	Feb 18, 2021	Feb NFTG
AB		300MG	A214387	003	Feb 18, 2021	Feb NFTG
>A> AB	BIONPHARMA INC	100MG	A213033	001	Apr 28, 2021	May CAHN
>A> AB		200MG	A213033	002	Apr 28, 2021	May CAHN
>A> AB		300MG	A213033	003	Apr 28, 2021	May CAHN
AB	HIKMA	100MG	A212835	001	Feb 18, 2021	Feb NFTG
AB		200MG	A212835	002	Feb 18, 2021	Feb NFTG

CAPSULE;ORAL  
DROXIDOPA

AB		300MG	A212835	003	Feb 18, 2021	Feb NFTG	
AB	LUPIN PHARMS	100MG	A211652	001	Feb 18, 2021	Feb NFTG	
AB		200MG	A211652	002	Feb 18, 2021	Feb NFTG	
AB		300MG	A211652	003	Feb 18, 2021	Feb NFTG	
AB	MSN PHARMS INC	100MG	A211741	001	Feb 18, 2021	Feb NFTG	
AB		200MG	A211741	002	Feb 18, 2021	Feb NFTG	
AB		300MG	A211741	003	Feb 18, 2021	Feb NFTG	
>D>	AB	MYLAN API	100MG	A213033	001	Apr 28, 2021	May CAHN
	AB		100MG	A213033	001	Apr 28, 2021	Apr NEWA
>D>	AB		200MG	A213033	002	Apr 28, 2021	May CAHN
	AB		200MG	A213033	002	Apr 28, 2021	Apr NEWA
>D>	AB		300MG	A213033	003	Apr 28, 2021	May CAHN
	AB		300MG	A213033	003	Apr 28, 2021	Apr NEWA
AB	SCIEGEN PHARMS INC	100MG	A214017	001	Feb 18, 2021	Feb NFTG	
AB		200MG	A214017	002	Feb 18, 2021	Feb NFTG	
AB		300MG	A214017	003	Feb 18, 2021	Feb NFTG	
AB	SUN PHARM	100MG	A214384	001	Feb 18, 2021	Feb NFTG	
AB		200MG	A214384	002	Feb 18, 2021	Feb NFTG	
AB		300MG	A214384	003	Feb 18, 2021	Feb NFTG	
AB	TASMAN PHARMA	100MG	A213661	001	Feb 18, 2021	Feb NFTG	
AB		200MG	A213661	002	Feb 18, 2021	Feb NFTG	
AB		300MG	A213661	003	Feb 18, 2021	Feb NFTG	
AB	TEVA PHARMS USA INC	100MG	A213162	001	Feb 18, 2021	Feb NFTG	
AB		200MG	A213162	002	Feb 18, 2021	Feb NFTG	
AB		300MG	A213162	003	Feb 18, 2021	Feb NFTG	
AB	ZYDUS PHARMS	100MG	A211818	001	Feb 18, 2021	Feb NFTG	
AB		200MG	A211818	002	Feb 18, 2021	Feb NFTG	
AB		300MG	A211818	003	Feb 18, 2021	Feb NFTG	

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL  
DRIZALMA SPRINKLE

+ SUN PHARMA GLOBAL	EQ 20MG BASE
+	EQ 30MG BASE
+	EQ 40MG BASE
+!	EQ 60MG BASE

N212516	001	Jul 19, 2019	Apr CDFR
N212516	002	Jul 19, 2019	Apr CDFR
N212516	003	Jul 19, 2019	Apr CDFR
N212516	004	Jul 19, 2019	Apr CDFR

## DULOXETINE HYDROCHLORIDE

AB SUNSHINE	EQ 20MG BASE
AB	EQ 30MG BASE
AB	EQ 60MG BASE

A212328	001	Feb 11, 2021	Feb NEWA
A212328	002	Feb 11, 2021	Feb NEWA
A212328	003	Feb 11, 2021	Feb NEWA

DUTASTERIDE

CAPSULE;ORAL  
DUTASTERIDE  
@ NOSTRUM LABS INC

0.5MG
-------

A204705	001	Nov 20, 2015	Apr CAHN
---------	-----	--------------	----------

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL  
ECOZA

+! RESILIA PHARMS	1%
-------------------	----

N205175	001	Oct 24, 2013	Feb CAHN
---------	-----	--------------	----------

EDETA TE CALCIUM DISODIUM

INJECTABLE;INJECTION  
CALCIUM DISODIUM VERSENATE

>A> +! BAUSCH	200MG/ML
>D> +! MEDICIS	200MG/ML
TABLET;ORAL	
CALCIUM DISODIUM VERSENATE	
>A> @ BAUSCH	500MG
>D> @ MEDICIS	500MG

N008922	001		May CAHN
N008922	001		May CAHN
N008922	002		May CAHN
N008922	002		May CAHN

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL  
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE  
+ @ AUROBINDO PHARMA LTD 600MG;300MG;300MG

N022343	001	Aug 15, 2018	Feb DISC
---------	-----	--------------	----------

EFINACONAZOLE

SOLUTION;TOPICAL

EFINACONAZOLE

AB	AUROBINDO PHARMA LTD	10%	A212066	001	Mar 29, 2021	Mar NEWA
	@ PERRIGO PHARMA INTL	10%	A211851	001	Dec 16, 2020	Jan DISC
AB	TEVA PHARMS USA	10%	A211827	001	Dec 16, 2020	Feb CTEC
	JUBLIA					

AB +! BAUSCH 10% N203567 001 Jun 06, 2014 Feb CTEC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	CIPLA	200MG;300MG	A090958	001	Apr 02, 2021	Mar NEWA
AB	LAURUS LABS LTD	200MG;300MG	A212114	001	Jul 26, 2019	Jan CMFD
>A> AB	LUPIN LTD	200MG;300MG	A204131	001	Jun 04, 2021	May NEWA
AB	MACLEODS PHARMS LTD	200MG;300MG	A203442	001	May 15, 2020	Feb CMFD
AB	MYLAN	200MG;300MG	A206436	001	Apr 09, 2018	Feb CMFD
AB	STRIDES PHARMA	200MG;300MG	A091055	001	Jan 13, 2021	Jan NEWA

ENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

&gt;A&gt; AB ACTAVIS LABS FL INC 40MG A209614 001 May 14, 2021 May NFTG

EPLERENONE

TABLET;ORAL

EPLERENONE

AB	CHARTWELL RX	25MG	A078482	001	Jul 30, 2008	Apr CAHN
AB		50MG	A078482	002	Jul 30, 2008	Apr CAHN
	@ PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020	Feb DISC
	@	50MG	A212765	002	Aug 10, 2020	Feb DISC
	INSPRA					
AB	+ UPJOHN	25MG	N021437	001	Sep 27, 2002	Apr CAHN
AB	+!	50MG	N021437	002	Sep 27, 2002	Apr CAHN
	@	100MG	N021437	003	Sep 27, 2002	Apr CAHN

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

EPOPROSTENOL SODIUM

AP2	SUN PHARM	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb CTEC
AP		EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Jan NFTG
AP2		EQ 1.5MG BASE/VIAL	A210473	002	Jan 15, 2021	Feb CTEC
AP		EQ 1.5MG BASE/VIAL	A210473	002	Jan 15, 2021	Jan NFTG
AP1	TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Feb CTEC
AP1		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Feb CTEC
	FOLAN					
AP1	+! GLAXOSMITHKLINE LLC	EQ 0.5MG BASE/VIAL	N020444	001	Sep 20, 1995	Feb CTEC
AP1	+!	EQ 1.5MG BASE/VIAL	N020444	002	Sep 20, 1995	Feb CTEC
	VELETRI					
AP2	+! ACTELION	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CAHN
AP2	+!	EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Feb CAHN
AP2	+! ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CHRS
AP2	+	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CTEC
AP2	+!	EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Feb CTEC

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP	! MYLAN LABS LTD	2MG/ML	A203258	001	Jul 20, 2018	Apr CHRS
AP	!	75MG/100ML	A203258	002	Jul 20, 2018	Apr CHRS
	INTEGRILIN					
	+ @ SCHERING	2MG/ML	N020718	001	May 18, 1998	Apr DISC
	+ @	75MG/100ML	N020718	002	May 18, 1998	Apr DISC

ERGOCALCIFEROL

CAPSULE;ORAL

DRISDOL

AA +! VALIDUS PHARMS 50,000 IU N003444 001 Feb CAHN

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

AB	MSN	EQ 25MG BASE	A214366	001	May 10, 2021	Apr NEWA
AB		EQ 100MG BASE	A214366	002	May 10, 2021	Apr NEWA
AB		EQ 150MG BASE	A214366	003	May 10, 2021	Apr NEWA

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP	GLAND PHARMA LTD	EQ 1GM BASE/VIAL	A212040	001	Mar 26, 2021	Mar NEWA
----	------------------	------------------	---------	-----	--------------	----------

ERYTHROMYCIN

SOLUTION;TOPICAL

ERYTHRA-DERM

AT	SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Apr CMFD
	TABLET;ORAL					
	ERYTHROMYCIN					
AB	TEVA PHARMS USA INC	250MG	A214549	001	Feb 11, 2021	Feb NEWA

AB		500MG	A214549	002	Feb 11, 2021	Feb NEWA
----	--	-------	---------	-----	--------------	----------

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

>D> AB	PAR PHARM INC	EQ 200MG BASE/5ML	A211991	001	Oct 23, 2019	May DISC
>A>	@	EQ 200MG BASE/5ML	A211991	001	Oct 23, 2019	May DISC
>D> AB		EQ 400MG BASE/5ML	A211991	002	Oct 23, 2019	May DISC
>A>	@	EQ 400MG BASE/5ML	A211991	002	Oct 23, 2019	May DISC

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELETS;ORAL

ESOMEPRAZOLE MAGNESIUM

>D> AB	AMTA	EQ 20MG BASE	A213859	001	Nov 18, 2020	May DISC
>A>	@	EQ 20MG BASE	A213859	001	Nov 18, 2020	May DISC
>D> AB		EQ 40MG BASE	A213859	002	Nov 18, 2020	May DISC
>A>	@	EQ 40MG BASE	A213859	002	Nov 18, 2020	May DISC
AB	ETHYPHARM	EQ 20MG BASE	A090841	001	Mar 31, 2021	Mar NEWA
AB		EQ 40MG BASE	A090841	002	Mar 31, 2021	Mar NEWA
AB	GRAVITI PHARMS	EQ 20MG BASE	A213486	001	Mar 19, 2021	Mar NEWA
AB		EQ 40MG BASE	A213486	002	Mar 19, 2021	Mar NEWA
AB	INDCHEMIE HEALTH	EQ 40MG BASE	A210559	002	Feb 26, 2021	Feb NEWA

ESTRADIOL

INSERT, EXTENDED RELEASE;VAGINAL

ESTRING

+! PFIZER 0.0075MG/24HR

N020472 001 Apr 26, 1996 Jan CAHN

ESTRADIOL CYTIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

@ PFIZER 1MG/ML

A085470 001

Mar CAHN

@ 3MG/ML

A085470 002

Mar CAHN

! 5MG/ML

A085470 003

Mar CAHN

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

>A>	TABLET;ORAL					
>A>	MYFEMBREE					
>A>	+! MYOVANT SCIENCES	1MG;0.5MG;40MG	N214846	001	May 26, 2021	May NEWA

ESTROPIRATE

TABLET;ORAL

OGEN .625

@ PFIZER 0.75MG

A083220 001

Jan CAHN

OGEN 1.25

@ PFIZER 1.5MG

A083220 002

Jan CAHN

OGEN 2.5

@ PFIZER 3MG

A083220 003

Jan CAHN

OGEN 5

PFIZER 6MG

A083220 004

Jan CAHN

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

@	NOSTRUM LABS INC	1MG
@		2MG
@		3MG

A203087	001	May 08, 2019	Jan CAHN
A203087	002	May 08, 2019	Jan CAHN
A203087	003	May 08, 2019	Jan CAHN

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

ETHINYL ESTRADIOL; ETONOGESTREL

AB TEVA PHARMS USA INC 0.015MG/24HR;0.12MG/24HR

A204305 001 Jan 13, 2021 Jan NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN

AB AMNEAL 0.035MG/24HR;0.15MG/24HR  
XULANE

A213950 001 Feb 25, 2021 Feb NEWA

AB ! MYLAN TECHNOLOGIES 0.035MG/24HR;0.15MG/24HR

A200910 001 Apr 16, 2014 Feb CTEC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

GEMMILY

AB XIROMED 0.02MG;1MG

A213317 001 Nov 09, 2020 Mar CAHN

EVEROLIMUS

TABLET;ORAL

AFINITOR

AB	+	NOVARTIS	10MG	
		EVEROLIMUS		N022334
	@	BIOCON PHARMA	2.5MG	A214182
AB			2.5MG	A214182
	@		5MG	A214182
AB			5MG	A214182
	@		7.5MG	A214182
AB			7.5MG	A214182
	@		10MG	A214182
AB			10MG	A214182
>A>	AB	BRECKENRIDGE	0.25MG	A205432
>A>	AB		0.5MG	A205432
>A>	AB		0.75MG	A205432
AB			2.5MG	A205426
AB			5MG	A205426
AB			7.5MG	A205426
AB			10MG	A205426

	002	Mar 30, 2009	Feb CTEC
	001	Feb 11, 2021	Feb DISC
	001	Feb 11, 2021	Feb NEWA
	002	Feb 11, 2021	Feb DISC
	002	Feb 11, 2021	Feb NEWA
	003	Feb 11, 2021	Feb DISC
	003	Feb 11, 2021	Feb NEWA
	004	Feb 11, 2021	Feb DISC
	004	Feb 11, 2021	Feb NEWA
	001	May 20, 2021	May NEWA
	002	May 20, 2021	May NEWA
	003	May 20, 2021	May NEWA
	001	Mar 05, 2021	Feb NEWA
	002	Mar 05, 2021	Feb NEWA
	003	Mar 05, 2021	Feb NEWA
	004	Mar 05, 2021	Feb NEWA

EXEMESTANE

TABLET;ORAL

AROMASIN

AB +! PFIZER 25MG

N020753 001 Oct 21, 1999 Mar CAHN

EXENATIDE SYNTHETICFOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS  
BYDUREON

+ @	ASTRAZENECA AB	2MG/VIAL	
	BYDUREON PEN		N022200
+ @	ASTRAZENECA AB	2MG	N022200

001	Jan 27, 2012	Feb DISC
002	Feb 28, 2014	Feb DISC

EZETIMIBI

TABLET;ORAL

ZETIA

AB +! ORGANON 10MG

N021445 001 Oct 25, 2002 Feb CAHN

EZETIMIBI; ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSZET

+	ALTHERA PHARMS	10MG;EQ 5MG BASE	
+		10MG;EQ 5MG BASE	N213072
+		10MG;EQ 10MG BASE	N213072
+		10MG;EQ 10MG BASE	N213072
+		10MG;EQ 20MG BASE	N213072
+		10MG;EQ 20MG BASE	N213072

001	Mar 23, 2021	Mar NEWA
001	Mar 23, 2021	Mar NEWA
002	Mar 23, 2021	Mar NEWA
002	Mar 23, 2021	Mar NEWA
003	Mar 23, 2021	Mar NEWA
003	Mar 23, 2021	Mar NEWA

TABLET;ORAL  
ROSZET

+!	10MG;EQ 40MG BASE	N 213072 004 Mar 23, 2021	Mar NEWA
+!	10MG;EQ 40MG BASE	N 213072 004 Mar 23, 2021	Mar NEWA

EZETIMIBE; SIMVASTATIN

## TABLET;ORAL

## EZETIMIBE AND SIMVASTATIN

@ MYLAN	10MG;10MG	A 200082 001 Dec 17, 2020	Jan DISC
@	10MG;20MG	A 200082 002 Dec 17, 2020	Jan DISC
@	10MG;40MG	A 200082 003 Dec 17, 2020	Jan DISC
@	10MG;80MG	A 200082 004 Dec 17, 2020	Jan DISC
VYTORIN			
AB + ORGANON	10MG;10MG	N 021687 001 Jul 23, 2004	Feb CAHN
AB +	10MG;20MG	N 021687 002 Jul 23, 2004	Feb CAHN
AB +	10MG;40MG	N 021687 003 Jul 23, 2004	Feb CAHN
AB +!	10MG;80MG	N 021687 004 Jul 23, 2004	Feb CAHN

FAMOTIDINE

## FOR SUSPENSION;ORAL

## FAMOTIDINE

AB AKORN	40MG/5ML	A 201995 001 May 30, 2014	Feb CAHN
AB NOVITIUM PHARMA	40MG/5ML	A 215043 001 Apr 20, 2021	Apr NEWA

FENOFIBRATE

## TABLET;ORAL

## FENOFIBRATE

AB AUSTARPHARMA	48MG	A 208476 001 Feb 10, 2021	Jan NEWA
AB	145MG	A 208476 002 Feb 10, 2021	Jan NEWA

FENOPROFEN CALCIUM

## CAPSULE;ORAL

## FENOPROFEN CALCIUM

@ RISING	EQ 200MG BASE	A 072394 001 Oct 17, 1988	Jan CAHN
@	EQ 300MG BASE	A 072395 001 Oct 17, 1988	Jan CAHN

FENTANYL CITRATE

## INJECTABLE; INJECTION

## FENTANYL CITRATE

@ FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A 212086 001 Sep 01, 2020	Mar DISC
----------------------	-------------------	---------------------------	----------

FERRIC CARBOXYMALTPOSE

## SOLUTION; INTRAVENOUS

## INJECTAFER

>A> +! AM REGENT	1GM IRON/20ML (50MG IRON/ML)	N 203565 003 Apr 28, 2021	May NEWA
------------------	------------------------------	---------------------------	----------

FERRIC MALTOL

## CAPSULE;ORAL

## ACCRUFER

+! SHIELD TX	30MG IRON	N 212320 001 Jul 25, 2019	Apr CMFD
--------------	-----------	---------------------------	----------

>A> FERRIC OXYHYDROXIDE

&gt;A&gt; INJECTABLE; INJECTION

## DEXFERRUM

>A> @ AM REGENT	EQ 50MG IRON/ML	N 040024 001 Feb 23, 1996	May CAIN
FERRLECIT			

>A> AB +! SANOFI AVENTIS US	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	N 020955 001 Feb 18, 1999	May CPOT
-----------------------------	--	---------------------------	----------

&gt;A&gt; INFED

>A> BP +! ALLERGAN	EQ 50MG IRON/ML	N 017441 001	May CAIN
--------------------	-----------------	--------------	----------

&gt;A&gt; IRON DEXTRAN

>A> @ SANOFI AVENTIS US	EQ 50MG IRON/ML	N 010787 002	May CAIN
-------------------------	-----------------	--------------	----------

&gt;A&gt; PROFERDEX

>A> @ NEW RIVER	EQ 50MG IRON/ML	N 017807 001	May CAIN
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE			

>A> AB WEST-WARD PHARMS INT	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	A 078215 001 Mar 31, 2011	May CPOT
-----------------------------	--	---------------------------	----------

## INJECTABLE; INTRAVENOUS

## VENOFER

>A> + AM REGENT	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	N 021135 002 Mar 20, 2005	May CPOT
-----------------	--------------------------------------	---------------------------	----------

>A> @	EQ 65MG IRON/3.25ML (EQ 20MG	N 021135 005 Mar 29, 2013	May CPOT
-------	------------------------------	---------------------------	----------

**INJECTABLE; INTRAVENOUS**  
**VENOFER**

>A>	@	IRON/ML)	EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)	N 021135	003	Mar 29, 2005	May CPOT
>A>	+!	IRON/ML)	EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	N 021135	001	Nov 06, 2000	May CPOT
>A>	+	IRON/ML)	EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	N 021135	004	Feb 09, 2007	May CPOT
		TABLET, CHEWABLE; ORAL					
		VELPHORO					
>A>	+! VIFOR FRESENIUS	IRON	EQ 500MG IRON	N 205109	001	Nov 27, 2013	May CPOT

**FERUMOXYTOL**

SOLUTION; INTRAVENOUS  
FERAHEME

AB	+! COVIS	IRON/ML)	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N 022180	001	Jun 30, 2009	Mar CAHN
AB	SANDOZ INC	IRON/ML)	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	A 206604	001	Jan 15, 2021	Jan NFTG

**FINASTERIDE**

TABLET; ORAL  
FINASTERIDE

>D> AB	ACTAVIS TOTOWA TEVA	5MG	A 077914	001	Mar 28, 2007	May DISC
>A>	@	5MG	A 077914	001	Mar 28, 2007	May DISC

**FINGOLIMOD HYDROCHLORIDE**

CAPSULE; ORAL  
FINGOLIMOD HYDROCHLORIDE

AB	DR REDDYS	BASE	EQ 0.5MG BASE	A 208000	001	Mar 05, 2021	Feb NEWA
	@ MYLAN	BASE	EQ 0.5MG BASE	A 208005	001	Jan 19, 2021	Jan DISC
AB		BASE	EQ 0.5MG BASE	A 208005	001	Jan 19, 2021	Jan NEWA
	@ ZYDUS PHARMS	BASE	EQ 0.5MG BASE	A 207994	001	Oct 14, 2020	Mar DISC

**FLECAINIDE ACETATE**

TABLET; ORAL  
TAMBOCOR

+ @	CNTY LINE PHARMS	50MG	N 018830	004	Aug 23, 1988	Jan DISC
+ @		100MG	N 018830	001	Oct 31, 1985	Jan DISC
+ @		150MG	N 018830	003	Jun 03, 1988	Jan DISC

**FLUDEOXYGLUCOSE F-18**

INJECTABLE; INTRAVENOUS  
FLUDEOXYGLUCOSE F18

AP	CARDINAL HEALTH 414	20-500mCi/ML	A 203603	002	Sep 27, 2018	Mar NEWA
	NUKEMED	4-500mCi/ML	A 203911	001	Apr 22, 2015	Jan CAHN
AP	PHARMALOGIC HLDGS	20-200mCi/ML	A 203664	001	Feb 04, 2014	Jan CAHN
AP	PRECISION NUCLEAR	20-500mCi/ML	A 204546	001	Apr 07, 2015	Mar CTEC

**FLUMAZENIL**

INJECTABLE; INJECTION  
FLUMAZENIL

AP	BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A 076755	002	Oct 12, 2004	Mar CMFD
AP		1MG/10ML (0.1MG/ML)	A 076755	001	Oct 12, 2004	Mar CMFD

**FLUOCINOLONE ACETONIDE**

OIL; TOPICAL  
FLUOCINOLONE ACETONIDE

AT	SOLARIS PHARMA CORP	0.01%	A 212760	001	Apr 02, 2021	Mar NEWA
AT		0.01%	A 212761	001	Apr 02, 2021	Mar NEWA
		OIL/DROPS; OTIC				
		FLUOCINOLONE ACETONIDE				
AT	SOLARIS PHARMA CORP	0.01%	A 212762	001	Apr 02, 2021	Mar NEWA
AT	TASMAN PHARMA	0.01%	A 213264	001	Feb 05, 2021	Jan NEWA

FLUOCINONIDE

CREAM;TOPICAL  
VANOS

>A> AB	+! BAUSCH	0.1%	N 021758	001	Feb 11, 2005	May CAHN
>D> AB	+! MEDICIS	0.1%	N 021758	001	Feb 11, 2005	May CAHN

FLUOROURACIL

INJECTABLE;INJECTION  
FLUOROURACIL

>D> AP	! FRESENIUS KABI USA	500MG/10ML (50MG/ML)	A 040279	002	Sep 30, 1998	May CHRS
>A> AP		500MG/10ML (50MG/ML)	A 040279	002	Sep 30, 1998	May CHRS
>D> AP	!	1GM/20ML (50MG/ML)	A 040279	001	Sep 30, 1998	May CHRS
>A> AP		1GM/20ML (50MG/ML)	A 040279	001	Sep 30, 1998	May CHRS
>D> AP	!	2.5GM/50ML (50MG/ML)	A 040278	001	Sep 30, 1998	May CHRS
>A> AP		2.5GM/50ML (50MG/ML)	A 040278	001	Sep 30, 1998	May CHRS
>D> AP	!	5GM/100ML (50MG/ML)	A 040278	002	Sep 30, 1998	May CHRS
>A> AP		5GM/100ML (50MG/ML)	A 040278	002	Sep 30, 1998	May CHRS
	@ NOVAST LABS	5GM/100ML (50MG/ML)	A 209271	001	Dec 11, 2019	Mar CPOT
>D> AP	! TEVA PHARMS USA	500MG/10ML (50MG/ML)	A 040333	001	Jan 27, 2000	May CHRS
>A> AP		500MG/10ML (50MG/ML)	A 040333	001	Jan 27, 2000	May CHRS

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

@ ACCORD HLTHCARE	EQ 10MG BASE	A 202729	001	Aug 27, 2020	Feb DISC
@	EQ 20MG BASE	A 202729	002	Aug 27, 2020	Feb DISC
@	EQ 40MG BASE	A 202729	003	Aug 27, 2020	Feb DISC

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

TORRENT	EQ 10MG BASE	A 206937	001	Oct 21, 2016	Mar CHRS	
!	EQ 20MG BASE	A 206937	002	Oct 21, 2016	Mar CHRS	
>D> AB	UPSHER SMITH LABS	EQ 10MG BASE	A 211696	001	Jan 30, 2019	May CAHN
>A> AB		EQ 10MG BASE	A 211696	001	Jan 30, 2019	May CAHN
>D> AB		EQ 20MG BASE	A 211696	002	Jan 30, 2019	May CAHN
>A> AB		EQ 20MG BASE	A 211696	002	Jan 30, 2019	May CAHN
	SARAFEM					
+ @ APIL		EQ 10MG BASE	N 021860	001	May 19, 2006	Mar DISC
+ @		EQ 20MG BASE	N 021860	003	May 19, 2006	Mar DISC

FLUOXYMESTERONE

TABLET;ORAL

FLUOXYMESTERONE

@ UPSHER SMITH LABS	10MG	A 088342	001	Oct 21, 1983	Jan DISC
---------------------	------	----------	-----	--------------	----------

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	CEROVENE INC	1MG	A 214534	001	Jan 07, 2021	Jan NEWA
AB		2.5MG	A 214534	002	Jan 07, 2021	Jan NEWA
AB		5MG	A 214534	003	Jan 07, 2021	Jan NEWA
AB		10MG	A 214534	004	Jan 07, 2021	Jan NEWA
AB	NOVITIUM PHARMA	1MG	A 214674	001	Mar 01, 2021	Feb NEWA
AB		2.5MG	A 214674	002	Mar 01, 2021	Feb NEWA
AB		5MG	A 214674	003	Mar 01, 2021	Feb NEWA
AB		10MG	A 214674	004	Mar 01, 2021	Feb NEWA
>A> AB	ZYDUS	1MG	A 214552	001	May 27, 2021	May NEWA
>A> AB		2.5MG	A 214552	002	May 27, 2021	May NEWA
>A> AB		5MG	A 214552	003	May 27, 2021	May NEWA
>A> AB		10MG	A 214552	004	May 27, 2021	May NEWA

FLURBIPROFEN SODIUM

SOLUTION/DROPS;OPHTHALMIC

FLURBIPROFEN SODIUM

!	BAUSCH AND LOMB	0.03%	A 074447	001	Jan 04, 1995	Jan CHRS
		0.03%	A 074447	001	Jan 04, 1995	Jan CTEC
	OCUFEN					
+ @	ALLERGAN	0.03%	N 019404	001	Dec 31, 1986	Jan DISC

FLUTAMIDE

CAPSULE;ORAL						
FLUTAMIDE						
@ CIPLA	125MG		A075780	001	Sep 19, 2001	Mar DISC
! PAR PHARM	125MG		A075298	001	Sep 18, 2001	Mar CHRS
	125MG		A075298	001	Sep 18, 2001	Mar CTEC

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL						
FLUVASTATIN SODIUM						
AB BEIJING	EQ 80MG BASE		A209397	001	Apr 26, 2021	Apr NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL						
FLUVOXAMINE MALEATE						
@ BIONPHARMA INC	100MG		A212182	002	Sep 16, 2020	Feb DISC

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS						
FOSAPREPITANT DIMEGLUMINE						
AP AUROBINDO PHARMA LTD	EQ 150MG BASE/VIAL		A210625	001	Jan 12, 2021	Jan NEWA
@ MYLAN LABS LTD	EQ 115MG BASE/VIAL		A204015	001	Sep 05, 2019	Mar DISC

FOSCARNET SODIUM

INJECTABLE;INJECTION						
FOSCARNET SODIUM						
AP FRESENIUS KABI USA	2.4GM/100ML		A212483	001	Jan 29, 2021	Jan NEWA
AP GLAND PHARMA LTD	2.4GM/100ML		A213001	001	Apr 21, 2021	Apr NEWA
FOSCAVIR						
AP +! CLINIGEN HLTHCARE	2.4GM/100ML		N020068	001	Sep 27, 1991	Jan CTEC

FOSDENOPTERIN HYDROBROMIDE

POWDER;INTRAVENOUS						
NULIBRY						
+! ORIGIN	EQ 9.5MG BASE/VIAL		N214018	001	Feb 26, 2021	Feb NEWA

FULVESTRANT

INJECTABLE;INTRAMUSCULAR						
FULVESTRANT						
AO AUROMEDICS PHARMA	50MG/ML		A208811	001	Jul 23, 2019	Jan CAHN

FUROSEMIDE

INJECTABLE;INJECTION						
FUROSEMIDE						
AP ACCORD HLTHCARE	10MG/ML		A070017	001	Dec 15, 1986	Apr CMFD
AP ATHENEX INC	10MG/ML		A214766	001	Jan 27, 2021	Jan NEWA
TABLET;ORAL						
LASIX						
AB + VALIDUS PHARMS	20MG		N016273	002		Feb CAHN
AB +	40MG		N016273	001		Feb CAHN
AB +!	80MG		N016273	003		Feb CAHN

GABAPENTIN

CAPSULE;ORAL						
GABAPENTIN						
AB ASCENT PHARMS INC	100MG		A214956	001	May 10, 2021	Apr NEWA
AB	300MG		A214956	002	May 10, 2021	Apr NEWA
AB	400MG		A214956	003	May 10, 2021	Apr NEWA
AB ZHEJIANG YONGTAI	100MG		A213603	001	Aug 17, 2020	Apr CMFD
@	100MG		A213603	001	Aug 17, 2020	Feb DISC
AB	300MG		A213603	002	Aug 17, 2020	Apr CMFD
@	300MG		A213603	002	Aug 17, 2020	Feb DISC
AB	400MG		A213603	003	Aug 17, 2020	Apr CMFD
@	400MG		A213603	003	Aug 17, 2020	Feb DISC

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

>D>	AB	YABAQ PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	May CHRS	
>A>	AB	!	EQ 4MG BASE	A077604	001	Feb 06, 2009	May CHRS	
		RAZADYNE						
>D>	AB	+!	JANSSEN PHARMS	EQ 4MG BASE	N021169	001	Feb 28, 2001	May DISC
>A>		+ @		EQ 4MG BASE	N021169	001	Feb 28, 2001	May DISC
>D>	AB	+		EQ 8MG BASE	N021169	002	Feb 28, 2001	May DISC
>A>		+ @		EQ 8MG BASE	N021169	002	Feb 28, 2001	May DISC
>D>	AB	+		EQ 12MG BASE	N021169	003	Feb 28, 2001	May DISC
>A>		+ @		EQ 12MG BASE	N021169	003	Feb 28, 2001	May DISC

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

AT		AKORN	0.5%	A203189	001	Sep 03, 2014	Feb CAHN
----	--	-------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP	!	JIANGSU HANSOH PHARM	EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Feb CHRS
AP	!		EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Feb CHRS
AP		MEITHEAL	200MG/5.26ML (38MG/ML)	A212129	001	Dec 11, 2020	Jan CAHN
AP			1GM/26.3ML (38MG/ML)	A212129	002	Dec 11, 2020	Jan CAHN
AP			2GM/52.6ML (38MG/ML)	A212129	003	Dec 11, 2020	Jan CAHN
		GEMZAR					
	+ @	LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Feb DISC
	+ @		EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Feb DISC

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB		ASCENT PHARMS INC	600MG	A214603	001	Jan 13, 2021	Jan NEWA
----	--	-------------------	-------	---------	-----	--------------	----------

GLYBURIDE

TABLET;ORAL

GLYNASE

AB	+	Pfizer	1.5MG	N020051	001	Mar 04, 1992	Feb CAHN
AB	+		3MG	N020051	002	Mar 04, 1992	Feb CAHN
	+ @		4.5MG	N020051	003	Sep 24, 1993	Feb CAHN
AB	+ !		6MG	N020051	004	Sep 24, 1993	Feb CAHN
		MICRONASE					
	+ @	Pfizer	1.25MG	N017498	001	May 01, 1984	Feb CAHN
	@		2.5MG	N017498	002	May 01, 1984	Feb CAHN
	+ @		5MG	N017498	003	May 01, 1984	Feb CAHN

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

AP		ATHENEX INC	0.2MG/ML	A210083	001	Feb 21, 2020	Jan CAHN
AP		XIROMED	0.2MG/ML	A212227	001	Mar 04, 2021	Feb NEWA

GLYCOPYRRONIUM TOSYLATE

CLOTH;TOPICAL

QBREXZA

>D>		+! DERMIRA INC	EQ 2.4% BASE	N210361	001	Jun 28, 2018	May CAHN
>A>		+! JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018	May CAHN

GRANISETRON HYDROCHLORIDE

SOLUTION;ORAL

GRANISOL

@ INTRA SANA LABS

EQ 2MG BASE/10ML

A078334 001 Feb 28, 2008 Jan CAHN

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB	!	AMNEAL PHARM	EQ 2MG BASE	A075109	002	Nov 25, 1998	Jan CHRS
	@	MYLAN	EQ 1MG BASE	A074796	001	Jan 27, 1997	Jan DISC
	@		EQ 2MG BASE	A074796	002	Jan 27, 1997	Jan DISC
AB		UNICHEM	EQ 1MG BASE	A214689	001	Mar 03, 2021	Feb NEWA

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB		EQ 2MG BASE	A214689	002	Mar 03, 2021	Feb NEWA	
<u>TABLET, EXTENDED RELEASE;ORAL</u>							
		GUANFACINE HYDROCHLORIDE					
>D>	AB	YICHANG HUMANWELL	EQ 1MG BASE	A213428	001	Nov 25, 2020	May DISC
>A>	@		EQ 1MG BASE	A213428	001	Nov 25, 2020	May DISC
>D>	AB		EQ 2MG BASE	A213428	002	Nov 25, 2020	May DISC
>A>	@		EQ 2MG BASE	A213428	002	Nov 25, 2020	May DISC
>D>	AB		EQ 3MG BASE	A213428	003	Nov 25, 2020	May DISC
>A>	@		EQ 3MG BASE	A213428	003	Nov 25, 2020	May DISC
>D>	AB		EQ 4MG BASE	A213428	004	Nov 25, 2020	May DISC
>A>	@		EQ 4MG BASE	A213428	004	Nov 25, 2020	May DISC

HALCINONIDE

SOLUTION;TOPICAL

HALOG

+! SUN PHARM IND'S INC 0.1%

N017823 001 Apr CRLD

HALOBETASOL PROPIONATE

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

	@ COSETTE	0.05%	A077721	001	Sep 07, 2006	Mar DISC
AB	! PERRIGO ISRAEL	0.05%	A076872	001	Dec 16, 2004	Mar CHRS
	ULTRAVATE					
+ @	SUN PHARM IND'S INC	0.05%	N019968	001	Dec 17, 1990	Mar DISC

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB	CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Apr CMFD
AB		5MG	A071131	001	Feb 17, 1987	Apr CMFD
AB		10MG	A071132	001	May 12, 1987	Apr CMFD

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALDOL

+ @ ORTHO MCNEIL EQ 2MG BASE/ML

N015922 001 Mar CRLD

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	200 UNITS/100ML	A212441	001	Jul 24, 2020	Apr CMFD
	@	200 UNITS/100ML	A212441	001	Jul 24, 2020	Jan DISC
<u>HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
AP	FRESENIUS KABI USA	200 UNITS/100ML	A212441	002	Jul 24, 2020	Apr CMFD
	@	200 UNITS/100ML	A212441	002	Jul 24, 2020	Jan DISC
<u>HEPARIN SODIUM PRESERVATIVE FREE</u>						
	@ SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014	Apr DISC

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

>D>	AA	UPSHER SMITH LABS	10MG	A209251	001	Jul 09, 2018	May CAHN
>A>	AA		10MG	A209251	001	Jul 09, 2018	May CAHN
>D>	AA		25MG	A209251	002	Jul 09, 2018	May CAHN
>A>	AA		25MG	A209251	002	Jul 09, 2018	May CAHN
>D>	AA		50MG	A209251	003	Jul 09, 2018	May CAHN
>A>	AA		50MG	A209251	003	Jul 09, 2018	May CAHN
>D>	AA		100MG	A209251	004	Jul 09, 2018	May CAHN
>A>	AA		100MG	A209251	004	Jul 09, 2018	May CAHN

HYDROCHLORTHIAZIDE

CAPSULE;ORAL

MICROZIDE

AB	+! TEVA BRANDED PHARM	12.5MG	N020504	001	Dec 27, 1996	Mar CAHN
----	-----------------------	--------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL  
ZESTORETIC

AB + ALMATICHA	12.5MG;10MG	N 019888	003	Nov 18, 1993	Jan CAHN
AB +!	12.5MG;20MG	N 019888	001	Sep 20, 1990	Jan CAHN
AB +!	25MG;20MG	N 019888	002	Jul 20, 1989	Jan CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL  
LOPRESSOR HCT

AB + VALIDUS PHARMS	25MG;50MG	N 018303	001	Dec 31, 1984	Feb CAHN
+ @	25MG;100MG	N 018303	002	Dec 31, 1984	Feb CAHN
+ @	50MG;100MG	N 018303	003	Dec 31, 1984	Feb CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL  
ZOHYDRO ER

>D> AB +! PERSION	10MG	N 202880	001	Oct 25, 2013	May CAHN
>D> AB +	15MG	N 202880	002	Oct 25, 2013	May CAHN
>D> AB +	20MG	N 202880	003	Oct 25, 2013	May CAHN
>D> AB +	30MG	N 202880	004	Oct 25, 2013	May CAHN
>D> AB +	40MG	N 202880	005	Oct 25, 2013	May CAHN
>D> AB +	50MG	N 202880	006	Oct 25, 2013	May CAHN
>A> AB +! RECRO GAINESVILLE	10MG	N 202880	001	Oct 25, 2013	May CAHN
>A> AB +	15MG	N 202880	002	Oct 25, 2013	May CAHN
>A> AB +	20MG	N 202880	003	Oct 25, 2013	May CAHN
>A> AB +	30MG	N 202880	004	Oct 25, 2013	May CAHN
>A> AB +	40MG	N 202880	005	Oct 25, 2013	May CAHN
>A> AB +	50MG	N 202880	006	Oct 25, 2013	May CAHN

TABLET, EXTENDED RELEASE;ORAL  
HYDROCODONE BITARTRATE

AB ALVOGEN PINE BROOK	20MG	A 208269	001	Mar 01, 2021	Feb NFTG
	30MG	A 208269	002	Mar 01, 2021	Feb NFTG
AB	40MG	A 208269	003	Mar 01, 2021	Feb NFTG
AB	60MG	A 208269	004	Mar 01, 2021	Feb NFTG
AB	80MG	A 208269	005	Mar 01, 2021	Feb NFTG
AB	100MG	A 208269	006	Mar 01, 2021	Feb NFTG
AB	120MG	A 208269	007	Mar 01, 2021	Feb NFTG

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL  
HYDROCODONE BITARTRATE AND IBUPROFEN

AB NOSTRUM LABS INC	5MG;200MG	A 077727	001	Nov 06, 2006	Jan CAHN
AB	7.5MG;200MG	A 077723	001	Nov 06, 2006	Jan CAHN
	10MG;200MG	A 077723	002	Nov 06, 2006	Mar CTEC
AB	10MG;200MG	A 077723	002	Nov 06, 2006	Jan CAHN
REPREXAIN					
>A> @ AMNEAL PHARMS NY	2.5MG;200MG	A 076642	003	Oct 19, 2007	Mar DISC
@	10MG;200MG	A 076642	004	Oct 19, 2007	Mar DISC

HYDROCORTISONE

CREAM;TOPICAL  
SYNACORT

>A> @ BAUSCH	0.5%	A 087459	001		May CAHN
>A> @	1%	A 087458	001		May CAHN
>A> @	2.5%	A 087457	001		May CAHN
>D> @ MEDICIS	0.5%	A 087459	001		May CAHN
>D> @	1%	A 087458	001		May CAHN
>D> @	2.5%	A 087457	001		May CAHN
ENEMA;RECTAL COLOCORT					
AB CHARTWELL	100MG/60ML	A 075172	001	Dec 03, 1999	Apr CAHN

HYDROCORTISONE PROBUTATE

CREAM;TOPICAL  
PANDEL

+! ANI PHARMS	0.1%	N 020453	001	Feb 28, 1997	Apr CAHN
---------------	------	----------	-----	--------------	----------

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

+ @ MERCK

EQ 50MG BASE/ML

N012052 001

Feb CRLD

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB COSETTE 0.2%

A213724 001 Feb 11, 2021 Feb NEWA

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ LANNETT CO INC 2MG  
@ 4MG  
@ 8MGA077471 002 Dec 09, 2009 Mar DISC  
A077471 003 Dec 09, 2009 Mar DISC  
A077471 001 Dec 09, 2009 Mar DISCHYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

AP1 +! COVIS 1250MG/5ML (250MG/ML)  
MAKENA PRESERVATIVE FREE

N021945 001 Feb 03, 2011 Mar CAHN

AP +! COVIS 250MG/ML (250MG/ML)  
SOLUTION; SUBCUTANEOUS  
MAKENA (AUTOINJECTOR)  
+! COVIS 275MG/1.1ML (250MG/ML)

N021945 002 Feb 19, 2016 Mar CAHN

N021945 004 Feb 14, 2018 Mar CAHN

HYDROXYUREA

TABLET; ORAL

SIKLOS

+! ADDMEDICA SAS 1GM

N208843 002 Dec 21, 2017 Mar CHRS

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB PRINSTON INC 10MG  
AB 25MG

A040580 003 May 27, 2005 Feb CMS1

A040580 002 May 27, 2005 Feb CMS1

IBRUTINIB

CAPSULE; ORAL

IBRUTINIB

AB ZYDUS 70MG  
AB 140MG

A211344 001 Mar 31, 2021 Mar NFTG

A211344 002 Mar 31, 2021 Mar NFTG

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB VINTAGE PHARMS 400MG

A071644 001 Feb 01, 1988 Feb DISC

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT

AP +! PFIZER 0.1MG/ML

N020491 001 Dec 28, 1995 Feb CAHN

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

ICATIBANT ACETATE

>D> AP DR REDDYS EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A213054 001 Oct 05, 2020 May DISC  
>A> @ EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A213054 001 Oct 05, 2020 May DISC  
>A> AP GLENMARK PHARMS LTD EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A213222 001 May 21, 2021 May NEWAICOSAPENT ETHYL

CAPSULE; ORAL

ICOSAPENT ETHYL

AB TEVA PHARMS USA 500MG

A209525 001 Sep 11, 2020 Mar DISC

AB 1GM

A209525 002 Sep 11, 2020 Mar DISC

VASCEPA

+ AMARIN PHARMS 500MG

N202057 002 Feb 16, 2017 Mar CTEC

ILIOPROST

SOLUTION; INHALATION

VENTAVIS

+! ACTELION

@

+!

10MCG/ML (10MCG/ML)

20MCG/2ML (10MCG/ML)

20MCG/ML (20MCG/ML)

N021779 002 Dec 08, 2005 Feb CAHN

N021779 001 Dec 29, 2004 Feb CAHN

N021779 003 Aug 07, 2009 Feb CAHN

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB TARO 3.75%

A205971 001 Jan 26, 2021 Jan NFTG

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

@ JUBILANT GENERICS

@

TIVORBEX

+ @ GENUS

+ @

25MG

50MG

20MG

40MG

A205215 001 Aug 25, 2017 Jan DISC

A205215 002 Aug 25, 2017 Jan DISC

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

@ AUROBINDO PHARMA LTD

75MG

A204243 001 Dec 27, 2016 Jan DISC

INFIGRATINIB PHOSPHATE

CAPSULE; ORAL

TRUSELTIQ

&gt;A&gt; + QED THERAP

&gt;A&gt; +!

25MG

100MG

N214622 001 May 28, 2021 May NEWA

N214622 002 May 28, 2021 May NEWA

TOPAMIDOL

INJECTABLE; INJECTION

ISOVUE-300

+! BRACCO

ISOVUE-370

+! BRACCO

SCANLUX-300

@ SANOCHEMIA CORP USA

SCANLUX-370

@ SANOCHEMIA CORP USA

61%

76%

61%

76%

N018735 002 Dec 31, 1985 Jan CTEC

N018735 003 Dec 31, 1985 Jan CTEC

A090394 001 Jun 18, 2010 Jan DISC

A090394 002 Jun 18, 2010 Jan DISC

IRBESARTAN

TABLET; ORAL

IRBESARTAN

&gt;D&gt; @ NEOPHARMA

&gt;D&gt; @

&gt;D&gt; @ 300MG

75MG

150MG

75MG

A203161 001 Sep 27, 2012 May CAHN

A203161 002 Sep 27, 2012 May CAHN

A203161 003 Sep 27, 2012 May CAHN

&gt;A&gt; @ US ANTIBIOTICS

&gt;A&gt; @

&gt;A&gt; @ 150MG

150MG

A203161 001 Sep 27, 2012 May CAHN

A203161 002 Sep 27, 2012 May CAHN

A203161 003 Sep 27, 2012 May CAHN

&gt;D&gt; @

300MG

A203161 001 Sep 27, 2012 May CAHN

A203161 002 Sep 27, 2012 May CAHN

A203161 003 Sep 27, 2012 May CAHN

&gt;D&gt; @ NEOPHARMA

&gt;D&gt; @

&gt;D&gt; @ 100MG/5ML (20MG/ML)

A200771 001 Feb 14, 2012 Mar DISC

A200771 002 Feb 14, 2012 Mar DISC

&gt;D&gt; @ 40MG/2ML (20MG/ML)

A078953 001 Apr 15, 2010 May CAHN

&gt;D&gt; @ 100MG/5ML (20MG/ML)

A078953 002 Apr 15, 2010 May CAHN

&gt;A&gt; @ US ANTIBIOTICS

&gt;A&gt; @

&gt;A&gt; @ 40MG/2ML (20MG/ML)

A078953 001 Apr 15, 2010 May CAHN

&gt;A&gt; @ 100MG/5ML (20MG/ML)

A078953 002 Apr 15, 2010 May CAHN

IRON DEXTRAN

INJECTABLE; INJECTION

DEXFERRUM

&gt;D&gt; @ AM REGENT

&gt;D&gt; INFED

EQ 50MG IRON/ML

N040024 001 Feb 23, 1996 May CAIN

&gt;D&gt; BP +! ALLERGAN

EQ 50MG IRON/ML

N017441 001 May CAIN

&gt;D&gt; IRON DEXTRAN

EQ 50MG IRON/ML

N010787 002 May CAIN

&gt;D&gt; @ SANOFI AVENTIS US

EQ 50MG IRON/ML

N010787 002 May CAIN

>D>	INJECTABLE; INJECTION PROFERDEX @ NEW RIVER	EQ 50MG IRON/ML	N 017807 001	May CAIN
<u>IRON_SUCROSE</u>				
	INJECTABLE; INTRAVENOUS VENOFLER			
>D>	+ AM REGENT	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N 021135 002 Mar 20, 2005	May CPOT
>D>	@	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N 021135 005 Mar 29, 2013	May CPOT
>D>	@	EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N 021135 003 Mar 29, 2005	May CPOT
>D>	+!	EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N 021135 001 Nov 06, 2000	May CPOT
>D>	+	EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N 021135 004 Feb 09, 2007	May CPOT
<u>ISOPROTERENOL HYDROCHLORIDE</u>				
	INJECTABLE; INJECTION ISOPROTERENOL HYDROCHLORIDE			
>A> AP	AMRING PHARMS	0.2MG/ML	A 211237 001 May 19, 2021	May NEWA
AP	AUROBINDO PHARMA LTD	0.2MG/ML	A 211864 001 Feb 09, 2021	Jan NEWA
AP	MICRO LABS	0.2MG/ML	A 210845 001 Feb 16, 2021	Feb NEWA
<u>ISOTRETINOIN</u>				
	CAPSULE; ORAL AMNESTEEM			
AB1	MYLAN PHARMS INC	10MG	A 075945 001 Nov 08, 2002	Mar CTEC
AB1		20MG	A 075945 002 Nov 08, 2002	Mar CTEC
AB1		40MG	A 075945 003 Nov 08, 2002	Mar CTEC
	CLARAVIS			
AB1	TEVA PHARMS USA	10MG	A 076356 001 Apr 11, 2003	Mar CTEC
AB1		20MG	A 076135 002 Apr 11, 2003	Mar CTEC
AB1		30MG	A 076135 003 May 11, 2006	Mar CTEC
AB1	!	40MG	A 076135 001 Apr 11, 2003	Mar CTEC
	ISOTRETINOIN			
AB2	ACTAVIS LABS FL	10MG	A 205063 001 Mar 31, 2021	Mar NFTG
AB2		20MG	A 205063 002 Mar 31, 2021	Mar NFTG
AB2		25MG	A 205063 003 Mar 31, 2021	Mar NFTG
AB2		30MG	A 205063 004 Mar 31, 2021	Mar NFTG
AB2		35MG	A 205063 005 Mar 31, 2021	Mar NFTG
AB2		40MG	A 205063 006 Mar 31, 2021	Mar NFTG
AB1	AMNEAL PHARMS NY	10MG	A 207792 001 Sep 29, 2017	Mar CTEC
AB1		20MG	A 207792 002 Sep 29, 2017	Mar CTEC
AB1		30MG	A 207792 003 Sep 29, 2017	Mar CTEC
AB1		40MG	A 207792 004 Sep 29, 2017	Mar CTEC
AB2	UPSHER SMITH LABS	40MG	A 213571 001 Apr 12, 2021	Apr NEWA
	MYORISAN			
AB1	DOUGLAS PHARMS	10MG	A 076485 001 Jan 19, 2012	Mar CTEC
AB1		20MG	A 076485 002 Jan 19, 2012	Mar CTEC
AB1		30MG	A 076485 004 Aug 25, 2015	Mar CTEC
AB1		40MG	A 076485 003 Jan 19, 2012	Mar CTEC
	ZENATANE			
AB1	DR REDDYS LABS LTD	10MG	A 202099 001 Mar 25, 2013	Mar CTEC
AB1		20MG	A 202099 002 Mar 25, 2013	Mar CTEC
AB1		30MG	A 202099 004 Feb 23, 2015	Mar CTEC
AB1		40MG	A 202099 003 Mar 25, 2013	Mar CTEC
<u>ITRACONAZOLE</u>				
	TABLET; ORAL ONMEL			
+ @	SEBELA IRELAND LTD	200MG	N 022484 001 Apr 29, 2010	Apr DISC
<u>IVERMECTIN</u>				
	LOTION; TOPICAL IVERMECTIN			
>D>	TARO	0.5%	A 210720 001 May 06, 2020	May CMKT
	TABLET; ORAL STROMECTOL			
+ @	MERCK SHARP DOHME	6MG	N 050742 001 Nov 22, 1996	Feb CRLD

IVOSIDENIB

TABLET;ORAL  
TIBSOVO  
+! SERVIER 250MG N211192 001 Jul 20, 2018 Apr CAHN

IXAZOMIB CITRATE

CAPSULE;ORAL  
NINLARO  
>D> + MILLENNIUM PHARMS EQ 2.3MG BASE N208462 001 Nov 20, 2015 May CAHN  
>D> + EQ 3MG BASE N208462 002 Nov 20, 2015 May CAHN  
>D> +! EQ 4MG BASE N208462 003 Nov 20, 2015 May CAHN  
>A> + TAKEDA PHARMS USA EQ 2.3MG BASE N208462 001 Nov 20, 2015 May CAHN  
>A> + EQ 3MG BASE N208462 002 Nov 20, 2015 May CAHN  
>A> +! EQ 4MG BASE N208462 003 Nov 20, 2015 May CAHN

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION  
KETAMINE HYDROCHLORIDE  
AP AUROMEDICS PHARMA EQ 10MG BASE/ML A076092 001 Sep 30, 2008 Jan CAHN  
AP EQ 50MG BASE/ML A076092 002 Dec 28, 2001 Jan CAHN  
AP EQ 100MG BASE/ML A076092 003 Oct 25, 2002 Jan CAHN

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL  
KETOCONAZOLE  
>A> AT XIROMED 2% A213601 001 May 21, 2021 May NEWA  
CREAM;TOPICAL  
KETOCONAZOLE  
>A> AB ENCUBE 2% A212443 001 May 20, 2021 May NEWA  
TABLET;ORAL  
KETOCONAZOLE  
@ MYLAN 200MG A075597 001 Dec 23, 1999 Mar DISC

KETOPROFEN

CAPSULE;ORAL  
KETOPROFEN  
@ RISING 50MG A074024 001 Dec 29, 1995 Jan CAHN  
@ 75MG A074024 002 Dec 29, 1995 Jan CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION  
KETOROLAC TROMETHAMINE  
@ AUROBINDO PHARMA LTD 15MG/ML A212939 001 Oct 20, 2020 Apr DISC  
@ 30MG/ML A212939 002 Oct 20, 2020 Apr DISC  
@ HOSPIRA 15MG/ML A074993 001 Jan 27, 1999 Mar DISC

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION  
LABETALOL HYDROCHLORIDE  
AP BAXTER HLTHCARE CORP 5MG/ML A076051 001 Jul 05, 2002 Mar CMFD  
TABLET;ORAL  
TRANDATE  
AB +! CNTY LINE PHARMS 200MG N018716 002 Aug 01, 1984 Apr CHRS

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL  
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE  
+ @ AUROBINDO PHARMA LTD 300MG;300MG N022344 001 May 15, 2018 Feb DISC

LAMOTRIGINE

TABLET, ORALLY DISINTEGRATING;ORAL  
LAMOTRIGINE  
AB AJANTA PHARMA LTD 25MG A213271 001 Jan 19, 2021 Jan NEWA  
AB 50MG A213271 002 Jan 19, 2021 Jan NEWA  
AB 100MG A213271 003 Jan 19, 2021 Jan NEWA  
AB 200MG A213271 004 Jan 19, 2021 Jan NEWA

LANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL  
LANSOPRAZOLE

AB	DR REDDYS LABS LTD	15MG	A210465	001	Feb 01, 2021	Jan NEWA
AB		30MG	A210465	002	Feb 01, 2021	Jan NEWA

LASMIDITAN SUCCINATE

TABLET;ORAL  
REYVOW

>D>	+	ELI LILLY AND CO	50MG	N211280	001	Jan 31, 2020	May CPOT
>A>	+		EQ 50MG BASE	N211280	001	Jan 31, 2020	May CPOT
>D>	+!		100MG	N211280	002	Jan 31, 2020	May CHRS
>A>	+		EQ 100MG BASE	N211280	002	Jan 31, 2020	May CHRS
>D>	+		200MG	N211280	003	Dec 18, 2020	May CHRS
>A>	+!		EQ 200MG BASE	N211280	003	Dec 18, 2020	May CHRS

LEFLUNOMIDE

TABLET;ORAL  
LEFLUNOMIDE

AB	AUROBINDO PHARMA LTD	10MG	A213652	001	Mar 29, 2021	Mar NEWA
AB		20MG	A213652	002	Mar 29, 2021	Mar NEWA
AB	AXUNIO	10MG	A213497	001	May 10, 2021	Apr NEWA
AB		20MG	A213497	002	May 10, 2021	Apr NEWA

LENALIDOMIDE

CAPSULE;ORAL  
LENALIDOMIDE

>A>	NATCO PHARMA LTD	5MG	A201452	001	May 21, 2021	May NFTG
>A> AB		10MG	A201452	002	May 21, 2021	May NFTG
>A> AB		15MG	A201452	003	May 21, 2021	May NFTG
>A> AB		25MG	A201452	004	May 21, 2021	May NFTG

LETROZOLE

TABLET;ORAL  
LETROZOLE  
@ APOTEX INC

2.5MG	A091303	001	Apr 19, 2012	Jan DISC
-------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

TABLET;ORAL  
LEUCOVORIN CALCIUM

>A> AB	EPIC PHARMA LLC	EQ 10MG BASE	A074544	003	May 19, 2021	May NEWA
>A> AB		EQ 15MG BASE	A074544	004	May 19, 2021	May NEWA

LEUPROLIDE MESYLATE

>A>	EMULSION;SUBCUTANEOUS					
>A>	CAMCEVI KIT					
>A>	+! FORESEE PHARMS	EQ 42MG BASE	N211488	001	May 25, 2021	May NEWA

LEVETIRACETAM

INJECTABLE; INTRAVENOUS  
LEVETIRACETAM IN SODIUM CHLORIDE

AP	AUROBINDO PHARMA LTD	1GM/100ML (10MG/ML)	A207160	002	Jan 04, 2017	Feb CPOT
AP		1.5GM/100ML (15MG/ML)	A207160	003	Jan 04, 2017	Feb CPOT
AP	GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Feb CPOT
AP		1.5GM/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Feb CDFR
AP	+! HQ SPECIALITY PHARMA	1GM/100ML (10MG/ML)	N202543	002	Nov 09, 2011	Feb CPOT
AP	+!	1.5GM/100ML (15MG/ML)	N202543	003	Nov 09, 2011	Feb CPOT
AP	NEXUS PHARMS	1GM/100ML (10MG/ML)	A213532	002	Jul 06, 2020	Feb CPOT
AP		1.5GM/100ML (15MG/ML)	A213532	003	Jul 06, 2020	Feb CPOT

SOLUTION;ORAL  
LEVETIRACETAM

AA	AKORN	100MG/ML	A090601	001	Feb 28, 2012	Feb CAHN
----	-------	----------	---------	-----	--------------	----------

TABLET;ORAL  
LEVETIRACETAM

AB	@ NOSTRUM LABS INC	250MG	A090511	001	Aug 18, 2011	Mar DISC
AB	@	500MG	A090511	002	Aug 18, 2011	Mar DISC
AB	@	500MG	A090511	002	Aug 18, 2011	Jan CAHN
AB	@	750MG	A090511	003	Aug 18, 2011	Mar DISC
AB	@	750MG	A090511	003	Aug 18, 2011	Jan CAHN
AB	@	1GM	A090511	004	Aug 18, 2011	Mar DISC

TABLET;ORAL  
LEVETIRACETAM

AB		1GM	A090511	004	Aug 18, 2011	Jan CAHN
	TABLET, EXTENDED RELEASE;ORAL ELEPSIA XR					
+ TRIPPOINT	1GM	N204417	001	Dec 20, 2018	Jan CAHN	
+!	1.5GM	N204417	002	Dec 20, 2018	Jan CAHN	
	LEVETIRACETAM					
>D>	@ OVERSEAS	750MG	A212688	001	Jun 11, 2020	May CMFD
>A> AB		750MG	A212688	001	Jun 11, 2020	May CMFD

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL XYZAL						
+ @ SANOFI AVENTIS US	2.5MG/5ML	N022157	001	Jan 28, 2008	Apr DISC	
TABLET;ORAL LEVO CETIRIZINE DIHYDROCHLORIDE						
AB ! GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011	Apr CHRS	
@ GRANULES	5MG	A090486	001	Mar 26, 2013	Apr CAHN	
>D> @ NEOPHARMA	5MG	A204323	001	Dec 20, 2016	May CAHN	
@	5MG	A204323	001	Dec 20, 2016	Mar DISC	
>A> @ US ANTIBIOTICS	5MG	A204323	001	Dec 20, 2016	May CAHN	
XYZAL						
+ @ SANOFI AVENTIS US	5MG	N022064	001	May 25, 2007	Apr DISC	

LEVORPHANOL TARTRATE

TABLET;ORAL LEVORPHANOL TARTRATE						
AB NOVITIUM PHARMA	3MG	A213479	002	Jan 12, 2021	Jan NEWA	
AB ! SENTYNL THERAPS INC	3MG	A074278	003	Jun 18, 2018	Jan CTEC	

LEVOOTHYROXINE SODIUM

CAPSULE;ORAL LEVOOTHYROXINE SODIUM						
AB @ TEVA PHARMS USA INC	0.075MG	A211369	001	Oct 28, 2020	Apr DISC	
	0.112MG	A211369	003	Apr 16, 2021	Apr NFTG	
AB @	0.15MG	A211369	002	Oct 28, 2020	Apr DISC	
TIROSINT						
+ INSTITUT BIOCHIMIQUE	0.075MG	N021924	004	Oct 13, 2006	Apr CTEC	
+ +	0.15MG	N021924	007	Oct 13, 2006	Apr CTEC	
POWDER;INTRAVENOUS LEVOOTHYROXINE SODIUM						
AB @ DR REDDYS	100MCG/VIAL	A208837	001	Mar 27, 2020	Feb DISC	
SOLUTION;INTRAVENOUS LEVOOTHYROXINE SODIUM						
>A> +! CUSTOPHARM INC	100MCG/ML	N214253	001	May 17, 2021	May NEWA	
SOLUTION;ORAL THYQUIDITY						
+! VISTAPHARM	100MCG/5ML	N214047	001	Nov 30, 2020	Apr CAHN	
TIROSINT-SOL						
+ INSTITUT BIOCHIMIQUE	37.5MCG/ML	N206977	013	Jan 13, 2021	Jan NEWA	
+ +	44MCG/ML	N206977	014	Jan 13, 2021	Jan NEWA	
+ +	62.5MCG/ML	N206977	015	Jan 13, 2021	Jan NEWA	

LIDOCAINE

OINTMENT;TOPICAL LIDOCAINE						
>D> AT @ NOVAST LABS	5%	A208604	001	Sep 20, 2017	May CAHN	
AT QUAGEN	5%	A212695	001	Apr 20, 2021	Apr NEWA	
>A> @ RISING	5%	A208604	001	Sep 20, 2017	May CAHN	
PATCH;TOPICAL LIDOCAINE						
AB NAL PHARM	5%	A205882	001	Apr 29, 2021	Apr NEWA	

LIDOCAINE HYDROCHLORIDE

JELLY;TOPICAL XYLOCAINE						
+ @ AKORN	2%	N008816	001		Jan DISC	
SOLUTION;ORAL LIDOCAINE HYDROCHLORIDE VISCOSUS						
AT LANNETT CO INC	2%	A040708	001	Feb 27, 2007	Jan CMFD	

LINACLOTIDE

	CAPSULE;ORAL LINACLOTIDE @ MYLAN	145MCG 145MCG 290MCG 290MCG	A209564 001 Feb 09, 2021 A209564 001 Feb 09, 2021 A209564 002 Feb 09, 2021 A209564 002 Feb 09, 2021	Feb DISC Jan NFTG Feb DISC Jan NFTG
AB	+! ALLERGAN	145MCG 290MCG	N202811 001 Aug 30, 2012 N202811 002 Aug 30, 2012	Feb CTEC Feb CTEC
AB	+			

LINCOMYCIN HYDROCHLORIDE

	INJECTABLE;INJECTION LINCOCIN +! PFIZER	EQ 300MG BASE/ML	N050317 001	Feb CAHN
AP	PRAZGEN	EQ 300MG BASE/ML	A212770 001 Mar 12, 2021	Mar NEWA

LIOTHYRONINE SODIUM

	TABLET;ORAL LIOTHYRONINE SODIUM ZYDUS	EQ 0.005MG BASE	A214803 001	Jan 22, 2021	Jan NEWA
AB		EQ 0.025MG BASE	A214803 002	Jan 22, 2021	Jan NEWA
AB		EQ 0.05MG BASE	A214803 003	Jan 22, 2021	Jan NEWA

LISINOPRIL

	TABLET;ORAL LISINOPRIL YILING	20MG	A208920 001	Mar 04, 2021	Feb NEWA
AB		30MG	A208920 002	Mar 04, 2021	Feb NEWA
AB		40MG	A208920 003	Mar 04, 2021	Feb NEWA

LOPINAVIR; RITONAVIR

>A>	AB	LOPINAVIR AND RITONAVIR HETERO LABS LTD III	100MG;25MG	A091677 001	Jun 04, 2021	May NFTG
>A>	AB		200MG;50MG	A091677 002	Jun 04, 2021	May NFTG

LORAZEPAM

	CONCENTRATE;ORAL LORAZEPAM AKORN	2MG/ML	A200169 001	Jan 30, 2012	Feb CAHN
--	--	--------	-------------	--------------	----------

LOTEPREDNOL ETABONATE

	GEL;OPHTHALMIC LOTEPREDNOL ETABONATE AKORN	0.5%	A212080 001	Feb 10, 2021	Jan NFTG
	SUSPENSION/DROPS;OPHTHALMIC LOTEPREDNOL ETABONATE				
AB	SUN PHARM	0.5%	A212450 001	Feb 26, 2021	Feb NEWA

LULICONAZOLE

>A>	+!	BAUSCH	1%	N204153 001	Nov 14, 2013	May CAHN
>D>	+!	MEDICIS	1%	N204153 001	Nov 14, 2013	May CAHN

LURASIDONE HYDROCHLORIDE

	TABLET;ORAL LURASIDONE HYDROCHLORIDE ALEMBIC PHARMS LTD	20MG	A213248 001	May 13, 2021	May NEWA
>A>	AB	40MG	A213248 002	May 13, 2021	May NEWA
>A>	AB	60MG	A213248 003	May 13, 2021	May NEWA
>A>	AB	80MG	A213248 004	May 13, 2021	May NEWA
>A>	AB	120MG	A213248 005	May 13, 2021	May NEWA
	WATSON LABS TEVA	20MG	A208016 001	Feb 02, 2021	Jan NEWA
		40MG	A208016 002	Feb 02, 2021	Jan NEWA
		60MG	A208016 003	Feb 02, 2021	Jan NEWA
		80MG	A208016 004	Feb 02, 2021	Jan NEWA
		120MG	A208016 005	Feb 02, 2021	Jan NEWA

MACITENTAN

TABLET;ORAL  
MACITENTAN

AB	ZYDUS	10MG	A211224	001	Apr 06, 2021	Mar NFTG
----	-------	------	---------	-----	--------------	----------

MAGNESIUM SULFATE

INJECTABLE;INJECTION  
MAGNESIUM SULFATE

AP	B BRAUN MEDICAL INC	2GM/50ML (40MG/ML)	A207967	001	Apr 26, 2021	Apr NEWA
AP		4GM/100ML (40MG/ML)	A207967	002	Apr 26, 2021	Apr NEWA
AP		4GM/50ML (80MG/ML)	A207967	003	Apr 26, 2021	Apr NEWA
AP	BAXTER HLTHCARE CORP	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE CORP	1GM/100ML	A211965	001	Aug 11, 2020	Feb CMFD
AP	BAXTER HLTHCARE CORP	MAGNESIUM SULFATE IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE CORP	2GM/50ML (40MG/ML)	A211966	001	Jun 01, 2020	Feb CMFD
AP		4GM/50ML (80MG/ML)	A211966	002	Jun 01, 2020	Feb CMFD
AP		4GM/100ML (40MG/ML)	A211966	003	Jun 01, 2020	Feb CMFD

MANGANESE SULFATE

INJECTABLE;INJECTION  
MANGANESE SULFATE

>D>	@ ABRAXIS PHARM	EQ 0.1MG MANGANESE/ML	N019228	001	May 05, 1987	May CRLD
>A>	+ @	EQ 0.1MG MANGANESE/ML	N019228	001	May 05, 1987	May CRLD

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION  
DEPO-PROVERA

AB	+ @ PFIZER	100MG/ML	N012541	002		Mar CAHN
>D>	+!	150MG/ML	N020246	001	Oct 29, 1992	Mar CAHN
>A>	+!	400MG/ML	N012541	003		May DISC
	+ @	400MG/ML	N012541	003		May DISC
	+!	400MG/ML	N012541	003		Mar CAHN
AB	INJECTABLE;SUBCUTANEOUS					
	DEPO-SUBQ PROVERA 104					
	+! PFIZER	104MG/0.65ML	N021583	001	Dec 17, 2004	Mar CAHN
AB	TABLET;ORAL					
	PROVERA					
AB	+ PFIZER	2.5MG	N011839	001		Mar CAHN
AB	+	5MG	N011839	003		Mar CAHN
AB	+!	10MG	N011839	004		Mar CAHN

MEFENAMIC ACID

CAPSULE;ORAL  
MEFENAMIC ACID  
@ STRIDES PHARMA

250MG

A209209 001 Sep 18, 2020 Mar DISC

MELOXICAM

CAPSULE;ORAL  
MELOXICAM

AB	LUPIN LTD	5MG	A209487	001	Jun 01, 2020	Feb CTEC
AB	!	10MG	A209487	002	Jun 01, 2020	Feb CTEC
AB	NOVITIUM PHARMA	5MG	A211398	001	Mar 09, 2021	Feb NEWA
AB		10MG	A211398	002	Mar 09, 2021	Feb NEWA

MELPHALAN

TABLET;ORAL  
MELPHALAN  
! ALVOGEN

2MG

A207809 001 Mar 22, 2017 Jan CAHN

MELPHALAN FLUFENAMIDE

POWDER;INTRAVENOUS  
PEPAXTO  
+! ONCOPEPTIDES AB

20MG/VIAL

N214383 001 Feb 26, 2021 Feb NEWA

MELPHALAN FLUFENAMIDE HYDROCHLORIDE

POWDER;INTRAVENOUS  
PEPAXTO  
+! ONCOPEPTIDES AB

EQ 20MG BASE/VIAL  
20MG/VIALN214383 001 Feb 26, 2021 Mar CPOT  
N214383 001 Feb 26, 2021 Mar CAIN

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

+ @ APOTEX EQ 50MG BASE/VIAL  
 MELPHALAN HYDROCHLORIDE

>A> AP HONG KONG EQ 50MG BASE/VIAL

N020207 001 Nov 18, 1992 Jan DISC

A212960 001 May 28, 2021 May NEWA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

AB YICHANG HUMANWELL 7MG

A211100 001 Apr 02, 2021 Mar NEWA

AB 14MG

A211100 002 Apr 02, 2021 Mar NEWA

AB 21MG

A211100 003 Apr 02, 2021 Mar NEWA

AB 28MG

A211100 004 Apr 02, 2021 Mar NEWA

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

&gt;D&gt; AA SAPTALIS PHARMS 2MG/ML

A210319 001 Aug 31, 2020 May CAHN

&gt;A&gt; AA SETON PHARMS 2MG/ML

A210319 001 Aug 31, 2020 May CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

@ VALIDUS PHARMS 25MG/ML  
 @ 50MG/ML  
 @ 75MG/ML  
 @ 100MG/ML

N005010 007 Feb CAHN

N005010 002 Feb CAHN

N005010 009 Feb CAHN

N005010 003 Feb CAHN

SYRUP; ORAL

DEMEROL

@ VALIDUS PHARMS 50MG/5ML

N005010 005 Feb CAHN

TABLET; ORAL

DEMEROL

+ @ VALIDUS PHARMS 50MG  
 + @ 100MG

N005010 001 Feb CAHN

N005010 004 Feb CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

AA ! ALEMBIC PHARMS LTD 200MG  
 AA ! 400MG  
 @ WATSON LABS 200MG  
 @ 400MG

A090122 001 Feb 18, 2009 Mar CHRS

A090122 002 Feb 18, 2009 Mar CHRS

A083304 001 Mar DISC

A083308 001 Mar DISC

MEROPENEM; VABORBACTAM

POWDER; INTRAVENOUS

VABOMERE

+ ! REMPEX 1GM/VIAL; 1GM/VIAL

N209776 001 Aug 29, 2017 Feb CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

>D> AB INDICUS PHARMA 500MG  
 >A> @ 500MG  
 >D> AB 850MG  
 >A> @ 850MG  
 >D> AB 1GM  
 >A> @ 1GM

A079148 001 Nov 25, 2008 May DISC

A079148 001 Nov 25, 2008 May DISC

A079148 002 Nov 25, 2008 May DISC

A079148 002 Nov 25, 2008 May DISC

A079148 003 Nov 25, 2008 May DISC

A079148 003 Nov 25, 2008 May DISC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB3 AJANTA PHARMA LTD 500MG  
 AB3 1GM  
 AB3 @ APOTEX 500MG  
 AB3 GRANULES 500MG  
 AB3 1GM  
 AB3 SCIEGEN PHARMS INC 500MG  
 AB3 1GM

A213962 001 Mar 09, 2021 Feb NEWA

A213962 002 Mar 09, 2021 Feb NEWA

A076706 001 Dec 14, 2004 Apr DISC

A213344 001 Jan 12, 2021 Jan NEWA

A213344 002 Jan 12, 2021 Jan NEWA

A213334 001 Apr 16, 2021 Apr NEWA

A213334 002 Apr 16, 2021 Apr NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE  
 @ TORRENT PHARMS LTD 500MG;EQ 15MG BASE  
 @ 850MG;EQ 15MG BASE

A202001 001 Feb 13, 2013 Jan DISC  
 A202001 002 Feb 13, 2013 Jan DISC

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

AA LANNETT CO INC 10MG/ML A212094 001 Mar 03, 2021 Feb NEWA

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB + @ VALIDUS PHARMS 1GM N017681 001 Mar DISC  
 AB +! 1GM N017681 001 Feb CAHN  
 AB ! AUROBINDO PHARMA LTD 1GM A205661 001 Jul 05, 2016 Mar CHRS

METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL

AA @ AUROBINDO PHARMA LTD 750MG A213967 001 Aug 12, 2020 Feb DISC  
 AA GRANULATION TECH 500MG A212623 001 Apr 30, 2021 Apr NEWA  
 AA 750MG A212623 002 Apr 30, 2021 Apr NEWA

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

>D> AP MYLAN LABS LTD EQ 250MG BASE/10ML (EQ 25MG BASE/ML) A201529 004 Mar 29, 2012 May DISC  
 >A> @ EQ 250MG BASE/10ML (EQ 25MG BASE/ML) A201529 004 Mar 29, 2012 May DISC  
 TABLET;ORAL  
 METHOTREXATE SODIUM  
 AB LOTUS PHARM CO LTD EQ 2.5MG BASE A209787 001 Apr 23, 2021 Apr NEWA

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB RISING 0.2MG A211919 001 Jan 15, 2021 Jan NEWA

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA ASCENT PHARMS INC 5MG/5ML A207417 001 Jan 29, 2021 Jan NEWA  
 AA 10MG/5ML A207417 002 Jan 29, 2021 Jan NEWA  
 @ LANNETT CO INC 5MG/5ML A207414 001 Dec 16, 2020 Jan DISC  
 @ 10MG/5ML A207414 002 Dec 16, 2020 Jan DISC

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

AB PRAZGEN 4MG A212262 001 Jun 27, 2019 Feb CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

>D> AP GENEYORK PHARMS EQ 40MG BASE/VIAL A212396 001 Apr 20, 2021 May CAHN  
 AP EQ 40MG BASE/VIAL A212396 001 Apr 20, 2021 Apr NEWA  
 >D> AP EQ 125MG BASE/VIAL A212396 002 Apr 20, 2021 May CAHN  
 AP EQ 125MG BASE/VIAL A212396 002 Apr 20, 2021 Apr NEWA  
 >D> AP EQ 500MG BASE/VIAL A212396 003 Apr 20, 2021 May CAHN  
 AP EQ 500MG BASE/VIAL A212396 003 Apr 20, 2021 Apr NEWA  
 >D> AP EQ 1GM BASE/VIAL A212396 004 Apr 20, 2021 May CAHN  
 AP EQ 1GM BASE/VIAL A212396 004 Apr 20, 2021 Apr NEWA  
 >D> AP EQ 2GM BASE/VIAL A212396 005 Apr 20, 2021 May CAHN  
 AP EQ 2GM BASE/VIAL A212396 005 Apr 20, 2021 Apr NEWA  
 >A> AP TIANJIN KINGYORK EQ 40MG BASE/VIAL A212396 001 Apr 20, 2021 May CAHN  
 >A> AP EQ 125MG BASE/VIAL A212396 002 Apr 20, 2021 May CAHN  
 >A> AP EQ 500MG BASE/VIAL A212396 003 Apr 20, 2021 May CAHN

**INJECTABLE; INJECTION**  
**METHYLPREDNISOLONE SODIUM SUCCINATE**

>A> AP	EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	May CAHN
>A> AP	EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	May CAHN

**METOLAZONE****TABLET; ORAL****METOLAZONE**

AB	BAYSHORE PHARMS LLC	2.5MG	A214799	001	Mar 30, 2021	Mar NEWA
AB		5MG	A214799	002	Mar 30, 2021	Mar NEWA
AB		10MG	A214799	003	Mar 30, 2021	Mar NEWA
AB	INNOGENIX	2.5MG	A213827	001	Mar 30, 2021	Mar NEWA
AB		5MG	A213827	002	Mar 30, 2021	Mar NEWA
AB		10MG	A213827	003	Mar 30, 2021	Mar NEWA
>D> AB	SANDOZ	5MG	A076466	001	Dec 19, 2003	May CHRS
>A> AB	!	5MG	A076466	001	Dec 19, 2003	May CHRS
>D> AB		10MG	A076466	002	Dec 19, 2003	May CHRS
>A> AB	!	10MG	A076466	002	Dec 19, 2003	May CHRS
>D>	ZAROXOLYN					
>D> AB	+ LANNETT CO INC	2.5MG	N017386	001		May DISC
>A>	+ @	2.5MG	N017386	001		May DISC
>D> AB	+ !	5MG	N017386	002		May DISC
>A>	+ @	5MG	N017386	002		May DISC
>D> AB	+ !	10MG	N017386	003		May DISC
>A>	+ @	10MG	N017386	003		May DISC

**METOPROLOL SUCCINATE****TABLET, EXTENDED RELEASE; ORAL****METOPROLOL SUCCINATE**

>D>	@ ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	May CMFD
>A> AB		EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	May CMFD
>D>	@	EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	May CMFD
>A> AB		EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	May CMFD
>D>	@	EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	May CMFD
>A> AB		EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	May CMFD
>D>	@	EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	May CMFD
>A> AB		EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	May CMFD
AB	YICHANG HUMANWELL	EQ 100MG TARTRATE	A213854	001	Feb 12, 2021	Feb NEWA
AB		EQ 200MG TARTRATE	A213854	002	Feb 12, 2021	Feb NEWA

**METOPROLOL TARTRATE****TABLET; ORAL****LOPRESSOR**

AB	+ VALIDUS PHARMS	50MG	N017963	001		Feb CAHN
AB	+	100MG	N017963	002		Feb CAHN

**MEXILETINE HYDROCHLORIDE****CAPSULE; ORAL****MEXILETINE HYDROCHLORIDE**

AB	RICONPHARMA LLC	150MG	A214352	001	Jan 25, 2021	Jan NEWA
AB		200MG	A214352	002	Jan 25, 2021	Jan NEWA
AB		250MG	A214352	003	Jan 25, 2021	Jan NEWA

**MICAFUNGIN SODIUM****INJECTABLE; INTRAVENOUS****MICAFUNGIN SODIUM**

>A> AP	XELLIA PHARMS APS	EQ 50MG BASE/VIAL	A211713	001	Jun 02, 2021	May NEWA
>A> AP		EQ 100MG BASE/VIAL	A211713	002	Jun 02, 2021	May NEWA

**MIDAZOLAM****SOLUTION; INTRAVENOUS****MIDAZOLAM IN 0.9% SODIUM CHLORIDE**

+! INFORLIFE	50MG/50ML (1MG/ML)	N211844	001	Mar 22, 2021	Mar NEWA
+!	100MG/100ML (1MG/ML)	N211844	002	Mar 22, 2021	Mar NEWA

**MIDODRINE HYDROCHLORIDE****TABLET; ORAL****MIDODRINE HYDROCHLORIDE**

AB	ALEMBIC PHARMS LTD	2.5MG	A214734	001	Jan 21, 2021	Jan NEWA
AB		5MG	A214734	002	Jan 21, 2021	Jan NEWA
AB		10MG	A214734	003	Jan 21, 2021	Jan NEWA

MIGLITOL

TABLET;ORAL

GLYSET

AB	+!	Pfizer	25MG	N020682	001	Dec 18, 1996	Feb CAHN
AB	+		50MG	N020682	002	Dec 18, 1996	Feb CAHN
AB	+		100MG	N020682	003	Dec 18, 1996	Feb CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP		CAPLIN	EQ 1MG BASE/ML	A214380	001	Apr 16, 2021	Apr NEWA
----	--	--------	----------------	---------	-----	--------------	----------

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL

AMZEEQ

+! VYNE EQ 4% BASE

ZILXI

+! VYNE EQ 1.5% BASE

INJECTABLE; INJECTION

MINOCIN

&gt;A&gt; +! REMPEX EQ 100MG BASE/VIAL

&gt;D&gt; +! REMPEX PHARMS EQ 100MG BASE/VIAL

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

&gt;D&gt; AB BARR LABS INC EQ 65MG BASE

&gt;A&gt; @ EQ 65MG BASE

&gt;D&gt; AB EQ 80MG BASE

&gt;A&gt; @ EQ 80MG BASE

&gt;D&gt; AB EQ 105MG BASE

&gt;A&gt; @ EQ 105MG BASE

&gt;D&gt; AB EQ 115MG BASE

&gt;A&gt; @ EQ 115MG BASE

SOLODYN

&gt;A&gt; + @ BAUSCH EQ 45MG BASE

&gt;A&gt; AB + EQ 55MG BASE

&gt;A&gt; AB + EQ 65MG BASE

&gt;A&gt; AB + EQ 80MG BASE

&gt;A&gt; + @ EQ 90MG BASE

&gt;A&gt; AB + EQ 105MG BASE

&gt;A&gt; AB +! EQ 115MG BASE

&gt;A&gt; + @ EQ 135MG BASE

&gt;D&gt; + @ MEDICIS EQ 45MG BASE

&gt;D&gt; AB + EQ 55MG BASE

&gt;D&gt; AB + EQ 65MG BASE

&gt;D&gt; AB + EQ 80MG BASE

&gt;D&gt; + @ EQ 90MG BASE

&gt;D&gt; AB + EQ 105MG BASE

&gt;D&gt; AB +! EQ 115MG BASE

&gt;D&gt; + @ EQ 135MG BASE

A065485	004	May 18, 2012	May DISC
A065485	004	May 18, 2012	May DISC
A065485	007	Apr 26, 2017	May DISC
A065485	007	Apr 26, 2017	May DISC
A065485	008	Apr 26, 2017	May DISC
A065485	008	Apr 26, 2017	May DISC
A065485	005	May 18, 2012	May DISC
A065485	005	May 18, 2012	May DISC
N050808	001	May 08, 2006	May CAHN
N050808	008	Aug 27, 2010	May CAHN
N050808	004	Jul 23, 2009	May CAHN
N050808	007	Aug 27, 2010	May CAHN
N050808	002	May 08, 2006	May CAHN
N050808	006	Aug 27, 2010	May CAHN
N050808	005	Jul 23, 2009	May CAHN
N050808	003	May 08, 2006	May CAHN
N050808	001	May 08, 2006	May CAHN
N050808	008	Aug 27, 2010	May CAHN
N050808	004	Jul 23, 2009	May CAHN
N050808	007	Aug 27, 2010	May CAHN
N050808	002	May 08, 2006	May CAHN
N050808	006	Aug 27, 2010	May CAHN
N050808	005	Jul 23, 2009	May CAHN
N050808	003	May 08, 2006	May CAHN

MINOXIDIL

TABLET;ORAL

LONITEN

+ @ PFIZER 2.5MG

+ @ 10MG

N018154	001	Feb CAHN
N018154	003	Feb CAHN

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MYRBETRIQ GRANULES

+! APGDI 8MG/ML

N213801 001 Mar 25, 2021 Mar NEWA

MOMETASONE FUROATE

OINTMENT;TOPICAL

MOMETASONE FUROATE

@ TORRENT 0.1%

A207899 001 Jul 13, 2018 Jan DISC

SPRAY, METERED;NASAL

MOMETASONE FUROATE

&gt;D&gt; AB APOTEX INC 0.05MG/SPRAY

A091161 001 Mar 22, 2016 May CHRS

&gt;A&gt; AB ! 0.05MG/SPRAY

A091161 001 Mar 22, 2016 May CHRS

NASONEX

&gt;D&gt; AB +! ORGANON 0.05MG/SPRAY

N020762 001 Oct 01, 1997 May DISC

SPRAY, METERED;NASAL  
NASONEX

>A>	+ @	0.05MG/SPRAY	N 020762	001	Oct 01, 1997	May DISC
AB	+ !	0.05MG/SPRAY	N 020762	001	Oct 01, 1997	Feb CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL  
KADIAN

>D> AB	+ ALLERGAN	40MG	N 020616	009	Jul 09, 2012	May DISC
>A>	+ @	40MG	N 020616	009	Jul 09, 2012	May DISC
>D>	+	70MG	N 020616	010	Jul 09, 2012	May DISC
>A>	+ @	70MG	N 020616	010	Jul 09, 2012	May DISC
>D>	+	130MG	N 020616	011	Jul 09, 2012	May DISC
>A>	+ @	130MG	N 020616	011	Jul 09, 2012	May DISC
>D>	+	150MG	N 020616	012	Jul 09, 2012	May DISC
>A>	+ @	150MG	N 020616	012	Jul 09, 2012	May DISC
>D>	+ !	200MG	N 020616	007	Feb 27, 2007	May DISC
>A>	+ @	200MG	N 020616	007	Feb 27, 2007	May DISC

## MORPHINE SULFATE

>D> AB	IMPAX LABS INC	40MG	A 200411	007	Jul 25, 2018	May CTEC
>A>		40MG	A 200411	007	Jul 25, 2018	May CTEC

INJECTABLE;INJECTION  
MORPHINE SULFATE

+! HOSPIRA INC	50MG/ML	N 202515	006	Apr 29, 2021	Apr NEWA
INTL MEDICATION SYS	1MG/ML	A 202861	001	Apr 29, 2021	Apr NFTG

## SOLUTION;ORAL

## MORPHINE SULFATE

@ ANI PHARMS	10MG/5ML	A 205509	001	Apr 17, 2018	Jan DISC
@	20MG/5ML	A 205509	002	Apr 17, 2018	Jan DISC
@	100MG/5ML	A 205509	003	Apr 17, 2018	Jan DISC

AA WINDER LABS LLC	10MG/5ML	A 211454	001	Feb 12, 2021	Feb NEWA
--------------------	----------	----------	-----	--------------	----------

AA	20MG/5ML	A 211454	002	Feb 12, 2021	Feb NEWA
----	----------	----------	-----	--------------	----------

AA	100MG/5ML	A 211454	003	Feb 12, 2021	Feb NEWA
----	-----------	----------	-----	--------------	----------

## TABLET;ORAL

## MORPHINE SULFATE

>A> AB MAYNE PHARMA INC	15MG	A 207270	001	Jun 02, 2021	May NEWA
>A> AB	30MG	A 207270	002	Jun 02, 2021	May NEWA
>D> AB UPSHER SMITH LABS	15MG	A 210610	001	Jul 22, 2019	May CAHN
>A> AB	15MG	A 210610	001	Jul 22, 2019	May CAHN
>D> AB	30MG	A 210610	002	Jul 22, 2019	May CAHN
>A> AB	30MG	A 210610	002	Jul 22, 2019	May CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
MOXIFLOXACIN HYDROCHLORIDE

AT1 UPSHER SMITH LABS	EQ 0.5% BASE	A 212616	001	Feb 10, 2021	Jan NEWA
-----------------------	--------------	----------	-----	--------------	----------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION  
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP AMNEAL	500MG/VIAL	A 211374	001	Mar 05, 2021	Feb NEWA
AP MEITHEAL	500MG/VIAL	A 212130	001	Jan 15, 2021	Jan CAHN
AP NANJING KING-FRIEND	500MG/VIAL	A 212130	001	Jan 15, 2021	Jan NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL  
MYCOPHENOLIC ACID

AB AMTA	180MG	A 214376	001	Feb 10, 2021	Jan NEWA
AB	360MG	A 214376	002	Feb 10, 2021	Jan NEWA

NABUMETONE

TABLET;ORAL  
NABUMETONE

AB ANNORA PHARMA	500MG	A 090445	001	Jan 12, 2011	Mar CAHN
AB	750MG	A 090445	002	Jan 12, 2011	Mar CAHN

NADOLOL

TABLET;ORAL  
NADOLOL

>D> AB NOVAST LABS	20MG	A 210786	001	Jun 01, 2018	May DISC
>A> @	20MG	A 210786	001	Jun 01, 2018	May DISC
>D> AB	40MG	A 210786	002	Jun 01, 2018	May DISC

TABLET;ORAL  
NADOLOL

>A>	@	40MG	A210786	002	Jun 01, 2018	May DISC
>D> AB		80MG	A210786	003	Jun 01, 2018	May DISC
>A>	@	80MG	A210786	003	Jun 01, 2018	May DISC
>D>	@ VGYAAN	20MG	A212856	001	Sep 13, 2019	May CMFD
>A> AB		20MG	A212856	001	Sep 13, 2019	May CMFD
>D>	@	40MG	A212856	002	Sep 13, 2019	May CMFD
>A> AB		40MG	A212856	002	Sep 13, 2019	May CMFD
>D>	@	80MG	A212856	003	Sep 13, 2019	May CMFD
>A> AB		80MG	A212856	003	Sep 13, 2019	May CMFD

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION  
NALOXONE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	1MG/ML	A213279	001	Jan 14, 2021	Jan NEWA
AP	BAXTER HLTHCARE CORP	0.4MG/ML	A214785	001	Jan 29, 2021	Jan NEWA
	SPRAY; NASAL KLOXXADO					
+!	HIKMA	8MG/SPRAY	N212045	001	Apr 29, 2021	Apr NEWA

NAPROXEN

SUSPENSION;ORAL  
NAPROXEN

AB	NOVITIUM PHARMA	25MG/ML	A211910	001	Mar 10, 2021	Feb NEWA
	TABLET;ORAL NAPROXEN					
AB	GRANULES	250MG	A074140	001	Dec 21, 1993	Feb CMFD
AB		375MG	A074140	002	Dec 21, 1993	Feb CMFD
AB		500MG	A074140	003	Dec 21, 1993	Feb CMFD

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS  
NEOSTIGMINE METHYLSULFATE

AP	CAPLIN	5MG/10ML (0.5MG/ML)	A213074	001	Apr 20, 2021	Apr NEWA
AP		10MG/10ML (1MG/ML)	A213074	002	Apr 20, 2021	Apr NEWA
AP	HONG KONG	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Mar NEWA
AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Mar NEWA
AP	MEITHEAL	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Apr CAHN
AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Apr CAHN

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL  
NICARDIPINE HYDROCHLORIDE

>D>	@ ANI PHARMS	20MG	A074670	001	Oct 28, 1996	May CMFD
>A> AB		20MG	A074670	001	Oct 28, 1996	May CMFD
>D>	@	30MG	A074670	002	Oct 28, 1996	May CMFD
>A> AB		30MG	A074670	002	Oct 28, 1996	May CMFD
>D>	EPIC PHARMA	20MG	A074928	001	Mar 19, 1998	May CTEC
>A> AB		20MG	A074928	001	Mar 19, 1998	May CTEC
>D>	!	30MG	A074928	002	Mar 19, 1998	May CTEC
>A> AB	!	30MG	A074928	002	Mar 19, 1998	May CTEC
	INJECTABLE; INJECTION NICARDIPINE HYDROCHLORIDE					
AP	! AM REGENT	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Apr CTEC
	!	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Feb CHRS
AP	AUROBINDO PHARMA LTD	25MG/10ML (2.5MG/ML)	A211121	001	Apr 08, 2021	Apr NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL  
NIFEDIPINE

!	PAR PHARM	30MG	A077899	001	Dec 13, 2006	Apr DISC
!		60MG	A077899	002	Dec 13, 2006	Apr DISC
!		90MG	A077899	003	May 25, 2012	Apr DISC

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL  
NISOLDIPINE

!	MYLAN	20MG	A079051	001	Jul 25, 2008	Jan CHRS
		30MG	A079051	002	Jul 25, 2008	Jan CHRS

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

MINITRAN

&gt;A&gt; @ BAUSCH 0.4MG/HR A089773 001 Aug 30, 1996 May CAHN

&gt;D&gt; @ MEDICIS 0.4MG/HR A089773 001 Aug 30, 1996 May CAHN

TABLET;SUBLINGUAL

NITROGLYCERIN

AB RUBICON 0.3MG A209779 001 May 03, 2021 Apr NEWA

AB 0.4MG A209779 002 May 03, 2021 Apr NEWA

AB 0.6MG A209779 003 May 03, 2021 Apr NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP ANDERSEN GLOBAL EQ 1MG BASE/ML A214455 001 Jan 22, 2021 Jan NEWA

AP BRECKENRIDGE EQ 1MG BASE/ML A214455 001 Jan 22, 2021 Mar CAHN

AP GLAND PHARMA LTD EQ 1MG BASE/ML A214323 001 May 06, 2021 Apr NEWA

AP SUN PHARM EQ 1MG BASE/ML A211980 001 Jan 29, 2021 Jan NEWA

SOLUTION; INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

+! BAXTER HLTHCARE CORP EQ 4MG BASE/250ML (EQ 16MCG  
BASE/ML) N214313 001 Jan 15, 2021 Jan NEWA+! EQ 8MG BASE/250ML (EQ 32MCG  
BASE/ML) N214313 002 Jan 15, 2021 Jan NEWANORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB ZYDUS EQ 10MG BASE A213441 001 Feb 24, 2021 Feb NEWA

AB EQ 50MG BASE A213441 003 Feb 24, 2021 Feb NEWA

AB EQ 75MG BASE A213441 004 Feb 24, 2021 Feb NEWA

NYSTATIN

OINTMENT;TOPICAL

NYSTATIN

AT MACLEODS PHARMS LTD 100,000 UNITS/GM A213826 001 Jan 14, 2021 Jan NEWA

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT ALEOR DERMACEUTICALS 100,000 UNITS/GM;0.1% A214090 001 Mar 31, 2021 Mar NEWA

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

@ ALVOGEN 0.3% A076830 001 Aug 31, 2004 Jan DISC

TABLET;ORAL

FLOXIN

+ @ JANSSEN PHARMS 200MG N019735 001 Dec 28, 1990 Jan CRLD

+ @ 300MG N019735 002 Dec 28, 1990 Jan CRLD

+ @ 400MG N019735 003 Dec 28, 1990 Jan CRLD

OFLOXACIN

&gt;D&gt; @ LARKEN LABS 400MG A076093 003 Sep 02, 2003 May CMFD

&gt;A&gt; AB 400MG A076093 003 Sep 02, 2003 May CMFD

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB HISUN PHARM HANGZHOU 2.5MG A206924 001 Dec 31, 2020 Feb CAHN

AB 5MG A206924 002 Dec 31, 2020 Feb CAHN

AB 7.5MG A206924 003 Dec 31, 2020 Feb CAHN

AB 10MG A206924 004 Dec 31, 2020 Feb CAHN

AB 15MG A206924 005 Dec 31, 2020 Feb CAHN

AB 20MG A206924 006 Dec 31, 2020 Feb CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB HISUN PHARM HANGZHOU 5MG A206892 001 Dec 31, 2020 Feb CAHN

AB 10MG A206892 002 Dec 31, 2020 Feb CAHN

AB 15MG A206892 003 Dec 31, 2020 Feb CAHN

AB 20MG A206892 004 Dec 31, 2020 Feb CAHN

>A>	<u>OLANZAPINE; SAMIDORPHAN L-MALATE</u>						
>A>	TABLET;ORAL						
>A>	LYBALVI						
>A>	+! ALKERMES INC	5MG;EQ 10MG BASE		N 213378	001	May 28, 2021	May NEWA
>A>	+	10MG;EQ 10MG BASE		N 213378	002	May 28, 2021	May NEWA
>A>	+	15MG;EQ 10MG BASE		N 213378	003	May 28, 2021	May NEWA
>A>	+	20MG;EQ 10MG BASE		N 213378	004	May 28, 2021	May NEWA
<u>OLOPATADINE HYDROCHLORIDE</u>							
	SOLUTION/DROPS;OPHTHALMIC						
	OLOPATADINE HYDROCHLORIDE						
	AKORN	EQ 0.2% BASE		A 204723	001	Dec 05, 2017	Mar CTEC
	SPRAY, METERED;NASAL						
	OLOPATADINE HYDROCHLORIDE						
AB	AMNEAL	0.665MG/SPRAY		A 210901	001	Jan 28, 2020	Mar CMFD
	@	0.665MG/SPRAY		A 210901	001	Jan 28, 2020	Jan DISC
<u>OMEGA-3-ACID ETHYL ESTERS</u>							
	CAPSULE;ORAL						
	LOVAZA						
AB	+! WOODWARD	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS		N 021654	001	Nov 10, 2004	Feb CAHN
<u>ONDANSETRON</u>							
	FILM;ORAL						
	ZUPLENZ						
	+ @ AQUESTIVE	4MG		N 022524	001	Jul 02, 2010	Feb CAHN
	+ @	8MG		N 022524	002	Jul 02, 2010	Feb CAHN
<u>ONDANSETRON HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION						
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
>D> AP	EMCURE PHARMS LTD	EQ 2MG BASE/ML		A 078945	001	Jan 03, 2013	May DISC
>A>	@	EQ 2MG BASE/ML		A 078945	001	Jan 03, 2013	May DISC
<u>ORITAVANCIN DIPHOSPHATE</u>							
	POWDER;INTRAVENOUS						
	KIMYRSA						
	+! MELINTA THERAP	EQ 1.2GM BASE/VIAL		N 214155	001	Mar 12, 2021	Mar NEWA
	ORBACTIV						
>D>	+! MELINTA THERAP	EQ 400MG BASE/VIAL		N 206334	001	Aug 06, 2014	May CAHN
>A>	+!	EQ 400MG BASE/VIAL		N 206334	001	Aug 06, 2014	May CAHN
<u>ORPHENADRINE CITRATE</u>							
	TABLET, EXTENDED RELEASE;ORAL						
	NORFLEX						
>A>	+ @ BAUSCH	100MG		N 012157	001		May CAHN
>D>	+ @ MEDICIS	100MG		N 012157	001		May CAHN
	ORPHENADRINE CITRATE						
	@ IMPAX PHARMS	100MG		A 040368	001	Jun 23, 2000	Jan DISC
<u>OSELTAMIVIR PHOSPHATE</u>							
	CAPSULE;ORAL						
	OSELTAMIVIR PHOSPHATE						
	@ MYLAN	EQ 30MG BASE		A 210157	001	Jan 21, 2021	Jan DISC
AB		EQ 30MG BASE		A 210157	001	Jan 21, 2021	Jan NEWA
	@	EQ 45MG BASE		A 210157	002	Jan 21, 2021	Jan DISC
AB		EQ 45MG BASE		A 210157	002	Jan 21, 2021	Jan NEWA
	@	EQ 75MG BASE		A 210157	003	Jan 21, 2021	Jan DISC
AB		EQ 75MG BASE		A 210157	003	Jan 21, 2021	Jan NEWA
<u>OXALIPLATIN</u>							
	INJECTABLE;INTRAVENOUS						
	OXALIPLATIN						
>D> AP	CIPLA	50MG/10ML (5MG/ML)		A 208523	001	Feb 10, 2017	May DISC
>A>	@	50MG/10ML (5MG/ML)		A 208523	001	Feb 10, 2017	May DISC
>D> AP		100MG/20ML (5MG/ML)		A 208523	002	Feb 10, 2017	May DISC
>A>	@	100MG/20ML (5MG/ML)		A 208523	002	Feb 10, 2017	May DISC

OXICONAZOLE NITRATE

LOTION;TOPICAL

OXISTAT

+! ANI PHARMS

EQ 1% BASE

N020209 001 Sep 30, 1992 Apr CAHN

OXYBUTYNIN CHLORIDE

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB

APPCO

5MG

A209025 001 Dec 21, 2017 Jan CAHN

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

@ LANNETT CO INC

5MG

A203823 001 Aug 01, 2014 Apr DISC

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

&gt;A&gt; AA

QUAGEN

5MG/5ML

A213761 001 Jun 02, 2021 May NEWA

&gt;A&gt; AA

100MG/5ML

A213761 002 Jun 02, 2021 May NEWA

TABLET;ORAL

OXAYDO

+ ZYLA

5MG

N202080 001 Jun 17, 2011 Mar CRLD

+ ZYLA

7.5MG

N202080 002 Jun 17, 2011 Mar CRLD

OXYCODONE HYDROCHLORIDE

AB

ALVOGEN

5MG

A202116 001 Dec 30, 2011 Apr CAHN

AB

15MG

A202116 002 Dec 30, 2011 Apr CAHN

AB

30MG

A202116 003 Dec 30, 2011 Apr CAHN

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

+ @ MYLAN SPECIALITY LP

50MG

N016848 001

Apr DISC

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA

&gt;D&gt;

+ CELGENE INTL

0.23MG

N209899 001 Mar 25, 2020 May CPOT

&gt;A&gt;

+

EQ 0.23MG BASE

N209899 001 Mar 25, 2020 May CPOT

&gt;D&gt;

+

0.46MG

N209899 002 Mar 25, 2020 May CPOT

&gt;A&gt;

+

EQ 0.46MG BASE

N209899 002 Mar 25, 2020 May CPOT

&gt;D&gt;

+!

0.92MG

N209899 003 Mar 25, 2020 May CPOT

&gt;A&gt;

+!

EQ 0.92MG BASE

N209899 003 Mar 25, 2020 May CPOT

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

&gt;D&gt;

@ ACCORD HLTHCARE

6MG/ML

A205720 001 Aug 17, 2018 May CMFD

&gt;A&gt; AP

@ MYLAN LABS LTD

6MG/ML

A205720 001 Aug 17, 2018 May CMFD

A091540 001 Sep 29, 2011 Mar DISC

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

ALOXI

+ @ HELSINN HLTHCARE

EQ 0.075MG BASE/1.5ML (EQ 0.05MG  
BASE/ML)

N021372 002 Feb 29, 2008 Apr DISC

+

@ EQ 0.25MG BASE/5ML (EQ 0.05MG  
BASE/ML)

N021372 001 Jul 25, 2003 Apr DISC

PALONOSETRON HYDROCHLORIDE

AP

ACCORD HLTHCARE

EQ 0.25MG BASE/5ML (EQ 0.05MG  
BASE/ML)

A204615 001 Mar 15, 2021 Mar NEWA

AP

! DR REDDYS LABS LTD

EQ 0.25MG BASE/5ML (EQ 0.05MG  
BASE/ML)

A201533 002 Apr 21, 2016 Apr CHRS

@ HOSPIRA INC

EQ 0.075MG BASE/1.5ML (EQ 0.05MG  
BASE/ML)

A207005 002 Sep 19, 2018 Apr DISC

@ QILU

EQ 0.075MG BASE/1.5ML (EQ 0.05MG  
BASE/ML)

A205648 002 Sep 19, 2018 Apr DISC

@ TEVA PHARMS USA

EQ 0.075MG BASE/1.5ML (EQ 0.05MG  
BASE/ML)

A090713 002 Mar 23, 2018 Apr DISC

SOLUTION;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

&gt;D&gt;

+ FRESENIUS KABI USA

EQ 0.25MG BASE/5ML (EQ 0.05MG  
BASE/ML)

N208109 001 Nov 21, 2017 May DISC

&gt;A&gt;

+ @

EQ 0.25MG BASE/5ML (EQ 0.05MG  
BASE/ML)

N208109 001 Nov 21, 2017 May DISC

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
PAROXETINE HYDROCHLORIDE

AB	CSPC OUYI	EQ 12.5MG BASE	A213485	001	Feb 16, 2021	Feb NEWA
AB		EQ 25MG BASE	A213485	002	Feb 16, 2021	Feb NEWA
AB		EQ 37.5MG BASE	A213485	003	Feb 16, 2021	Feb NEWA

&gt;A&gt; PEGCETACOPLAN

>A> SOLUTION;SUBCUTANEOUS  
>A> EMPAVELI  
>A> +! APELLIS PHARMS 1080MG/20ML (54MG/ML)

N215014 001 May 14, 2021 May NEWA

PEMETREXED

SOLUTION;INTRAVENOUS  
PEMETREXED

+ @ ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	Jan DISC
+ @	500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	Jan DISC
+ @	1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	Jan DISC

PENICILLIN G POTASSIUM

INJECTABLE;INJECTION  
PENICILLIN G POTASSIUM

AP	HQ SPECLT PHARMA	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009	Mar CAHN
AP		5,000,000 UNITS/VIAL	A065149	002	Jul 23, 2009	Mar CAHN
AP		20,000,000 UNITS/VIAL	A065149	003	Jul 23, 2009	Mar CAHN

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL  
PENICILLIN V POTASSIUM

@ DAVA PHARMS INC	EQ 125MG BASE/5ML	A062981	001	Feb 10, 1989	Mar DISC
@	EQ 250MG BASE/5ML	A062981	002	Feb 10, 1989	Mar DISC
PENICILLIN-VK					
TEVA	EQ 125MG BASE/5ML	A060456	001		Mar CTEC
!	EQ 250MG BASE/5ML	A060456	002		Mar CTEC

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION  
PENTAMIDINE ISETHIONATE

AP	EMCURE PHARMS LTD	300MG/VIAL	A213806	001	Jan 07, 2021	Jan NEWA
----	-------------------	------------	---------	-----	--------------	----------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL  
PENTOXIL

>D> AB	UPSHER SMITH LABS	400MG	A074962	001	Mar 31, 1999	May DISC
>A>	@	400MG	A074962	001	Mar 31, 1999	May DISC
	TRENTAL					
	+ @ VALIDUS PHARMS	400MG	N018631	001	Aug 30, 1984	Feb CAHN

PERAMPANEL

TABLET;ORAL  
PERAMPANEL

>A> AB	ACCORD HLTHCARE	2MG	A209877	001	Jun 08, 2021	May NFTG
>A> AB		4MG	A209877	002	Jun 08, 2021	May NFTG
>A> AB		6MG	A209877	003	Jun 08, 2021	May NFTG
>A> AB		8MG	A209877	004	Jun 08, 2021	May NFTG
>A> AB		10MG	A209877	005	Jun 08, 2021	May NFTG
>A> AB		12MG	A209877	006	Jun 08, 2021	May NFTG
>A> AB	TEVA PHARMS USA INC	2MG	A209801	001	Jun 08, 2021	May NFTG
>A> AB		4MG	A209801	002	Jun 08, 2021	May NFTG
>A> AB		6MG	A209801	003	Jun 08, 2021	May NFTG
>A> AB		8MG	A209801	004	Jun 08, 2021	May NFTG
>A> AB		10MG	A209801	005	Jun 08, 2021	May NFTG
>A> AB		12MG	A209801	006	Jun 08, 2021	May NFTG

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS  
BIORPHEN

+! ETON PHARMS	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Feb CPOT
+ @	10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Apr DISC
+!	10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Mar NEWA

SOLUTION; INTRAVENOUSPHENYLEPHRINE HYDROCHLORIDE

AP2	AUROBINDO PHARMA LTD	10MG/ML (10MG/ML)	A210696	001	Jan 07, 2021	Jan NEWA
AP1	GLAND PHARMA LTD	10MG/ML (10MG/ML)	A211920	003	Apr 08, 2021	Apr NEWA
AP2	+! HIKMA	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Jan CAHN
AP2	+!	50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Jan CAHN
AP2	+!	100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Jan CAHN
AP1	PROVEPHARM SAS	10MG/ML (10MG/ML)	A211081	001	Jul 17, 2020	Jan CAHN
AP1		50MG/5ML (10MG/ML)	A211081	002	Jul 17, 2020	Jan CAHN
AP1		100MG/10ML (10MG/ML)	A211081	003	Jul 17, 2020	Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDESYRUP; ORALPHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	AKORN	5MG/5ML; 6.25MG/5ML	A040675	001	Dec 23, 2014	Feb CAHN
----	-------	---------------------	---------	-----	--------------	----------

PHYTONADIONEINJECTABLE; INJECTIONPHYTONADIONE

>D> BP	! INTL MEDICATION	1MG/0.5ML	A083722	001	May CRLD
>A> BP	+!	1MG/0.5ML	A083722	001	May CRLD

&gt;A&gt; PIFLUFOLASTAT F-18

&gt;A&gt; SOLUTION; INTRAVENOUS

&gt;A&gt; PYLARIFY

&gt;A&gt; +! PROGENICS PHARMS INC 50ML (1-80mCi/ML)

N214793 001 May 26, 2021 May NEWA

PIOGLITAZONE HYDROCHLORIDETABLET; ORALPIOGLITAZONE HYDROCHLORIDE

AB	ANNORA PHARMA	EQ 15MG BASE	A204133	001	Apr 07, 2014	Jan CAHN
AB		EQ 30MG BASE	A204133	002	Apr 07, 2014	Jan CAHN
AB		EQ 45MG BASE	A204133	003	Apr 07, 2014	Jan CAHN
>D>	@ NEOPHARMA	EQ 15MG BASE	A078383	001	Mar 12, 2013	May CAHN
>D>	@	EQ 30MG BASE	A078383	002	Mar 12, 2013	May CAHN
>D>	@	EQ 45MG BASE	A078383	003	Mar 12, 2013	May CAHN
AB	SHUANGCHENG	EQ 15MG BASE	A210165	001	Jan 22, 2021	Jan NEWA
AB		EQ 30MG BASE	A210165	002	Jan 22, 2021	Jan NEWA
AB		EQ 45MG BASE	A210165	003	Jan 22, 2021	Jan NEWA
>A>	@ US ANTIBIOTICS	EQ 15MG BASE	A078383	001	Mar 12, 2013	May CAHN
>A>	@	EQ 30MG BASE	A078383	002	Mar 12, 2013	May CAHN
>A>	@	EQ 45MG BASE	A078383	003	Mar 12, 2013	May CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUMINJECTABLE; INJECTIONPIPERACILLIN AND TAZOBACTAM

AB	MYLAN LABS LTD	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Apr DISC
	@	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Mar DISC
AP	PROVEPHARM SAS	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan CAHN
AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan CAHN
AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan CAHN
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan CAHN
AP		EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018	Jan CAHN
AP	SAGENT PHARMS INC	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A208674	001	Feb 16, 2021	Feb NEWA
AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A208674	002	Feb 16, 2021	Feb NEWA
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A208674	003	Feb 16, 2021	Feb NEWA
AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A208675	001	Feb 16, 2021	Feb NEWA
AP	! WOCKHARDT BIO AG	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Jan CHRS
AP	!	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Jan CHRS
AP	!	EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Jan CHRS
AP	!	EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan CHRS

INJECTABLE; INJECTION

ZOSYN

+ @ WYETH PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N 050684 001 Oct 22, 1993	Jan DISC
+ @	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N 050684 002 Oct 22, 1993	Jan DISC
+ @	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N 050684 003 Oct 22, 1993	Jan DISC
+ @	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N 050684 004 Oct 22, 1993	Jan DISC

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

>A>	@ BAUSCH	EQ 0.2MG BASE/INH	N 020014 001 Nov 30, 1992	May CAHN
>D>	@ MEDICIS	EQ 0.2MG BASE/INH	N 020014 001 Nov 30, 1992	May CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB	NOSTRUM LABS INC	10MG	A 074118 002 Jun 15, 1993	Jan CMS1
----	------------------	------	---------------------------	----------

POLYMYXIN B SULFATEINJECTABLE; INJECTION  
POLYMYXIN B SULFATE

>A>	@ GLAND	EQ 500,000 UNITS BASE/VIAL	A 207322 001 Apr 14, 2016	May DISC
>D> AP	! GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A 207322 001 Apr 14, 2016	May DISC
>D> AP	XELLIA PHARMS APS	EQ 500,000 UNITS BASE/VIAL	A 202766 001 Jan 15, 2014	May CHRS
>A> AP	!	EQ 500,000 UNITS BASE/VIAL	A 202766 001 Jan 15, 2014	May CHRS

POMALIDOMIDE

CAPSULE; ORAL

POMALIDOMIDE

@ BRECKENRIDGE	1MG	A 210111 001 Oct 30, 2020	Feb DISC
@	2MG	A 210111 002 Oct 30, 2020	Feb DISC
@	3MG	A 210111 003 Oct 30, 2020	Feb DISC
@	4MG	A 210111 004 Oct 30, 2020	Feb DISC
@ EUGIA PHARMA	1MG	A 210249 001 Oct 30, 2020	Apr DISC
@	2MG	A 210249 002 Oct 30, 2020	Apr DISC
@	3MG	A 210249 003 Oct 30, 2020	Apr DISC
@	4MG	A 210249 004 Oct 30, 2020	Apr DISC
POMALYST			
+ CELGENE	1MG	N 204026 001 Feb 08, 2013	Apr CTEC
+	2MG	N 204026 002 Feb 08, 2013	Apr CTEC
+	3MG	N 204026 003 Feb 08, 2013	Apr CTEC
+!	4MG	N 204026 004 Feb 08, 2013	Apr CTEC

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

>D>	+ ARIAD	EQ 10MG BASE	N 203469 004 Dec 18, 2020	May CAHN
>D>	+	EQ 15MG BASE	N 203469 001 Dec 14, 2012	May CAHN
>D>	+	EQ 30MG BASE	N 203469 003 Apr 23, 2015	May CAHN
>D>	+!	EQ 45MG BASE	N 203469 002 Dec 14, 2012	May CAHN
>A>	+ TAKEDA PHARMS USA	EQ 10MG BASE	N 203469 004 Dec 18, 2020	May CAHN
>A>	+	EQ 15MG BASE	N 203469 001 Dec 14, 2012	May CAHN
>A>	+	EQ 30MG BASE	N 203469 003 Apr 23, 2015	May CAHN
>A>	+!	EQ 45MG BASE	N 203469 002 Dec 14, 2012	May CAHN

PONESIMOD

TABLET; ORAL

PONVORY

+ JANSSEN PHARMS	2MG	N 213498 001 Mar 18, 2021	Mar NEWA
+	3MG	N 213498 002 Mar 18, 2021	Mar NEWA
+	4MG	N 213498 003 Mar 18, 2021	Mar NEWA
+	5MG	N 213498 004 Mar 18, 2021	Mar NEWA
+	6MG	N 213498 005 Mar 18, 2021	Mar NEWA
+	7MG	N 213498 006 Mar 18, 2021	Mar NEWA
+	8MG	N 213498 007 Mar 18, 2021	Mar NEWA
+	9MG	N 213498 008 Mar 18, 2021	Mar NEWA
+	10MG	N 213498 009 Mar 18, 2021	Mar NEWA
+!	20MG	N 213498 010 Mar 18, 2021	Mar NEWA

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL

>A> NOXAFIL POWDERMIX KIT  
 >A> +! MSD MERCK CO 300MG N214770 001 May 31, 2021 May NEWA  
 TABLET, DELAYED RELEASE;ORAL  
 POSACONAZOLE  
 AB AET PHARMA 100MG A213454 001 Feb 01, 2021 Jan NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB GRANULES 8MEQ A214686 001 Feb 16, 2021 Feb NEWA  
 AB 10MEQ A214686 002 Feb 16, 2021 Feb NEWA  
 FOR SOLUTION;ORAL  
 POTASSIUM CHLORIDE  
 AA STRIDES PHARMA 20MEQ A211667 001 Mar 11, 2021 Mar NEWA  
 INJECTABLE;INJECTION  
 POTASSIUM CHLORIDE 10MEQ  
 @ FRESENIUS KABI USA 14.9MG/ML A211087 001 Sep 09, 2020 Mar DISC  
 @ 746MG/100ML A211087 002 Sep 09, 2020 Mar DISC  
 AP NEXUS PHARMS 14.9MG/ML A214727 001 Mar 18, 2021 Mar NFTG  
 AP 745MG/100ML A214727 002 Mar 18, 2021 Mar NFTG  
 POTASSIUM CHLORIDE 20MEQ  
 @ FRESENIUS KABI USA 29.8MG/ML A211087 003 Sep 09, 2020 Mar DISC  
 AP 1.49GM/100ML A211087 005 May 07, 2021 Apr NEWA  
 AP NEXUS PHARMS 29.8MG/ML A214727 003 Mar 18, 2021 Mar NFTG  
 AP 1.49GM/100ML A214727 004 Mar 18, 2021 Mar NFTG  
 POTASSIUM CHLORIDE 40MEQ  
 @ FRESENIUS KABI USA 2.98GM/100ML A211087 004 Sep 09, 2020 Mar DISC  
 AP NEXUS PHARMS 2.98GM/100ML A214727 005 Mar 18, 2021 Mar NFTG  
 SOLUTION;ORAL  
 POTASSIUM CHLORIDE  
 AA GRANULES 20MEQ/15ML A213392 001 Jan 29, 2021 Jan NEWA  
 AA 40MEQ/15ML A213392 002 Jan 29, 2021 Jan NEWA  
 >A> AA SAPTALIS PHARMS 20MEQ/15ML A211648 001 May 21, 2021 May NEWA  
 >A> AA 40MEQ/15ML A211648 002 May 21, 2021 May NEWA

TABLET, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

AB1 AMTA 10MEQ A214395 001 Jan 28, 2021 Jan NEWA  
 AB1 20MEQ A214395 002 Jan 28, 2021 Jan NEWA  
 AB1 AUROBINDO PHARMA LTD 10MEQ A214728 001 Mar 31, 2021 Mar NEWA  
 AB1 15MEQ A214728 002 Mar 31, 2021 Mar NEWA  
 AB1 20MEQ A214728 003 Mar 31, 2021 Mar NEWA  
 @ CENTAUR PHARMS PVT 10MEQ A213588 001 Aug 21, 2020 Mar DISC  
 @ 20MEQ A213588 002 Aug 21, 2020 Mar DISC

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

+! BAXTER HLTHCARE 150MG/100ML;450MG/100ML N017648 005 Nov 26, 2002 Mar CTNA  
 +! 150MG/100ML;450MG/100ML N017648 005 Nov 26, 2002 Mar CTEC  
 @ FRESENIUS KABI USA 150MG/100ML;450MG/100ML A212347 001 Sep 17, 2020 Mar DISC  
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%  
 AP +! BAXTER HLTHCARE 150MG/100ML;900MG/100ML N017648 001 Mar CTNA  
 AP +! 150MG/100ML;900MG/100ML N017648 001 Mar CHRS  
 >A> AP FRESENIUS KABI USA 150MG/100ML;900MG/100ML A212347 003 Jun 02, 2021 May NEWA  
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%  
 +! BAXTER HLTHCARE 300MG/100ML;900MG/100ML N017648 002 Mar CTNA  
 +! 300MG/100ML;900MG/100ML N017648 002 Mar CHRS  
 + 300MG/100ML;900MG/100ML N017648 002 Mar CTEC  
 @ FRESENIUS KABI USA 300MG/100ML;900MG/100ML A212347 002 Sep 17, 2020 Mar DISC  
 SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%  
 @ BAXTER HLTHCARE 75MG/100ML;900MG/100ML N017648 004 Mar CTNA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB ASCENT PHARMS INC 5MEQ A214420 001 Feb 05, 2021 Jan NEWA  
 AB 10MEQ A214420 002 Feb 05, 2021 Jan NEWA  
 AB 15MEQ A214420 003 Feb 05, 2021 Jan NEWA  
 AB BIONPHARMA INC 10MEQ A212799 001 Jun 29, 2020 Apr CMFD

**TABLET, EXTENDED RELEASE;ORAL  
POTASSIUM CITRATE**

AB	@	10MEQ	A212799	001	Jun 29, 2020	Feb DISC
		15MEQ	A212799	002	Jun 29, 2020	Apr CMFD
AB	@	15MEQ	A212799	002	Jun 29, 2020	Feb DISC
AB	EYWA	5MEQ	A214426	001	Feb 19, 2021	Feb NEWA
AB		10MEQ	A214426	002	Feb 19, 2021	Feb NEWA
AB		15MEQ	A214426	003	Feb 19, 2021	Feb NEWA

**PRALSETINIB**

CAPSULE;ORAL  
GAVRETO  
+! GENENTECH INC 100MG

N213721 001 Sep 04, 2020 Mar CAHN

**PRAMIPEXOLE DIHYDROCHLORIDE**

TABLET;ORAL  
PRAMIPEXOLE DIHYDROCHLORIDE

AB	NOSTRUM LABS INC	0.125MG	A091450	001	Oct 08, 2010	Apr CAHN
AB		0.25MG	A091450	002	Oct 08, 2010	Apr CAHN
AB		0.5MG	A091450	003	Oct 08, 2010	Apr CAHN
AB		1MG	A091450	004	Oct 08, 2010	Apr CAHN
AB		1.5MG	A091450	005	Oct 08, 2010	Apr CAHN

**PRASUGREL HYDROCHLORIDE**

TABLET;ORAL  
PRASUGREL  
@ DR REDDYS LABS LTD EQ 5MG BASE  
@ EQ 10MG BASE

A205926 001 Jul 07, 2020 Jan DISC  
A205926 002 Jul 07, 2020 Jan DISC

**PRAVASTATIN SODIUM**

TABLET;ORAL  
PRAVASTATIN SODIUM

AB	BIOCON PHARMA	10MG	A209869	001	Apr 13, 2018	Jan CAHN
AB		20MG	A209869	002	Apr 13, 2018	Jan CAHN
AB		40MG	A209869	003	Apr 13, 2018	Jan CAHN
AB		80MG	A209869	004	Apr 13, 2018	Jan CAHN
	@ HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018	Jan DISC
	@	40MG	A206061	002	Nov 23, 2018	Jan DISC
	@	80MG	A206061	003	Nov 23, 2018	Jan DISC

**PRAZOSIN HYDROCHLORIDE**

CAPSULE;ORAL  
PRAZOSIN HYDROCHLORIDE  
AB ANI PHARMS EQ 1MG BASE  
AB EQ 2MG BASE  
AB EQ 5MG BASE

A072577 002 May 16, 1989 Feb CMFD  
A072577 001 May 16, 1989 Feb CMFD  
A072577 003 May 16, 1989 Feb CMFD

**PREDNISOLONE**

SYRUP;ORAL  
PREDNISOLONE  
AA CHARTWELL RX 15MG/5ML  
TABLET;ORAL  
PREDNISOLONE  
@ RISING 5MG

A040323 001 May 13, 1999 Mar CMFD  
A084773 001 Jan CAHN

**PREDNISOLONE SODIUM PHOSPHATE**

SOLUTION;ORAL  
PREDNISOLONE SODIUM PHOSPHATE  
>A> @ BAUSCH EQ 15MG BASE/5ML  
>D> @ MEDICIS PHARMS EQ 15MG BASE/5ML

A075250 001 Jul 12, 2002 May CAHN  
A075250 001 Jul 12, 2002 May CAHN

**PREDNISONE**

TABLET;ORAL  
PREDNISONE  
@ RISING 10MG  
@ 20MG  
@ 50MG  
AB STRIDES PHARMA 10MG  
AB 20MG

A089983 001 Jan 12, 1989 Jan CAHN  
A085813 001 Jan CAHN  
A089984 001 Jan 12, 1989 Jan CAHN  
A208412 001 Feb 11, 2021 Feb NEWA  
A208412 002 Feb 11, 2021 Feb NEWA

## TABLET, DELAYED RELEASE;ORAL

RAYOS

+ HORIZON	1MG	N202020	001	Jul 26, 2012	Apr CAHN
+ !	2MG	N202020	002	Jul 26, 2012	Apr CAHN
	5MG	N202020	003	Jul 26, 2012	Apr CAHN

PREGABALIN

## CAPSULE;ORAL

LYRICA

AB + UPJOHN	25MG	N021446	001	Dec 30, 2004	Apr CAHN
AB +	50MG	N021446	002	Dec 30, 2004	Apr CAHN
AB +	75MG	N021446	003	Dec 30, 2004	Apr CAHN
AB +	100MG	N021446	004	Dec 30, 2004	Apr CAHN
AB +	150MG	N021446	005	Dec 30, 2004	Apr CAHN
AB +	200MG	N021446	006	Dec 30, 2004	Apr CAHN
AB +	225MG	N021446	007	Dec 30, 2004	Apr CAHN
AB +!	300MG	N021446	008	Dec 30, 2004	Apr CAHN

PREGABALIN

AB ALKEM LABS LTD	25MG	A207799	007	Sep 30, 2019	Feb CMS1
AB	50MG	A207799	008	Sep 30, 2019	Feb CMS1

## SOLUTION;ORAL

LYRICA

AA +! UPJOHN	20MG/ML	N022488	001	Jan 04, 2010	Apr CAHN
--------------	---------	---------	-----	--------------	----------

## TABLET, EXTENDED RELEASE;ORAL

LYRICA CR

AB + UPJOHN	82.5MG	N209501	001	Oct 11, 2017	Apr CAHN
AB +	165MG	N209501	002	Oct 11, 2017	Apr CAHN
AB +!	330MG	N209501	003	Oct 11, 2017	Apr CAHN

PREGABALIN

AB ALVOGEN PINE BROOK	82.5MG	A211593	001	Apr 13, 2021	Apr NFTG
AB	165MG	A211593	002	Apr 13, 2021	Apr NFTG
AB	330MG	A211593	003	Apr 13, 2021	Apr NFTG
AB APOTEX	165MG	A213313	001	Apr 13, 2021	Apr NFTG
AB	330MG	A213313	002	Apr 13, 2021	Apr NFTG
AB MSN	82.5MG	A213226	001	Apr 13, 2021	Apr NFTG
AB	165MG	A213226	002	Apr 13, 2021	Apr NFTG
AB	330MG	A213226	003	Apr 13, 2021	Apr NFTG
AB MYLAN	82.5MG	A211948	001	Apr 13, 2021	Apr NFTG
AB SUN PHARM	82.5MG	A211889	001	Apr 13, 2021	Apr NFTG
AB	165MG	A211889	002	Apr 13, 2021	Apr NFTG
AB	330MG	A211889	003	Apr 13, 2021	Apr NFTG

PROCHLORPERAZINE EDISYLATE

## INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

AP CAPLIN	EQ 5MG BASE/ML	A214379	001	Apr 22, 2021	Apr NEWA
-----------	----------------	---------	-----	--------------	----------

PROMETHAZINE HYDROCHLORIDE

## SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

@ AMNEAL PHARMS	6.25MG/5ML	A040882	001	Dec 30, 2009	Feb DISC
-----------------	------------	---------	-----	--------------	----------

PROPAFENONE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

AB ZYDUS	225MG	A214184	001	Apr 21, 2021	Apr NEWA
AB	325MG	A214184	002	Apr 21, 2021	Apr NEWA
AB	425MG	A214184	003	Apr 21, 2021	Apr NEWA

PROPANTHELINE BROMIDE

## TABLET;ORAL

PROPANTHELINE BROMIDE

@ HIKMA	15MG	A080927	002		Apr DISC
---------	------	---------	-----	--	----------

PROPRANOLOL HYDROCHLORIDE

## TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

@ WATSON LABS	60MG	A070178	002	Apr 23, 2018	Apr DISC
---------------	------	---------	-----	--------------	----------

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

BD QUAGEN 50MG A080154 001 Mar CMFD

PYRAZINAMIDE

TABLET;ORAL

PYRAZINAMIDE

AB NOVITIUM PHARMA 500MG A080157 001 Apr CMFD

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

@ MYLAN	EQ 50MG BASE	A202228	001	Feb 02, 2021	Feb DISC
AB @	EQ 50MG BASE	A202228	001	Feb 02, 2021	Jan NEWA
AB @	EQ 150MG BASE	A202228	002	Feb 02, 2021	Feb DISC
AB @	EQ 150MG BASE	A202228	002	Feb 02, 2021	Jan NEWA
AB @	EQ 200MG BASE	A202228	003	Feb 02, 2021	Feb DISC
AB @	EQ 200MG BASE	A202228	003	Feb 02, 2021	Jan NEWA
AB @	EQ 300MG BASE	A202228	004	Feb 02, 2021	Feb DISC
AB @	EQ 300MG BASE	A202228	004	Feb 02, 2021	Jan NEWA
AB @	EQ 400MG BASE	A202228	005	Feb 02, 2021	Feb DISC
AB @	EQ 400MG BASE	A202228	005	Feb 02, 2021	Jan NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

@ RISING 324MG

A089894 001 Dec 15, 1988 Jan CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ WOCKHARDT LTD EQ 150MG BASE  
@ EQ 300MG BASEA075208 001 Dec 17, 1998 Jan DISC  
A075208 002 Dec 17, 1998 Jan DISCRANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

>A> AB ACCORD HLTHCARE	500MG	A212930	001	May 18, 2021	May NEWA
	1GM	A212930	002	May 18, 2021	May NEWA
>A> AB @ AMNEAL	500MG	A207690	001	Mar 11, 2021	Apr DISC
AB @	500MG	A207690	001	Mar 11, 2021	Mar NEWA
AB @	1GM	A207690	002	Mar 11, 2021	Apr DISC
AB @	1GM	A207690	002	Mar 11, 2021	Mar NEWA
AB GRAVITI PHARMS	500MG	A212889	001	Jan 28, 2021	Jan NEWA
AB @	1GM	A212889	002	Jan 28, 2021	Jan NEWA
AB PRAXGEN	500MG	A212781	001	Mar 23, 2020	Feb CAHN
AB @	1GM	A212781	002	Mar 23, 2020	Feb CAHN

RILUZOLE

FILM;ORAL

EXSERVAN

+! MITSUBISHI HOLDINGS 50MG

N212640 001 Nov 22, 2019 Feb CAHN

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERDAL

+ @ JANSSEN PHARMS 0.5MG  
+ @ 1MG  
+ @ 2MG  
+ @ 3MG  
+ @ 4MGN021444 001 Apr 02, 2003 Feb DISC  
N021444 002 Apr 02, 2003 Feb DISC  
N021444 003 Apr 02, 2003 Feb DISC  
N021444 004 Dec 23, 2004 Feb DISC  
N021444 005 Dec 23, 2004 Feb DISC

AB ! JUBILANT GENERICS 1MG A090839 002 Nov 04, 2011 Feb CHRS

RITONAVIR

CAPSULE;ORAL

RITONAVIR

@ HIKMA 100MG

A205801 001 Dec 03, 2020 Mar DISC

ROPIVACAINE HYDROCHLORIDE

## SOLUTION; INJECTION

## NAROPIN

+ @ FRESENIUS KABI USA	50MG/10ML (5MG/ML)
+ @	75MG/10ML (7.5MG/ML)
ROPIVACAINE HYDROCHLORIDE	
@ MYLAN ASI	150MG/30ML (5MG/ML)
@	200MG/20ML (10MG/ML)

N020533	013	May 01, 1998	Mar CRLD
N020533	012	Sep 24, 1996	Mar CRLD
A090318	002	Sep 23, 2014	Jan DISC
A090318	004	Sep 23, 2014	Jan DISC

ROSUVASTATIN CALCIUM

## TABLET; ORAL

## CRESTOR

AB + IPR	EQ 5MG BASE	N021366	002	Aug 12, 2003	Apr CPOT
AB +	EQ 10MG BASE	N021366	003	Aug 12, 2003	Apr CPOT
AB +!	EQ 40MG BASE	N021366	005	Aug 12, 2003	Apr CPOT
ROSVUVESTATIN CALCIUM					
AB ACCORD HLTHCARE	EQ 5MG BASE	A206434	001	Oct 31, 2016	Apr CPOT
AB	EQ 10MG BASE	A206434	002	Oct 31, 2016	Apr CPOT
AB	EQ 20MG BASE	A206434	003	Oct 31, 2016	Apr CPOT
AB	EQ 40MG BASE	A206434	004	Oct 31, 2016	Apr CPOT
AB ALKEM LABS LTD	EQ 5MG BASE	A206465	001	Mar 21, 2017	Apr CPOT
AB	EQ 10MG BASE	A206465	002	Mar 21, 2017	Apr CPOT
AB	EQ 20MG BASE	A206465	003	Mar 21, 2017	Apr CPOT
AB	EQ 40MG BASE	A206465	004	Mar 21, 2017	Apr CPOT
AB ALLIED	EQ 5MG BASE	A079168	001	Jul 19, 2016	Apr CPOT
AB	EQ 10MG BASE	A079168	002	Jul 19, 2016	Apr CPOT
AB	EQ 20MG BASE	A079168	003	Jul 19, 2016	Apr CPOT
AB	EQ 40MG BASE	A079168	004	Jul 19, 2016	Apr CPOT
AB @ AMNEAL PHARMS CO	EQ 5MG BASE	A208850	001	Oct 16, 2018	Apr CPOT
AB @	EQ 10MG BASE	A208850	002	Oct 16, 2018	Apr CPOT
AB @	EQ 20MG BASE	A208850	003	Oct 16, 2018	Apr CPOT
AB @	EQ 40MG BASE	A208850	004	Oct 16, 2018	Apr CPOT
AB @ APOTEX INC	EQ 5MG BASE	A079145	001	Jul 19, 2016	Apr CPOT
AB @	EQ 10MG BASE	A079145	002	Jul 19, 2016	Apr CPOT
AB @	EQ 20MG BASE	A079145	003	Jul 19, 2016	Apr CPOT
AB @	EQ 40MG BASE	A079145	004	Jul 19, 2016	Apr CPOT
AB AUROBINDO PHARMA LTD	EQ 5MG BASE	A079170	001	Jul 19, 2016	Apr CPOT
AB	EQ 10MG BASE	A079170	002	Jul 19, 2016	Apr CPOT
AB	EQ 20MG BASE	A079170	003	Jul 19, 2016	Apr CPOT
AB	EQ 40MG BASE	A079170	004	Jul 19, 2016	Apr CPOT
AB BIOCON LTD	EQ 5MG BASE	A207752	001	Oct 31, 2016	Apr CPOT
AB	EQ 10MG BASE	A207752	002	Oct 31, 2016	Apr CPOT
AB	EQ 20MG BASE	A207752	003	Oct 31, 2016	Apr CPOT
AB	EQ 40MG BASE	A207752	004	Oct 31, 2016	Apr CPOT
AB CADILA PHARMS LTD	EQ 5MG BASE	A207453	001	Nov 23, 2016	Apr CPOT
AB	EQ 10MG BASE	A207453	002	Nov 23, 2016	Apr CPOT
AB	EQ 20MG BASE	A207453	003	Nov 23, 2016	Apr CPOT
AB	EQ 40MG BASE	A207453	004	Nov 23, 2016	Apr CPOT
AB CHANGZHOU PHARM	EQ 5MG BASE	A207408	001	Oct 31, 2016	Apr CPOT
AB	EQ 10MG BASE	A207408	002	Oct 31, 2016	Apr CPOT
AB	EQ 20MG BASE	A207408	003	Oct 31, 2016	Apr CPOT
AB	EQ 40MG BASE	A207408	004	Oct 31, 2016	Apr CPOT
AB GLENMARK PHARMS	EQ 5MG BASE	A079172	001	Jul 19, 2016	Apr CPOT
AB	EQ 10MG BASE	A079172	002	Jul 19, 2016	Apr CPOT
AB	EQ 20MG BASE	A079172	003	Jul 19, 2016	Apr CPOT
AB	EQ 40MG BASE	A079172	004	Jul 19, 2016	Apr CPOT
AB HETERO LABS LTD V	EQ 5MG BASE	A207616	001	Oct 31, 2016	Apr CPOT
AB	EQ 10MG BASE	A207616	002	Oct 31, 2016	Apr CPOT
AB	EQ 20MG BASE	A207616	003	Oct 31, 2016	Apr CPOT
AB	EQ 40MG BASE	A207616	004	Oct 31, 2016	Apr CPOT
>D> AB INVENTIA	EQ 5MG BASE	A207653	001	Feb 05, 2021	May DISC
>A> @	EQ 5MG BASE	A207653	001	Feb 05, 2021	May DISC
AB	EQ 5MG BASE	A207653	001	Feb 05, 2021	Apr CPOT
AB	5MG	A207653	001	Feb 05, 2021	Jan NEWA
>D> AB	EQ 10MG BASE	A207653	002	Feb 05, 2021	May DISC
>A> @	EQ 10MG BASE	A207653	002	Feb 05, 2021	May DISC
AB	EQ 10MG BASE	A207653	002	Feb 05, 2021	Apr CPOT
AB	10MG	A207653	002	Feb 05, 2021	Jan NEWA
>D> AB	EQ 20MG BASE	A207653	003	Feb 05, 2021	May DISC
>A> @	EQ 20MG BASE	A207653	003	Feb 05, 2021	May DISC
AB	EQ 20MG BASE	A207653	003	Feb 05, 2021	Apr CPOT
AB	20MG	A207653	003	Feb 05, 2021	Jan NEWA

TABLET;ORAL  
ROSVASTATIN CALCIUM

>D>	AB		EQ 40MG BASE	A207653	004	Feb 05, 2021	May DISC
>A>	@		EQ 40MG BASE	A207653	004	Feb 05, 2021	May DISC
AB			EQ 40MG BASE	A207653	004	Feb 05, 2021	Apr CPOT
AB			40MG	A207653	004	Feb 05, 2021	Jan NEWA
AB	LUPIN		EQ 5MG BASE	A205587	001	Jul 31, 2017	Apr CPOT
AB			EQ 10MG BASE	A205587	002	Jul 31, 2017	Apr CPOT
AB			EQ 20MG BASE	A205587	003	Jul 31, 2017	Apr CPOT
AB			EQ 40MG BASE	A205587	004	Jul 31, 2017	Apr CPOT
AB	MSN		EQ 5MG BASE	A208898	001	Nov 22, 2017	Apr CPOT
AB			EQ 10MG BASE	A208898	002	Nov 22, 2017	Apr CPOT
AB			EQ 20MG BASE	A208898	003	Nov 22, 2017	Apr CPOT
AB			EQ 40MG BASE	A208898	004	Nov 22, 2017	Apr CPOT
	@ MYLAN		EQ 5MG BASE	A079161	001	Jul 19, 2016	Apr CPOT
	@		EQ 10MG BASE	A079161	002	Jul 19, 2016	Apr CPOT
	@		EQ 20MG BASE	A079161	003	Jul 19, 2016	Apr CPOT
	@		EQ 40MG BASE	A079161	004	Jul 19, 2016	Apr CPOT
AB	RENATA		EQ 5MG BASE	A207062	001	Oct 31, 2016	Apr CPOT
AB			EQ 10MG BASE	A207062	002	Oct 31, 2016	Apr CPOT
AB			EQ 20MG BASE	A207062	003	Oct 31, 2016	Apr CPOT
AB			EQ 40MG BASE	A207062	004	Oct 31, 2016	Apr CPOT
AB	SANDOZ INC		EQ 5MG BASE	A079171	001	Jul 19, 2016	Apr CPOT
AB			EQ 10MG BASE	A079171	002	Jul 19, 2016	Apr CPOT
AB			EQ 20MG BASE	A079171	003	Jul 19, 2016	Apr CPOT
AB			EQ 40MG BASE	A079171	004	Jul 19, 2016	Apr CPOT
	@ SCIEGEN PHARMS INC		EQ 5MG BASE	A206381	001	Apr 24, 2019	Apr CPOT
	@		EQ 10MG BASE	A206381	002	Apr 24, 2019	Apr CPOT
	@		EQ 20MG BASE	A206381	003	Apr 24, 2019	Apr CPOT
	@		EQ 40MG BASE	A206381	004	Apr 24, 2019	Apr CPOT
AB	SHANDONG		EQ 5MG BASE	A207375	001	May 07, 2019	Apr CPOT
AB			EQ 10MG BASE	A207375	002	May 07, 2019	Apr CPOT
AB			EQ 20MG BASE	A207375	003	May 07, 2019	Apr CPOT
AB			EQ 40MG BASE	A207375	004	May 07, 2019	Apr CPOT
AB	SUN PHARM		EQ 5MG BASE	A079169	001	Jul 19, 2016	Apr CPOT
AB			EQ 10MG BASE	A079169	002	Jul 19, 2016	Apr CPOT
AB			EQ 20MG BASE	A079169	003	Jul 19, 2016	Apr CPOT
AB			EQ 40MG BASE	A079169	004	Jul 19, 2016	Apr CPOT
	@ SUNSHINE		EQ 5MG BASE	A210667	001	Apr 01, 2020	Apr CPOT
	@		EQ 10MG BASE	A210667	002	Apr 01, 2020	Apr CPOT
	@		EQ 20MG BASE	A210667	003	Apr 01, 2020	Apr CPOT
	@		EQ 40MG BASE	A210667	004	Apr 01, 2020	Apr CPOT
	@ TEVA PHARMS USA		EQ 5MG BASE	A079166	001	Jul 19, 2016	Apr CPOT
	@		EQ 10MG BASE	A079166	002	Jul 19, 2016	Apr CPOT
	@		EQ 20MG BASE	A079166	003	Jul 19, 2016	Apr CPOT
	@		EQ 40MG BASE	A079166	004	Jul 19, 2016	Apr CPOT
AB	TORRENT		EQ 5MG BASE	A201619	001	Oct 31, 2016	Apr CPOT
AB			EQ 10MG BASE	A201619	002	Oct 31, 2016	Apr CPOT
AB			EQ 20MG BASE	A201619	003	Oct 31, 2016	Apr CPOT
AB			EQ 40MG BASE	A201619	004	Oct 31, 2016	Apr CPOT
	@ UMEDICA LABS PVT LTD		EQ 5MG BASE	A207626	001	Apr 09, 2019	Apr CPOT
	@		EQ 10MG BASE	A207626	002	Apr 09, 2019	Apr CPOT
	@		EQ 20MG BASE	A207626	003	Apr 09, 2019	Apr CPOT
	@		EQ 40MG BASE	A207626	004	Apr 09, 2019	Apr CPOT
AB	WATSON LABS INC		EQ 5MG BASE	A079167	001	Apr 29, 2016	Apr CPOT
AB			EQ 10MG BASE	A079167	002	Apr 29, 2016	Apr CPOT
AB			EQ 20MG BASE	A079167	003	Apr 29, 2016	Apr CPOT
AB			EQ 40MG BASE	A079167	004	Apr 29, 2016	Apr CPOT
AB	ZHEJIANG YONGTAI		EQ 5MG BASE	A212059	001	Nov 04, 2019	Apr CPOT
AB			5MG	A212059	001	Nov 04, 2019	Feb CMFD
AB			EQ 10MG BASE	A212059	002	Nov 04, 2019	Apr CPOT
AB			10MG	A212059	002	Nov 04, 2019	Feb CMFD
AB			EQ 20MG BASE	A212059	003	Nov 04, 2019	Apr CPOT
AB			20MG	A212059	003	Nov 04, 2019	Feb CMFD
AB			EQ 40MG BASE	A212059	004	Nov 04, 2019	Apr CPOT
AB			40MG	A212059	004	Nov 04, 2019	Feb CMFD
	@ ZYDUS PHARMS		EQ 5MG BASE	A206513	001	Mar 01, 2019	Apr CPOT
	@		EQ 10MG BASE	A206513	002	Mar 01, 2019	Apr CPOT
	@		EQ 20MG BASE	A206513	003	Mar 01, 2019	Apr CPOT
	@		EQ 40MG BASE	A206513	004	Mar 01, 2019	Apr CPOT

RUFINAMIDE

SUSPENSION;ORAL

RUFINAMIDE

AB	ALKEM LABS LTD	40MG/ML	A213410	001	Feb 23, 2021	Feb NEWA
	TABLET;ORAL					
	RUFINAMIDE					
AB	HETERO LABS LTD III	200MG	A204993	001	May 11, 2021	Apr NEWA
AB		400MG	A204993	002	May 11, 2021	Apr NEWA
>D>	@ MYLAN	200MG	A205095	001	May 16, 2016	May CMFD
>A> AB		200MG	A205095	001	May 16, 2016	May CMFD
>D>	@	400MG	A205095	002	May 16, 2016	May CMFD
>A> AB		400MG	A205095	002	May 16, 2016	May CMFD

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

SAPROPTERIN DIHYDROCHLORIDE

AB	DR REDDYS	100MG/PACKET	A209452	001	Mar 30, 2021	Mar NEWA
----	-----------	--------------	---------	-----	--------------	----------

SCOPOLAMINE

SYSTEM;TRANSDERMAL

TRANSDERM SCOP

AB	+! BAXTER HLTHCARE CORP	1MG/72HR	N017874	001		Mar CAHN
----	-------------------------	----------	---------	-----	--	----------

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

SELEGILINE HYDROCHLORIDE

AB	NOVITIUM PHARMA	5MG	A075352	001	Nov 30, 1998	Apr CMFD
----	-----------------	-----	---------	-----	--------------	----------

SELENIUS ACID

SOLUTION;INTRAVENOUS

SELENIUS ACID

+!	AM REGENT	EQ 60MCG BASE/ML (EQ 60MCG BASE/ML)	N209379	002	Jan 25, 2021	Jan NEWA
----	-----------	--	---------	-----	--------------	----------

SELEXIPAG

TABLET;ORAL

UPTRAVI

+!	ACTELION	0.2MG	N207947	001	Dec 21, 2015	Feb CAHN
+!		0.4MG	N207947	002	Dec 21, 2015	Feb CAHN
+		0.6MG	N207947	003	Dec 21, 2015	Feb CAHN
+		0.8MG	N207947	004	Dec 21, 2015	Feb CAHN
+		1MG	N207947	005	Dec 21, 2015	Feb CAHN
+		1.2MG	N207947	006	Dec 21, 2015	Feb CAHN
+		1.4MG	N207947	007	Dec 21, 2015	Feb CAHN
+		1.6MG	N207947	008	Dec 21, 2015	Feb CAHN

SELINEXOR

TABLET;ORAL

XPOVIO

+	KARYOPHARM THERAPS	40MG	N212306	002	Apr 15, 2021	Apr NEWA
+		50MG	N212306	003	Apr 15, 2021	Apr NEWA
+		60MG	N212306	004	Apr 15, 2021	Apr NEWA

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	EQ 25MG BASE	A076881	001	Feb 06, 2007	Jan CMFD
AB		EQ 50MG BASE	A076881	002	Feb 06, 2007	Jan CMFD
AB		EQ 100MG BASE	A076881	003	Feb 06, 2007	Jan CMFD
AB	ASCENT PHARMS INC	EQ 25MG BASE	A214790	001	May 03, 2021	Apr NEWA
AB		EQ 50MG BASE	A214790	002	May 03, 2021	Apr NEWA
AB		EQ 100MG BASE	A214790	003	May 03, 2021	Apr NEWA
>A> AB	GRANULES	EQ 25MG BASE	A078403	001	Jan 08, 2008	May CAHN
>A> AB		EQ 50MG BASE	A078403	002	Jan 08, 2008	May CAHN
>A> AB		EQ 100MG BASE	A078403	003	Jan 08, 2008	May CAHN
AB	SCIEGEN PHARMS INC	EQ 25MG BASE	A076442	001	Apr 30, 2007	Apr CMFD
AB		EQ 50MG BASE	A076442	002	Apr 30, 2007	Apr CMFD
AB		EQ 100MG BASE	A076442	003	Apr 30, 2007	Apr CMFD
>D> AB	WOCKHARDT	EQ 25MG BASE	A078403	001	Jan 08, 2008	May CAHN
>D> AB		EQ 50MG BASE	A078403	002	Jan 08, 2008	May CAHN
>D> AB		EQ 100MG BASE	A078403	003	Jan 08, 2008	May CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL  
SEVELAMER CARBONATE

>A> AB	BIONPHARMA INC	800MG/PACKET	A209374	001	May 17, 2021	May NEWA
	@ IMPAX	800MG/PACKET	A211316	001	Nov 20, 2020	Mar DISC
	@	2.4GM/PACKET	A211316	002	Nov 20, 2020	Mar DISC
	TABLET;ORAL SEVELAMER CARBONATE					
AB	ANXIN	800MG	A212970	001	Apr 09, 2020	Mar CMFD
AB	LUPIN LTD	800MG	A204600	001	Jan 14, 2021	Jan NEWA

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL  
SILDENAFIL CITRATE

AB	APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Apr NEWA
AB	HETERO LABS LTD V	EQ 10MG BASE/ML	A213014	001	May 11, 2021	Apr NEWA
	TABLET;ORAL SILDENAFIL CITRATE					
AB	REYOUNG	EQ 25MG BASE	A208494	001	Jun 12, 2020	Mar CAHN
AB		EQ 50MG BASE	A208494	002	Jun 12, 2020	Mar CAHN
AB		EQ 100MG BASE	A208494	003	Jun 12, 2020	Mar CAHN
>D> AB	WATSON LABS INC	EQ 25MG BASE	A202506	001	Nov 25, 2020	May DISC
>A>	@	EQ 25MG BASE	A202506	001	Nov 25, 2020	May DISC
>D> AB		EQ 50MG BASE	A202506	002	Nov 25, 2020	May DISC
>A>	@	EQ 50MG BASE	A202506	002	Nov 25, 2020	May DISC
>D> AB		EQ 100MG BASE	A202506	003	Nov 25, 2020	May DISC
>A>	@	EQ 100MG BASE	A202506	003	Nov 25, 2020	May DISC

SIMVASTATIN

TABLET;ORAL  
SIMVASTATIN

AB	BIOCON PHARMA	5MG	A078034	001	Dec 20, 2006	Mar CAHN
AB		10MG	A078034	002	Dec 20, 2006	Mar CAHN
AB		20MG	A078034	003	Dec 20, 2006	Mar CAHN
AB		40MG	A078034	004	Dec 20, 2006	Mar CAHN
AB		80MG	A078034	005	Dec 20, 2006	Mar CAHN
AB	HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	Apr CMFD
AB		20MG	A206557	002	Nov 13, 2017	Apr CMFD
AB		40MG	A206557	003	Nov 13, 2017	Apr CMFD
AB		80MG	A206557	004	Nov 13, 2017	Apr CMFD
	ZOCOR					
AB	+ ORGANON	5MG	N019766	001	Dec 23, 1991	Feb CAHN
AB	+	10MG	N019766	002	Dec 23, 1991	Feb CAHN
AB	+	20MG	N019766	003	Dec 23, 1991	Feb CAHN
AB	+	40MG	N019766	004	Dec 23, 1991	Feb CAHN

SINECATECHINS

OINTMENT;TOPICAL  
VEREGEN

+!	ANI PHARMS	15%	N021902	001	Oct 31, 2006	Apr CAHN
----	------------	-----	---------	-----	--------------	----------

SIROLIMUS

TABLET;ORAL  
SIROLIMUS

AB	ALKEM LABS LTD	0.5MG	A214753	001	Mar 12, 2021	Mar NEWA
AB		1MG	A214753	002	Mar 12, 2021	Mar NEWA
AB		2MG	A214753	003	Mar 12, 2021	Mar NEWA

SODIUM ACETATE

INJECTABLE;INJECTION  
SODIUM ACETATE

AP	MILLA PHARMS	2MEO/ML	A214805	001	May 04, 2021	Apr NFTG
----	--------------	---------	---------	-----	--------------	----------

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 23.4%

FRESENIUS KABI USA

SOLUTION;INTRAVENOUS

SODIUM CHLORIDE 14.6%

FRESENIUS KABI USA

50MEO/20ML (2.5MEO/ML)

100MEO/40ML (2.5MEO/ML)

A212248	001	Apr 28, 2021	Apr NFTG
A212070	001	Apr 28, 2021	Apr NFTG

A212070	002	Apr 28, 2021	Apr NFTG
---------	-----	--------------	----------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION  
FERRLECIT

>D> AB	+! SANOFI AVENTIS US	62.5MG/5ML	N 020955	001	Feb 18, 1999	May CPOT
>D> AB	SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE WEST-WARD PHARMS INT	62.5MG/5ML	A 078215	001	Mar 31, 2011	May CPOT

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS  
SODIUM FLUORIDE F-18

AP	NUKEMED	10-200mCi/ML	A 203912	001	Apr 22, 2015	Jan CAHN
	@ UCSF RODIOPHARM	10-200mCi/ML	A 204437	001	Mar 13, 2014	Apr DISC

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL  
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

AB	NOVEL LABS INC	0.398GM;1.102GM	A 079247	001	Dec 30, 2011	Jan CMFD
	OSMOPREP					

AB	+! SALIX PHARMS	0.398GM;1.102GM	N 021892	001	Mar 16, 2006	Jan CTEC
----	-----------------	-----------------	----------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL  
KIONEX

AA	ANI PHARMS	454GM/BOT	A 040029	001	Feb 06, 1998	Mar CAHN
AA	L PERRIGO CO	454GM/BOT	A 040029	001	Feb 06, 1998	Mar CAHN
	SUSPENSION; ORAL, RECTAL					
	KIONEX					
	@ ANI PHARMS	15GM/60ML	A 040028	001	Sep 17, 2007	Mar CAHN
	@ L PERRIGO CO	15GM/60ML	A 040028	001	Sep 17, 2007	Mar CAHN
	SODIUM POLYSTYRENE SULFONATE					
	@ ANI PHARMS	15GM/60ML	A 090590	001	May 13, 2011	Mar CAHN
	@ L PERRIGO CO	15GM/60ML	A 090590	001	May 13, 2011	Mar CAHN

SOLIFENACIN SUCCINATE

TABLET; ORAL  
SOLIFENACIN SUCCINATE

@ ZYDUS PHARMS	5MG	A 207721	001	Oct 19, 2020	Mar DISC
@	10MG	A 207721	002	Oct 19, 2020	Mar DISC

SORAFENIB TOSYLATE

TABLET; ORAL  
NEXAVAR

>D> AB	+! BAYER HLTHCARE	EQ 200MG BASE	N 021923	001	Dec 20, 2005	May CTEC
>A>	+!	EQ 200MG BASE	N 021923	001	Dec 20, 2005	May CTEC
	SORAFENIB TOSYLATE					
>D> AB	TEVA PHARMS USA INC	EQ 200MG BASE	A 209567	001	Nov 12, 2020	May DISC

>A>	@	EQ 200MG BASE	A 209567	001	Nov 12, 2020	May DISC
-----	---	---------------	----------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

TABLET; ORAL  
SOTALOL HYDROCHLORIDE

@ MYLAN	80MG	A 077616	001	Feb 07, 2007	Feb DISC
@	120MG	A 077616	002	Feb 07, 2007	Feb DISC
@	160MG	A 077616	003	Feb 07, 2007	Feb DISC

SOTORASIB

>A>	TABLET; ORAL					
>A>	LUMAKRAS					
>A>	+! AMGEN INC	120MG	N 214665	001	May 28, 2021	May NEWA

STERILE WATER FOR INJECTION

LIQUID; N/A  
STERILE WATER FOR INJECTION

!	NEPHRON	100% (5ML)	A 211222	001	Feb 10, 2021	Jan NEWA
---	---------	------------	----------	-----	--------------	----------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCCINYLCHOLINE CHLORIDE

AP	ACCORD HLTHCARE	20MG/ML	A213705	001	May 20, 2020	Mar CMFD
AP	HIKMA	20MG/ML	A213229	001	Jun 12, 2020	Apr CMFD
	@	20MG/ML	A213229	001	Jun 12, 2020	Feb DISC
AP	SAGENT PHARMS INC	20MG/ML	A215022	001	Mar 29, 2021	Mar NEWA

SUCROFERRIC OXYHYDROXIDE

TABLET, CHEWABLE; ORAL

VELPHORO

>D>	+! VIFOR FRESENIUS	500MG	N205109	001	Nov 27, 2013	May CPOT
-----	--------------------	-------	---------	-----	--------------	----------

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

@ RISING

500MG

A085844 001

Jan CAHN

SULFASALAZINE

TABLET; ORAL

AZULFIDINE

AB	+! PFIZER	500MG	N007073	001		Mar CAHN
AB	+! PFIZER	500MG	N007073	002	Apr 06, 1983	Mar CAHN

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

@ RISING

500MG

A085628 001

Jan CAHN

SUMATRIPTAN

SPRAY; NASAL

SUMATRIPTAN

AB	CIPLA	20MG/SPRAY	A214209	001	Feb 22, 2021	Feb NEWA
AB	FLORIDA	20MG/SPRAY	A208967	001	Feb 17, 2021	Mar CAHN
AB	PHARMASERVE NW	20MG/SPRAY	A208967	001	Feb 17, 2021	Feb NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

>D> AP	MYLAN ASI	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	May DISC
>A>	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	May DISC
	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Jan DISC
	SPRAY; NASAL					
	SUMATRIPTAN					
AB	PERRIGO UK FINCO	5MG/SPRAY	A213465	002	Sep 21, 2020	Feb CMS1

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

@ CONCORD BIOTECH LTD

EQ 0.5MG BASE

A213112 001 Nov 10, 2020 Apr DISC

TADALAFIL

TABLET; ORAL

CIALIS

AB1	+	LILLY	2.5MG	N021368	004	Jan 07, 2008	Feb CTEC
AB1	+		5MG	N021368	001	Nov 21, 2003	Feb CTEC
AB1	+		10MG	N021368	002	Nov 21, 2003	Feb CTEC
		Tadalafil					
AB1		ACCORD HLTHCARE	2.5MG	A209167	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A209167	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A209167	003	Oct 23, 2019	Feb CTEC
AB1		AJANTA PHARMA LTD	2.5MG	A209654	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A209654	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A209654	003	Mar 26, 2019	Feb CTEC
AB1		ALEMBIC PHARMS LTD	2.5MG	A204809	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A204809	002	Mar 26, 2019	Feb CTEC

**TABLET;ORAL**  
**TADALAFIL**

AB1		10MG	A204809	003	Mar 26, 2019	Feb CTEC
AB1	AMNEAL PHARMS CO	2.5MG	A209744	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A209744	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A209744	003	Mar 26, 2019	Feb CTEC
AB1	AUROBINDO PHARMA LTD	2.5MG	A206285	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A206285	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A206285	003	Mar 26, 2019	Feb CTEC
AB1	CIPPLA	2.5MG	A209539	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A209539	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A209539	003	Mar 26, 2019	Feb CTEC
AB1	DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A210069	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A210069	003	Mar 26, 2019	Feb CTEC
AB1	@ GLENMARK PHARMS LTD	2.5MG	A210716	001	Dec 29, 2020	Feb DISC
AB1	@	5MG	A210716	002	Dec 29, 2020	Feb DISC
AB1	@	10MG	A210716	003	Dec 29, 2020	Feb DISC
AB1	@	20MG	A210716	004	Dec 29, 2020	Feb DISC
AB1	HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A209908	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A209908	003	Mar 26, 2019	Feb CTEC
AB1	LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A210567	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A210567	003	Mar 26, 2019	Feb CTEC
AB1	MACLEODS PHARMS LTD	2.5MG	A207244	001	Oct 07, 2019	Feb CTEC
AB1		5MG	A207244	002	Oct 07, 2019	Feb CTEC
AB1		10MG	A207244	003	Oct 07, 2019	Feb CTEC
AB1	MYLAN	2.5MG	A206956	001	Apr 29, 2019	Feb CTEC
AB1		5MG	A206957	001	Apr 29, 2019	Feb CTEC
AB1		10MG	A206956	002	Apr 29, 2019	Feb CTEC
AB1	QILU	2.5MG	A210420	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A210420	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A210420	003	Mar 26, 2019	Feb CTEC
AB1	SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A208934	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A208934	003	Mar 26, 2019	Feb CTEC
AB1	SUNSHINE	2.5MG	A211335	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A211335	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A211335	003	Mar 26, 2019	Feb CTEC
AB1	TEVA PHARMS USA	2.5MG	A090141	001	May 22, 2018	Feb CTEC
AB1		5MG	A090141	002	May 22, 2018	Feb CTEC
AB1		10MG	A090141	003	May 22, 2018	Feb CTEC
AB1	TORRENT	2.5MG	A211839	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A211839	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A211839	003	Mar 26, 2019	Feb CTEC
AB1	UMEDICA LABS PVT LTD	2.5MG	A211298	001	Oct 23, 2020	Feb CTEC
AB1		5MG	A211298	002	Oct 23, 2020	Feb CTEC
AB1		10MG	A211298	003	Oct 23, 2020	Feb CTEC
AB1	UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A209250	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A209250	003	Mar 26, 2019	Feb CTEC
AB1	YANGLING BUCHANG	2.5MG	A208824	001	Oct 27, 2020	Feb CTEC
AB1		5MG	A208824	002	Oct 27, 2020	Feb CTEC
AB1		10MG	A208824	003	Oct 27, 2020	Feb CTEC
AB1	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A206693	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A206693	003	Mar 26, 2019	Feb CTEC

**TAVABOROLE**

**SOLUTION;TOPICAL**  
**TAVABOROLE**

AB	CIPPLA	5%	A212224	001	Feb 09, 2021	Jan NEWA
AB	FLATWING	5%	A211963	001	Feb 03, 2021	Feb CPOT
AB		5.0%	A211963	001	Feb 03, 2021	Jan NEWA
AB	IDENTIRX	5%	A211963	001	Feb 03, 2021	Feb CAHN
AB	LUPIN LTD	5%	A212168	001	Feb 08, 2021	Jan NEWA
AB	TARO PHARMS	5%	A212215	001	May 07, 2021	Apr NEWA

TELMISARTAN

TABLET;ORAL  
TELMISARTAN

AB	CELLTRION	20MG	A078710 001 Jan 08, 2014	Feb CMFD
AB		40MG	A078710 002 Jan 08, 2014	Feb CMFD
AB		80MG	A078710 003 Jan 08, 2014	Feb CMFD

TEMOZOLOMIDE

CAPSULE;ORAL  
TEMOZOLOMIDE

@ HERITAGE	5MG	A078879 001 Mar 01, 2010	Feb CAHN
@	20MG	A078879 002 Mar 01, 2010	Feb CAHN
@	100MG	A078879 003 Mar 01, 2010	Feb CAHN
@	140MG	A078879 005 Mar 01, 2010	Feb CAHN
@	180MG	A078879 006 Mar 01, 2010	Feb CAHN
@	250MG	A078879 004 Mar 01, 2010	Feb CAHN
@ WATSON LABS TEVA	5MG	A203959 001 Apr 18, 2017	Jan DISC
@	20MG	A203959 002 Apr 18, 2017	Jan DISC
@	100MG	A203959 003 Apr 18, 2017	Jan DISC
@	140MG	A203959 004 Apr 18, 2017	Jan DISC
@	250MG	A203959 005 Apr 18, 2017	Jan DISC

TEPOTINIB HYDROCHLORIDE

TABLET;ORAL  
TEPMETKO

+! EMD SERONO INC	EQ 225MG BASE	N214096 001 Feb 03, 2021	Feb NEWA
-------------------	---------------	--------------------------	----------

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL  
TERAZOSIN HYDROCHLORIDE

>D>	@ HERITAGE PHARMA	EQ 1MG BASE	A075614 002 Jan 30, 2001	May CMFD
>A> AB		EQ 1MG BASE	A075614 002 Jan 30, 2001	May CMFD
>D>	@	EQ 2MG BASE	A075614 001 Jan 30, 2001	May CMFD
>A> AB		EQ 2MG BASE	A075614 001 Jan 30, 2001	May CMFD
>D>	@	EQ 5MG BASE	A075614 003 Jan 30, 2001	May CMFD
>A> AB		EQ 5MG BASE	A075614 003 Jan 30, 2001	May CMFD
>D>	@	EQ 10MG BASE	A075614 004 Jan 30, 2001	May CMFD
>A> AB		EQ 10MG BASE	A075614 004 Jan 30, 2001	May CMFD

TERIFLUNOMIDE

TABLET;ORAL  
TERIFLUNOMIDE

@ IMPAX	14MG	A209677 001 Jun 17, 2020	Feb DISC
---------	------	--------------------------	----------

TESTOSTERONE

GEL;TRANSDERMAL  
TESTOSTERONE

AB2	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM PACKET)	A204570 002 Jul 17, 2020	Feb NEWA
AB2		1.62% (40.5MG/2.5GM PACKET)	A204570 003 Jul 17, 2020	Feb NEWA
	GEL, METERED;TRANSDERMAL TESTOSTERONE			
AB	ALEOR DERMACEUTICALS	1.62% (20.25MG/1.25GM ACTUATION)	A213922 001 Mar 03, 2021	Feb NEWA
	SOLUTION, METERED;TRANSDERMAL TESTOSTERONE			
>D> AT	APOTEX	30MG/1.5ML ACTUATION	A209181 001 Nov 25, 2020	May DISC
>A>	@	30MG/1.5ML ACTUATION	A209181 001 Nov 25, 2020	May DISC
>A> AT	DASH PHARMS	30MG/1.5ML ACTUATION	A212301 001 Jan 11, 2021	May CAHN
>D> AT	FEMPHARM	30MG/1.5ML ACTUATION	A212301 001 Jan 11, 2021	May CAHN
AT		30MG/1.5ML ACTUATION	A212301 001 Jan 11, 2021	Jan NEWA

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION  
DEPO-TESTOSTERONE

@ PFIZER	50MG/ML	A085635 001	Mar CAHN
AO !	100MG/ML	A085635 002	Mar CAHN
AO !	200MG/ML	A085635 003	Mar CAHN

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

>D>	AB	AJANTA PHARMA LTD	12.5MG	A213621	001	Dec 04, 2020	May DISC
>A>	@		12.5MG	A213621	001	Dec 04, 2020	May DISC
>D>	AB		25MG	A213621	002	Dec 04, 2020	May DISC
>A>	@		25MG	A213621	002	Dec 04, 2020	May DISC

TETRACAIN HYDROCHLORIDESOLUTION;OPHTHALMIC  
TETRACAIN HYDROCHLORIDE

>D>	+!	BAUSCH	0.5%	N210821	001	Mar 12, 2019	May CAHN
>A>	+!	BAUSCH LOMB IRELAND	0.5%	N210821	001	Mar 12, 2019	May CAHN

THEOPHYLLINETABLET, EXTENDED RELEASE;ORAL  
THEOPHYLLINE

>D>		ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010	May CTEC
>A>	AB		300MG	A090430	001	Oct 27, 2010	May CTEC
>D>	!		450MG	A090430	002	Oct 27, 2010	May CTEC
>A>	AB	!	450MG	A090430	002	Oct 27, 2010	May CTEC
>A>	AB	GLENMARK PHARMS LTD	300MG	A212184	001	Jun 03, 2021	May NEWA
>A>	AB		450MG	A212184	002	Jun 03, 2021	May NEWA

THIAMINE HYDROCHLORIDEINJECTABLE;INJECTION  
THIAMINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	100MG/ML	A080575	001		Apr CMFD
----	--	----------------------	----------	---------	-----	--	----------

THIORIDAZINE HYDROCHLORIDETABLET;ORAL  
THIORIDAZINE HYDROCHLORIDE

MYLAN		10MG	A088004	002	Mar 15, 1983	Jan CTEC
		25MG	A088004	003	Mar 15, 1983	Jan CTEC
		50MG	A088004	004	Mar 15, 1983	Jan CTEC
!		100MG	A088004	001	Nov 18, 1983	Jan CTEC
@ SUN PHARM INDUSTRIES		10MG	A089953	004	Aug 01, 1986	Jan DISC
@		25MG	A089953	003	Aug 01, 1986	Jan DISC
@		50MG	A089953	002	Aug 01, 1986	Jan DISC
@		100MG	A089953	001	Oct 07, 1988	Jan DISC

THIOTEPAPOWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL  
THIOTEPA

AP		GLAND PHARMA LTD	15MG/VIAL	A214222	001	Mar 08, 2021	Feb NEWA
----	--	------------------	-----------	---------	-----	--------------	----------

TIAGABINE HYDROCHLORIDETABLET;ORAL  
TIAGABINE HYDROCHLORIDE

@ WILSHIRE PHARMS INC		2MG	A206857	001	Oct 13, 2017	Jan DISC
@		4MG	A206857	002	Oct 13, 2017	Jan DISC
@		12MG	A206857	003	Oct 13, 2017	Jan DISC
@		16MG	A206857	004	Oct 13, 2017	Jan DISC

TIGECYCLINEPOWDER;INTRAVENOUS  
TIGECYCLINE

>A>	AP	HONG KONG	50MG/VIAL	A214020	001	May 13, 2021	May NEWA
-----	----	-----------	-----------	---------	-----	--------------	----------

TIMOLOL MALEATESOLUTION, GEL FORMING/DROPS;OPHTHALMIC  
TIMOLOL MALEATE

AB	!	ALEMBIC PHARMS LTD	EQ 0.25% BASE	A212942	001	Oct 22, 2020	Apr CHRS
AB	!		EQ 0.5% BASE	A212942	002	Oct 22, 2020	Apr CHRS

TIMOPTIC-XE

AB	+	VALEANT PHARMS LLC	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Apr CHRS
AB	+		EQ 0.5% BASE	N020330	002	Nov 04, 1993	Apr CHRS

SOLUTION/DROPS;OPHTHALMIC  
TIMOLOL MALEATE

AT		MANKIND PHARMA	EQ 0.25% BASE	A078771	001	Sep 28, 2009	Apr CAHN
AT1			EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr CAHN

TIOPRONIN

TABLET;ORAL

TIOPRONIN

AB TEVA PHARMS USA INC 100MG A214326 001 Apr 26, 2021 Apr NFTG

TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION

SPIRIVA RESPIMAT

+! BOEHRINGER INGELHEIM EQ 0.00125MG BASE/INH

N021936 002 Sep 15, 2015 Mar CHRS

TIROFIBAN HYDROCHLORIDE

SOLUTION;INTRAVENOUS

AGGRASTAT

+ MEDICURE EQ 5MG BASE/100ML (EQ 0.05MG  
BASE/ML)@ EQ 25MG BASE/500ML (EQ 0.05MG  
BASE/ML)

TIROFIBAN HYDROCHLORIDE

AP GLAND PHARMA LTD EQ 12.5MG BASE/250ML (EQ 0.05MG  
BASE/ML) A206888 001 Apr 08, 2021 Apr NFTGTIVOZANIB HYDROCHLORIDE

CAPSULE;ORAL

FOTIVDA

+ AVEO PHARMS EQ 0.89MG BASE N212904 001 Mar 10, 2021 Mar NEWA

+! EQ 1.34MG BASE N212904 002 Mar 10, 2021 Mar NEWA

TIZANIDINE HYDROCHLORIDE

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB CADILA EQ 2MG BASE A208187 001 Mar 09, 2018 Feb CAHN

AB @ MYLAN EQ 4MG BASE A208187 002 Mar 09, 2018 Feb CAHN

@ EQ 2MG BASE A076354 001 Mar 28, 2003 Jan DISC

@ EQ 4MG BASE A076354 002 Mar 28, 2003 Feb DISC

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

AN ALKEM LABS LTD 300MG/5ML A212848 001 Apr 01, 2021 Mar NEWA

AN AUROBINDO PHARMA LTD 300MG/5ML A210871 001 Jan 22, 2021 Jan NEWA

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT GLAND PHARMA LTD 0.3% A212628 001 Mar 09, 2021 Feb NEWA

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

AP GLAND PHARMA LTD EQ 10MG BASE/ML A209621 001 Feb 11, 2021 Feb NEWA

AP @ GLAND PHARMA LTD EQ 40MG BASE/ML A209621 002 Feb 11, 2021 Feb NEWA

&gt;A&gt; AP GLAND PHARMA LTD EQ 1.2GM BASE/VIAL A211189 001 May 18, 2021 May NEWA

TOBRAMYCIN SULFATE (PHARMACY BULK)

AP ! FRESENIUS KABI USA EQ 40MG BASE/ML A065120 001 Nov 29, 2002 Jan CTEC

AP GLAND PHARMA LTD EQ 40MG BASE/ML A209346 001 Feb 09, 2021 Jan NEWA

TOFACITINIB CITRATE

SOLUTION;ORAL

XELJANZ

+! PFIZER EQ 1MG/ML BASE N213082 001 Sep 25, 2020 Feb CMS1

TABLET;ORAL

&gt;A&gt; TOFACITINIB CITRATE A212943 001 Jun 01, 2021 May NFTG

&gt;A&gt; AB AJANTA PHARMA LTD EQ 10MG BASE A212943 001 Jun 01, 2021 May NFTG

TOLCAPONE

TABLET;ORAL

TOLCAPONE

@ ALVOGEN 100MG A207729 001 Jul 29, 2020 Jan DISC

TOLTERODINE TARTRATE

	CAPSULE, EXTENDED RELEASE;ORAL TOLTERODINE TARTRATE					
AB	AJANTA PHARMA LTD	2MG	A213397	001	May 19, 2020	Jan CMFD
AB		4MG	A213397	002	May 19, 2020	Jan CMFD
AB	AMTA	2MG	A213858	001	Feb 02, 2021	Jan NEWA
AB		4MG	A213858	002	Feb 02, 2021	Jan NEWA

TOLVAPtan

	TABLET;ORAL SAMSCA					
AB	+ OTSUKA	15MG	N022275	001	May 19, 2009	Feb CAHN
	+!	30MG	N022275	002	May 19, 2009	Feb CAHN
	+ @	60MG	N022275	003	May 19, 2009	Feb CAHN

TOPIRAMATE

	CAPSULE, EXTENDED RELEASE;ORAL TOPIRAMATE					
AB2	GLENMARK PHARMS LTD	25MG	A210278	001	Feb 01, 2021	Jan NFTG
AB2		50MG	A210278	002	Feb 01, 2021	Jan NFTG
AB2		100MG	A210278	003	Feb 01, 2021	Jan NFTG
AB2		150MG	A210278	004	Feb 01, 2021	Jan NFTG
AB2		200MG	A210278	005	Feb 01, 2021	Jan NFTG
AB1	ZYDUS PHARMS	25MG	A207382	001	Nov 24, 2017	Jan CTEC
AB1		50MG	A207382	002	Nov 24, 2017	Jan CTEC
AB1		100MG	A207382	003	Nov 24, 2017	Jan CTEC
	TROKENDI XR					
AB1	+ SUPERNUS PHARMS	25MG	N201635	001	Aug 16, 2013	Jan CTEC
AB1	+	50MG	N201635	002	Aug 16, 2013	Jan CTEC
AB1	+	100MG	N201635	003	Aug 16, 2013	Jan CTEC

TRAMADOL HYDROCHLORIDE

	TABLET;ORAL TRAMADOL HYDROCHLORIDE					
AB	@ GRAVITI PHARMS	50MG	A075968	001	Jun 25, 2002	Apr CAHN
	POLYGEN PHARMS	50MG	A206706	001	Jul 02, 2019	Feb CMFD
	TABLET, EXTENDED RELEASE;ORAL TRAMADOL HYDROCHLORIDE					
	@ ANCHEN PHARMS	100MG	A200491	001	Jun 27, 2012	Apr DISC
	@	200MG	A200491	002	Jun 27, 2012	Apr DISC
	@	300MG	A200491	003	Jun 27, 2012	Apr DISC

TRANEXAMIC ACID

	INJECTABLE;INJECTION CYKLOKAPRON					
AP	+! PFIZER TRANEXAMIC ACID	100MG/ML	N019281	001	Dec 30, 1986	Mar CAHN
AP	PROVEPHARM SAS	100MG/ML	A212676	001	Jul 17, 2019	Jan CAHN
	@ ZYDUS PHARMS	100MG/ML	A205228	001	Jul 17, 2017	Apr DISC
	TABLET;ORAL TRANEXAMIC ACID					
	@ APOTEX INC	650MG	A202286	001	Jan 27, 2014	Mar DISC

TRANYLCYPROMINE SULFATE

	TABLET;ORAL TRANYLCYPROMINE SULFATE					
AB	NOVITIUM PHARMA	EQ 10MG BASE	A206856	001	Apr 17, 2018	Apr CAHN

TRAVOPROST

	SOLUTION/DROPS;OPHTHALMIC TRAVOPROST					
AT	MICRO LABS	0.004%	A203767	001	Mar 19, 2021	Mar NEWA

TRAZODONE HYDROCHLORIDE

	TABLET;ORAL TRAZODONE HYDROCHLORIDE					
AB	AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Feb CMFD
AB		100MG	A204852	002	Feb 05, 2020	Feb CMFD
AB		150MG	A204852	003	Feb 05, 2020	Feb CMFD
AB		300MG	A204852	004	Feb 05, 2020	Feb CMFD
	@ RISING	50MG	A072484	001	Apr 30, 1990	Jan CAHN

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

TREPROSTINIL

AP	ALEMBIC GLOBAL	1MG/ML	A211574	001	Feb 11, 2021	Feb NEWA
AP		2.5MG/ML	A211574	002	Feb 11, 2021	Feb NEWA
AP		5MG/ML	A211574	003	Feb 11, 2021	Feb NEWA
AP		10MG/ML	A211574	004	Feb 11, 2021	Feb NEWA

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	SAPTALIS PHARMS	0.025%	A040671	001	Jun 09, 2006	Jan CAHN
AT		0.1%	A040671	002	Jun 09, 2006	Jan CAHN
	OINTMENT;TOPICAL					
	TRIAMCINOLONE ACETONIDE					

AT	PERRIGO ISRAEL	0.05%	A212460	001	Feb 05, 2021	Jan NEWA
----	----------------	-------	---------	-----	--------------	----------

TRIAZOLAM

TABLET;ORAL

HALCION

AB	+ PFIZER	0.125MG	N017892	003	Apr 26, 1985	Feb CAHN
AB	+!	0.25MG	N017892	001	Nov 15, 1982	Feb CAHN
	@	0.5MG	N017892	002	Nov 15, 1982	Feb CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

CLOQUIE

AB	CHARTWELL RX	250MG	A209731	001	Oct 21, 2019	Mar CAHN
AB	CHARTWELL RX	250MG	A209415	001	Sep 16, 2019	Mar CAHN

TRILACICLIB DIHYDROCHLORIDE

POWDER;INTRAVENOUS

COSELA

	+! G1 THERAP	EQ 300MG BASE/VIAL	N214200	001	Feb 12, 2021	Feb NEWA
--	--------------	--------------------	---------	-----	--------------	----------

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TIGAN

+ @ KING PHARMS LLC	300MG	N017531	006	Dec 13, 2001	Apr DISC
AB ! SUN PHARM INDUSTRIES	300MG	A076570	001	Aug 28, 2003	Apr CHRS

TROSPiUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPiUM CHLORIDE

AB	AMTA	60MG	A214760	001	Apr 30, 2021	Apr NEWA
----	------	------	---------	-----	--------------	----------

UMBRALiSiB TOSYLATE

TABLET;ORAL

UKONIQ

+! TG THERAPS	EQ 200MG BASE	N213176	001	Feb 05, 2021	Feb NEWA
---------------	---------------	---------	-----	--------------	----------

URSODiOL

CAPSULE;ORAL

URSODiOL

AB	STRIDES PHARMA	300MG	A210344	001	Jan 22, 2021	Jan NEWA
----	----------------	-------	---------	-----	--------------	----------

VALBENAZiNE TOSYLATE

CAPSULE;ORAL

INGREZZA

>A>	+ NEUROCRINE	EQ 60MG BASE	N209241	003	Apr 23, 2021	May NEWA
-----	--------------	--------------	---------	-----	--------------	----------

VALGANCiCLOViR HYDROCHLORIDE

TABLET;ORAL

VALGANCiCLOViR HYDROCHLORIDE

AB	MYLAN	EQ 450MG BASE	A205151	001	Mar 03, 2021	Feb NEWA
----	-------	---------------	---------	-----	--------------	----------

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

AA CHARTWELL RX 250MG/5ML A075782 001 Dec 22, 2000 Mar CMFD

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

@ HIKMA	EQ 500MG BASE/VIAL	A 203300	001	Aug 11, 2020	Feb DISC	
@	EQ 1GM BASE/VIAL	A 203300	002	Aug 11, 2020	Feb DISC	
>D>	@ HOSPIRA	EQ 1.5GM BASE/VIAL	A 062912	003	Jul 10, 2020	May CMFD
>A>	!	EQ 1.5GM BASE/VIAL	A 062912	003	Jul 10, 2020	May CMFD

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

LEVITRA

+ @ BAYER HLTHCARE

EQ 5MG BASE

N 021400 001 Aug 19, 2003 Apr DISC

+ @

EQ 10MG BASE

N 021400 002 Aug 19, 2003 Apr DISC

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOSTRICT

+! PAR STERILE PRODUCTS

20UNITS/100ML (0.2UNITS/ML)

N 204485 005 Apr 21, 2021 Apr NEWA

VENLAFAKINE HYDROCHLORIDE

TABLET;ORAL

VENLAFAKINE HYDROCHLORIDE

@ MYLAN	EQ 25MG BASE	A 077166	001	Jun 13, 2008	Jan DISC
@	EQ 37.5MG BASE	A 077166	002	Jun 13, 2008	Jan DISC
@	EQ 50MG BASE	A 077166	003	Jun 13, 2008	Jan DISC
@	EQ 75MG BASE	A 077166	004	Jun 13, 2008	Jan DISC
@	EQ 100MG BASE	A 077166	005	Jun 13, 2008	Jan DISC

TABLET, EXTENDED RELEASE;ORAL

VENLAFAKINE HYDROCHLORIDE

AB DEXCEL PHARMA EQ 75MG BASE A 213927 001 Jan 21, 2021 Jan NEWA

VERICIGUAT

TABLET;ORAL

VERQUVO

+ MERCK SHARP DOHME

2.5MG

N 214377 001 Jan 19, 2021 Jan NEWA

+

5MG

N 214377 002 Jan 19, 2021 Jan NEWA

+!

10MG

N 214377 003 Jan 19, 2021 Jan NEWA

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

AA ANNORA PHARMA 500MG/PACKET A 213519 001 Jan 26, 2021 Jan NEWA  
>A> AA DEXCEL PHARMA 500MG/PACKET A 214992 001 May 13, 2021 May NEWA

TABLET;ORAL

VIGABATRIN

AB DR REDDYS 500MG A 211539 001 Jan 29, 2021 Jan NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VILAZODONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	10MG	A 208209	001	Apr 27, 2021	Apr NEWA
AB		20MG	A 208209	002	Apr 27, 2021	Apr NEWA
AB		40MG	A 208209	003	Apr 27, 2021	Apr NEWA
AB	INVAGEN PHARMS	10MG	A 208200	001	Apr 07, 2021	Mar NEWA
AB		40MG	A 208200	002	Apr 07, 2021	Mar NEWA

VILOXAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

QELBREE

+ SUPERNUS PHARMS

EQ 100MG BASE

N 211964 001 Apr 02, 2021 Apr NEWA

+

EQ 150MG BASE

N 211964 002 Apr 02, 2021 Apr NEWA

+!

EQ 200MG BASE

N 211964 003 Apr 02, 2021 Apr NEWA

VINORELBINE TARTRATE

INJECTABLE; INJECTION  
 VINORELBINE TARTRATE  
 @ FRESENIUS KABI USA

EQ 10MG BASE/ML

A076849 001 Apr 18, 2005 Jan DISC

VOCLOSPORIN

CAPSULE; ORAL  
 LUPKYNIS  
 +! AURINIA

7.9MG

N213716 001 Jan 22, 2021 Jan NEWA

VORICONAZOLE

INJECTABLE; INTRAVENOUS  
 VORICONAZOLE

AP ALMAJECT 200MG/VIAL

A206398 001 Mar 23, 2016 Feb CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION  
 ZINC CHLORIDE

&gt;A&gt; AP EXELA PHARMA EQ 1MG ZINC/ML

A212007 001 May 21, 2021 May NFTG

ZOLPIDEM TARTRATE

TABLET, ORALLY DISINTEGRATING; ORAL  
 TOVALT ODT

+ @ BIOVAIL LABS INTL 5MG  
 + @ 10MG

N021412 001 Apr 25, 2007 Apr CRLD  
 N021412 002 Apr 25, 2007 Apr CRLD

ZONISAMIDE

CAPSULE; ORAL  
 ZONEGRAN

AB + CONCORDIA 25MG

N020789 003 Aug 22, 2003 Mar CAHN

+ @ 50MG

N020789 002 Aug 22, 2003 Mar CAHN

AB +! 100MG

N020789 001 Mar 27, 2000 Mar CAHN

ZONISAMIDE

AB UNICHEM 25MG

A214492 001 Jan 26, 2021 Jan NEWA

AB 50MG

A214492 002 Jan 26, 2021 Jan NEWA

AB 100MG

A214492 003 Jan 26, 2021 Jan NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL  
ACETAMINOPHEN, ASPIRIN AND CAFFEINE  
GRANULES 250MG;250MG;65MG A214039 001 Feb 23, 2021 Feb NEWA

BUDESONIDE

SPRAY, METERED;NASAL  
RHINOCORT ALLERGY  
+! J AND J CONSUMER INC 0.032MG/SPRAY N020746 003 Mar 23, 2015 Mar CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL  
CETIRIZINE HYDROCHLORIDE ALLERGY  
APOTEX 10MG A207235 001 Aug 12, 2016 Mar CMFD  
@ 10MG A207235 001 Aug 12, 2016 Jan DISC

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY  
>D> CIPLA LTD 5MG A077318 001 Jul 25, 2013 May DISC  
>A> @ 5MG A077318 001 Jul 25, 2013 May DISC

>D> 10MG A077318 002 Jul 25, 2013 May DISC

>A> 10MG A077318 002 Jul 25, 2013 May DISC

TABLET, CHEWABLE;ORAL  
CHILDREN'S ZYRTEC ALLERGY  
+ @ J AND J CONSUMER INC 2.5MG N021621 007 Nov 30, 2020 Apr DISC

DICLOFENAC SODIUM

GEL;TOPICAL  
DICLOFENAC SODIUM  
>A> AUROLIFE PHARMA LLC 1% A204306 001 May 06, 2019 May CAHN  
>D> MYLAN 1% A204306 001 May 06, 2019 May CAHN

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL  
FLONASE ALLERGY RELIEF  
+ GLAXOSMITHKLINE CONS 0.05MG/SPRAY N205434 001 Jul 23, 2014 Apr CHRS  
FLUTICASONE PROPIONATE  
! HIKMA 0.05MG/SPRAY A207957 001 May 26, 2016 Apr CHRS

IBUPROFEN

SUSPENSION;ORAL  
IBUPROFEN  
GUARDIAN DRUG 100MG/5ML A210149 001 Aug 17, 2018 Jan CMFD  
STRIDES PHARMA 100MG/5ML A211666 001 Feb 22, 2021 Feb NEWA

TABLET;ORAL

IBUPROFEN  
@ MERRO PHARM 200MG A070985 001 Oct 02, 1987 Apr DISC  
@ YICHANG HUMANWELL 200MG A214003 001 Oct 19, 2020 Apr DISC

IVERMECTIN

LOTION;TOPICAL  
IVERMECTIN  
>A> TARO 0.5% A210720 001 May 06, 2020 May CMKT

KETOCONAZOLE

SHAMPOO;TOPICAL  
NIZORAL ANTI-DANDRUFF  
+! KRAMER 1% N020310 001 Oct 10, 1997 Feb CTNA

LEVO CETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL  
LEVO CETIRIZINE DIHYDROCHLORIDE  
APOTEX 5MG A211443 001 Apr 21, 2021 Apr NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL  
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE  
>A> GUARDIAN DRUG 2MG;125MG A214541 001 May 27, 2021 May NEWA

LORATADINE

SYRUP; ORAL				
LORATADINE				
HETERO LABS LTD III	1MG/ML			
TABLET; ORAL		A210409	001	May 07, 2021
LORATADINE				Apr NEWA
UNIQUE PHARM	10MG	A214684	001	Jan 07, 2021
TABLET, ORALLY DISINTEGRATING; ORAL				Jan NEWA
LORATADINE				
@ GLAXOSMITHKLINE	10MG	A075822	001	Feb 10, 2003
@ TENSHI	5MG	A212795	001	Sep 18, 2020
				Mar DISC

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL				
NICORETTE				
+ @ GLAXOSMITHKLINE	EQ 2MG BASE	N022360	001	May 18, 2009
+!	EQ 4MG BASE	N022360	002	May 18, 2009
				Mar CAHN

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC				
OLOPATADINE HYDROCHLORIDE				
ALEMBIC PHARMS LTD	EQ 0.1% BASE	A209919	001	Dec 07, 2018
	EQ 0.2% BASE	A209420	001	Apr 29, 2019
APOTEX INC	EQ 0.2% BASE	A090918	001	Dec 05, 2017
BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015
@ CIPLA	EQ 0.2% BASE	A206087	001	Dec 05, 2017
FDC LTD	EQ 0.1% BASE	A209282	001	Sep 26, 2019
MYLAN	EQ 0.1% BASE	A204392	001	Mar 21, 2018
USV	EQ 0.1% BASE	A203152	001	Dec 07, 2015
				Feb CMKT
				Jan CMKT
				Feb CMKT
				Mar CMKT
				Feb CMKT
				Apr CMKT

OMEPRAZOLE

TABLET, DELAYED RELEASE; ORAL				
OMEPRAZOLE				
>D>	@ APOTEX	20MG	A210070	001
>A>		20MG	A210070	001
				Feb 11, 2019
				May CMFD
				Feb 11, 2019
				May CMFD

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL				
POLYETHYLENE GLYCOL 3350				
ANNORA PHARMA	17GM/SCOOPFUL	A214990	001	Apr 14, 2021
				Apr NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL				
RANITIDINE HYDROCHLORIDE				
@ WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006
ZANTAC 150				Jan DISC
+ @ SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004
+ @	EQ 150MG BASE	N021698	002	Mar 13, 2007
ZANTAC 75				Apr DISC
+ @ SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995
				Apr DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 05 MAY 2021**

NO MAY 2021 APPROVALS

## **ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST**

The list of Orphan Designations and Approvals is available at:

<https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2021 ADDITIONS

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	>A> 10996208	Apr 30, 2038	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGITALER</u>						
N 205636 002	10918816	Dec 14, 2035	DP			
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344 001	>A> 9592195	Dec 05, 2031	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u></b>						
N 209410 003	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025		U-219		
	9072697	Nov 23, 2025		U-3054		
<b><u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u></b>						
N 209410 004	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025		U-219		
	9072697	Nov 23, 2025		U-3054		
<b><u>AMLODIPINE BENZOATE - KATERZIA</u></b>						
N 211340 001	10894039	Oct 06, 2037	U-185			
	10894039	Oct 06, 2037	U-3			
	10952998	Oct 06, 2037	DP			
	10959991	Oct 06, 2037		U-158		
	10959991	Oct 06, 2037		U-39		
<b><u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u></b>						
N 210045 001	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<b><u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u></b>						
N 210045 002	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<b><u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u></b>						
N 210045 003	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<b><u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u></b>						
N 210875 001	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
<b><u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u></b>						
N 210875 002	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10888499 10959943	Feb 14, 2022 Apr 19, 2036	DP	U-2825		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10888499 10959943	Feb 14, 2022 Apr 19, 2036	DP	U-2825		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	10888499 10959943	Feb 14, 2022 Apr 19, 2036	DP	U-2825		
<u>APREPITANT - CINVANTI</u>						
N 209296 001	10953018	Sep 18, 2035		U-2161		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	>A> 10980803 >A> 10980803	Sep 24, 2033 Sep 24, 2033		U-1632 U-543		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	>A> 10980803 >A> 10980803	Sep 24, 2033 Sep 24, 2033		U-1632 U-543		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	>A> 10980803 >A> 10980803	Sep 24, 2033 Sep 24, 2033		U-1632 U-543		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	>A> 10980803 >A> 10980803	Sep 24, 2033 Sep 24, 2033		U-1632 U-543		
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENNU</u>						
N 209381 001	10918723	Sep 10, 2033		U-2310		
<u>ASENAPINE MALEATE - ASENAPINE MALEATE</u>						
A 206098 002				PC		Jun 08, 2021
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 213424 001				CGT		Sep 21, 2021
<u>AXITINIB - INLYTA</u>						
N 202324 001	10869924	Nov 05, 2036		U-3044		
<u>AXITINIB - INLYTA</u>						
N 202324 002	10869924	Nov 05, 2036		U-3044		
<u>AZACITIDINE - ONUREG</u>						
N 214120 001				ODE-320		Sep 01, 2027
<u>AZACITIDINE - ONUREG</u>						
N 214120 002				ODE-320		Sep 01, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003				I-811 NCE		Oct 16, 2022 Oct 24, 2023
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001				NCE		Oct 24, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>BEMPEDOIC ACID - NEXLETOL</u></b>						
N 211616 001	10941095	Dec 23, 2023		U-2747		
<b><u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u></b>						
N 211617 001	10941095	Dec 23, 2023		U-2746		
<b><u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u></b>						
N 214094 001					NCE ODE-333	Dec 03, 2025 Dec 03, 2027
<b><u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u></b>						
N 214094 002					NCE ODE-333	Dec 03, 2025 Dec 03, 2027
<b><u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u></b>						
N 210251 001					M-82	Feb 24, 2024
<b><u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u></b>						
N 210557 001 >A> 6794489		Jun 28, 2025	DS DP			
<b><u>BREXANOLONE - ZULRESSO</u></b>						
N 211371 001	10940156	Mar 08, 2037		U-2552		
<b><u>BREXIPRAZOLE - REXULTI</u></b>						
N 205422 001	RE48059	Dec 23, 2028	DS			
<b><u>BREXIPRAZOLE - REXULTI</u></b>						
N 205422 002	RE48059	Dec 23, 2028	DS			
<b><u>BREXIPRAZOLE - REXULTI</u></b>						
N 205422 003	RE48059	Dec 23, 2028	DS			
<b><u>BREXIPRAZOLE - REXULTI</u></b>						
N 205422 004	RE48059	Dec 23, 2028	DS			
<b><u>BREXIPRAZOLE - REXULTI</u></b>						
N 205422 005	RE48059	Dec 23, 2028	DS			
<b><u>BREXIPRAZOLE - REXULTI</u></b>						
N 205422 006	RE48059	Dec 23, 2028	DS			
<b><u>BRIVARACETAM - BRIVIACT</u></b>						
N 205836 001					NPP	May 10, 2021
<b><u>BRIVARACETAM - BRIVIACT</u></b>						
N 205836 002					NPP	May 10, 2021
<b><u>BRIVARACETAM - BRIVIACT</u></b>						
N 205836 003					NPP	May 10, 2021
<b><u>BRIVARACETAM - BRIVIACT</u></b>						
N 205836 004					NPP	May 10, 2021
<b><u>BRIVARACETAM - BRIVIACT</u></b>						
N 205836 005					NPP	May 10, 2021
<b><u>BRIVARACETAM - BRIVIACT</u></b>						
N 205838 001					NPP	May 10, 2021

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	>A> 11000522	Apr 30, 2032	U-3119			
	>A> 11000522	Apr 30, 2032	U-3120			
	>A> 11000522	Apr 30, 2032	U-3121			
	>A> 11000522	Apr 30, 2032	U-3122			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001				NPP		Mar 22, 2024
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002				NPP		Mar 22, 2024
<u>BUPIVACAINE - POSIMIR</u>						
N 204803 001	8153149	Sep 15, 2025	DP		NP	Feb 01, 2024
	8153661	Sep 15, 2025	U-3074			
	8753665	Sep 15, 2025	DP U-3074			
	8846072	Sep 15, 2025	DP U-3074			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF</u>						
N 211988 001	>A> 10098957	Apr 20, 2035	U-3118			
	>A> 10213510	Apr 20, 2035	DP U-3118			
	>A> 10398686	Mar 13, 2034	DP			
	>A> 10632199	Apr 20, 2035	DP U-3118			
	>A> 10898575	Apr 20, 2035	DP U-3118			
	>A> 10980886	Apr 20, 2035	DP			
	>A> 9592227	Mar 13, 2034	DP U-3118			
	>A> 9694079	Apr 20, 2035	DP U-3118			
	>A> 9744163	Mar 13, 2034	DP			
	>A> 9801945	Apr 20, 2035	DP U-3118			
	>A> 9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF</u>						
N 211988 002	>A> 10098957	Apr 20, 2035	U-3118			
	>A> 10213510	Apr 20, 2035	DP U-3118			
	>A> 10398686	Mar 13, 2034	DP			
	>A> 10632199	Apr 20, 2035	DP U-3118			
	>A> 10898575	Apr 20, 2035	DP U-3118			
	>A> 10980886	Apr 20, 2035	DP			
	>A> 9592227	Mar 13, 2034	DP U-3118			
	>A> 9694079	Apr 20, 2035	DP U-3118			
	>A> 9744163	Mar 13, 2034	DP			
	>A> 9801945	Apr 20, 2035	DP U-3118			
	>A> 9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF</u>						
N 211988 003	>A> 10098957	Apr 20, 2035	U-3118			
	>A> 10213510	Apr 20, 2035	DP U-3118			
	>A> 10398686	Mar 13, 2034	DP			
	>A> 10632199	Apr 20, 2035	DP U-3118			
	>A> 10898575	Apr 20, 2035	DP U-3118			
	>A> 10980886	Apr 20, 2035	DP			
	>A> 9592227	Mar 13, 2034	DP U-3118			
	>A> 9694079	Apr 20, 2035	DP U-3118			
	>A> 9744163	Mar 13, 2034	DP			
	>A> 9801945	Apr 20, 2035	DP U-3118			
	>A> 9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF</u>						
N 211988 004	>A> 10098957	Apr 20, 2035	U-3118			
	>A> 10213510	Apr 20, 2035	DP U-3118			
	>A> 10398686	Mar 13, 2034	DP			
	>A> 10632199	Apr 20, 2035	DP U-3118			
	>A> 10898575	Apr 20, 2035	DP U-3118			
	>A> 10980886	Apr 20, 2035	DP			
	>A> 9592227	Mar 13, 2034	DP U-3118			
	>A> 9694079	Apr 20, 2035	DP U-3118			
	>A> 9744163	Mar 13, 2034	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>BUPIVACAINE; MELOXICAM - ZYNRELEF</u></b>						
N 211988 004	>A> 9801945 >A> 9913909	Apr 20, 2035 Mar 13, 2034	DP U-3118 U-3118			
<b><u>BUPRENORPHINE - SUBLOCADE</u></b>						
N 209819 001	>A> 11000520	Nov 06, 2035	U-3111			
<b><u>BUPRENORPHINE - SUBLOCADE</u></b>						
N 209819 002	>A> 11000520	Nov 06, 2035	U-3111			
<b><u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u></b>						
N 204242 001	10946010	Sep 18, 2032	DP			
<b><u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u></b>						
N 204242 002	10874661 10946010	Sep 18, 2032 Sep 18, 2032	DP DP			
<b><u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u></b>						
N 204242 003	10946010	Sep 18, 2032	DP			
<b><u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u></b>						
N 204242 004	10946010	Sep 18, 2032	DP			
<b><u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u></b>						
N 204242 005	10946010	Sep 18, 2032	DP			
<b><u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u></b>						
N 204242 006	10946010	Sep 18, 2032	DP			
<b><u>CABAZITAXEL - JEVTANA KIT</u></b>						
N 201023 001				M-128		Dec 18, 2023
<b><u>CABOTEGRAVIR SODIUM - VOCABRIA</u></b>						
N 212887 001	10927129 8410103	Apr 28, 2026 Apr 28, 2026	DS DP DS DP U-3061		NCE	Jan 21, 2026
<b><u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u></b>						
N 212888 001	10927129 6838464 7125879 8080551 8410103	Apr 28, 2026 Feb 26, 2021 Apr 21, 2025 Apr 11, 2023 Apr 28, 2026	DS DP DS DP DS DP U-3059 DS DP DS DP U-3060		NCE	Jan 21, 2026
<b><u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u></b>						
N 212888 002	10927129 6838464 7125879 8080551 8410103	Apr 28, 2026 Feb 26, 2021 Apr 21, 2025 Apr 11, 2023 Apr 28, 2026	DS DP DS DP DS DP U-3059 DS DP DS DP U-3060		NCE	Jan 21, 2026
<b><u>CABOZANTINIB S-MALATE - CABOMETYX</u></b>						
N 208692 001				I-854		Jan 22, 2024
<b><u>CABOZANTINIB S-MALATE - CABOMETYX</u></b>						
N 208692 002				I-854		Jan 22, 2024
<b><u>CABOZANTINIB S-MALATE - CABOMETYX</u></b>						
N 208692 003				I-854		Jan 22, 2024
<b><u>CALCITONIN SALMON - CALCITONIN-SALMON</u></b>						
A 212416 001				>A> CGT		Nov 10, 2021

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	10864181	Mar 15, 2033	U-3017			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	8680052	Mar 09, 2033	U-2979			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10918608	Oct 14, 2035	U-3071	ODE-326	Jul 31, 2027	
	10918608	Oct 14, 2035	U-3072	ODE-332	Jul 31, 2027	
	10918608	Oct 14, 2035	U-3073			
	10966939	Jun 17, 2035	DP U-2780			
	10966939	Jun 17, 2035	DP U-2781			
<u>CARGLUMIC ACID - CARBAGLU</u>						
N 022562 001				>A> ODE-345		Jan 22, 2028
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	10287586	Nov 12, 2030	DS DP	NCE	Feb 25, 2026	
	10533174	May 04, 2021	DP	ODE-347	Feb 25, 2028	
	10781450	Nov 12, 2030	U-3089			
	8524880	Apr 02, 2026	DS DP U-3087			
	8524880	Apr 02, 2026	DS DP U-3088			
	9228187	Nov 12, 2030	DS DP			
	9416361	May 04, 2021	DS			
	9447415	Jun 28, 2025	DS DP			
	9758783	Nov 12, 2030	U-3088			
	9758783	Nov 12, 2030	U-3089			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10933053	Sep 09, 2034	U-3090			
	10933053	Sep 09, 2034	U-3091			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001				>A> ODE*	Apr 29, 2021	
				>A> ODE*	May 26, 2024	
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 001				CGT	Sep 20, 2021	
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 002				CGT	Sep 20, 2021	
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 003				CGT	Sep 20, 2021	
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 004				CGT	Sep 20, 2021	
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 005				CGT	Sep 20, 2021	
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	6706276	Mar 06, 2022	DP			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPPIO</u>						
N 209589 001				NPP	Aug 15, 2021	
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	10786518	Jul 19, 2038	U-2978			
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575 001				NCE	Dec 14, 2022	
				NP	Jan 10, 2023	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575 001					NCE NP	Dec 14, 2022 Jan 10, 2023
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10894012	Feb 07, 2037	U-3014			
	10933060	Feb 07, 2037	U-3014			
	>A> 10973811	Feb 07, 2037	U-2226			
	>A> 10987347	Feb 07, 2037	U-2225			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					I-852 ODE-328	Jan 14, 2024 Jan 14, 2028
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					I-852 ODE-328	Jan 14, 2024 Jan 14, 2028
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002					>A> NCE	Apr 30, 2024
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 001	10993952	Feb 15, 2036	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 002	10993952	Feb 15, 2036	DP			
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	10918694	Feb 28, 2037	DP			
<u>CYSTEAMINE BITARTRATE - PROSYSBI</u>						
N 203389 001	10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROSYSBI</u>						
N 203389 002	10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROSYSBI</u>						
N 213491 001	10905662	Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
	8026284	Sep 22, 2027	U-1399		ODE*	Dec 22, 2024
	8026284*PED	Mar 22, 2028			PED	Feb 14, 2023
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
<u>CYSTEAMINE BITARTRATE - PROSYSBI</u>						
N 213491 002	10905662	Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
	8026284	Sep 22, 2027	U-1399		ODE*	Dec 22, 2024
	8026284*PED	Mar 22, 2028			PED	Feb 14, 2023
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>CYSTEINE HYDROCHLORIDE - ELCYS</b></u>						
N 210660 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
<u><b>CYSTEINE HYDROCHLORIDE - NOURESS</b></u>						
N 212535 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
<u><b>CYTARABINE; DAUNORUBICIN - VYXEOS</b></u>						
N 209401 001	10028912	Sep 29, 2034	DP U-3149	>A> NPP		Mar 30, 2024
	10028912	Sep 29, 2034	DP U-3150	>A> ODE-350		Mar 30, 2028
	10166184	Oct 15, 2032	DP U-3149			
	10835492	Oct 15, 2032	U-3150			
	7850990	Jan 23, 2027	DP U-3147			
	8022279	Sep 14, 2027	DP U-3147			
	8092828	Apr 01, 2029	U-3147			
	8431806	Apr 22, 2025	DP U-3147			
<u><b>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</b></u>						
N 022512 001	6087380	Dec 28, 2021	DS DP U-1931			
	6087380*PED	Jun 28, 2022				
	9034822	Jan 20, 2031		U-1759		
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023		DP		
	9925174*PED	Dec 14, 2023				
<u><b>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</b></u>						
N 022512 002	6087380	Dec 28, 2021	DS DP U-1931			
	6087380*PED	Jun 28, 2022				
	9034822	Jan 20, 2031		U-1759		
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023		DP		
	9925174*PED	Dec 14, 2023				
<u><b>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</b></u>						
N 022512 003	6087380	Dec 28, 2021	DS DP U-1931			
	6087380*PED	Jun 28, 2022				
	7866474	Aug 31, 2027		DP	Y	
	7866474*PED	Mar 02, 2028				
	7932273	Sep 07, 2025		DS DP		
	7932273*PED	Mar 07, 2026				
	9034822	Jan 20, 2031		U-1759		
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023		DP		
	9925174*PED	Dec 14, 2023				
<u><b>DAPAGLIFLOZIN - FARXIGA</b></u>						
N 202293 001					>A> I-857	Apr 30, 2024
<u><b>DAPAGLIFLOZIN - FARXIGA</b></u>						
N 202293 002	10973836	Mar 09, 2040	U-3127		>A> I-857	Apr 30, 2024
<u><b>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE</b></u>						
N 214231 001	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
<u><b>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)</b></u>						
N 214231 002	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>DEFERIPRONE - DEFERIPRONE</u></b>						
A 208800 001					PC	Mar 27, 2021
<b><u>DEFERIPRONE - FERRIPROX</u></b>						
N 021825 001	>A> 7049328	Jun 28, 2021	U-3083	>A>	I-859	Apr 30, 2024
<b><u>DEFERIPRONE - FERRIPROX</u></b>						
N 021825 002	>A> 7049328	Jun 28, 2021	U-3083	>A>	I-859	Apr 30, 2024
<b><u>DEFERIPRONE - FERRIPROX</u></b>						
N 208030 001	>A> 7049328 >A> 8703156	Jun 28, 2021 Oct 26, 2029	U-3083 DP U-3083	>A>	I-859	Apr 30, 2024
<b><u>DEFERIPRONE - FERRIPROX</u></b>						
N 208030 002	>A> 7049328 >A> 8703156	Jun 28, 2021 Oct 26, 2029	U-3083 DP U-3083	>A>	I-859	Apr 30, 2024
<b><u>DEFERIPRONE - FERRIPROX</u></b>						
N 212269 001	>A> 10780055 >A> 10780055 10940115 10940116 >A> 7049328 >A> 7049328	Oct 25, 2038 Oct 25, 2038 Oct 25, 2038 Oct 25, 2038 Jun 28, 2021 Jun 28, 2021	DP U-3083 DP U-735 DP U-3083 DP U-3083 U-735	>A>	I-859	Apr 30, 2024
<b><u>DEGARELIX ACETATE - FIRMAGON</u></b>						
N 022201 001	10973870	Feb 10, 2029	U-1978			
<b><u>DEGARELIX ACETATE - FIRMAGON</u></b>						
N 022201 002	10973870	Feb 10, 2029	U-1978			
<b><u>DEUTETRABENAZINE - AUSTEDO</u></b>						
N 208082 001	10959996 10959996*PED 8524733 8524733*PED 9233959 9233959*PED 9296739 9296739*PED 9550780 9550780 9550780*PED 9814708 9814708*PED	Mar 07, 2036 Sep 07, 2036 Mar 27, 2031 Sep 27, 2031 Sep 18, 2033 Mar 18, 2034 Sep 18, 2033 Mar 18, 2034 Sep 18, 2033 Sep 18, 2033 Sep 18, 2034 Sep 18, 2033 Sep 18, 2033 Sep 18, 2034 Sep 18, 2033 Sep 18, 2033 Sep 18, 2034 DS DP DP	U-3055 ODE-134 PED PED	NCE ODE-134 PED PED	Apr 03, 2022 Apr 03, 2024 Oct 03, 2022 Oct 03, 2024	
<b><u>DEUTETRABENAZINE - AUSTEDO</u></b>						
N 208082 002	10959996 10959996*PED 8524733 8524733*PED 9233959 9233959*PED 9296739 9296739*PED 9550780 9550780 9550780*PED 9814708 9814708*PED	Mar 07, 2036 Sep 07, 2036 Mar 27, 2031 Sep 27, 2031 Sep 18, 2033 Mar 18, 2034 Sep 18, 2033 Mar 18, 2034 Sep 18, 2033 Sep 18, 2033 Sep 18, 2034 Sep 18, 2033 Sep 18, 2033 Sep 18, 2034 DS DP DP	U-3055 ODE-134 PED PED	NCE ODE-134 PED PED	Apr 03, 2022 Apr 03, 2024 Oct 03, 2022 Oct 03, 2024	
<b><u>DEUTETRABENAZINE - AUSTEDO</u></b>						
N 208082 003	10959996 10959996*PED 8524733 8524733*PED	Mar 07, 2036 Sep 07, 2036 Mar 27, 2031 Sep 27, 2031	U-3055 ODE-134 PED PED	NCE ODE-134 PED PED	Apr 03, 2022 Apr 03, 2024 Oct 03, 2022 Oct 03, 2024	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>DEUTETRABENAZINE - AUSTEDO</u></b>						
N 208082 003	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<b><u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u></b>						
N 212994 001	>A> 10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	>A> 10584113	Dec 09, 2037	DP			
	>A> 10759778	Dec 09, 2037	DP			
	>A> 10858341	Dec 09, 2037	U-3094			
	>A> 10954213	Dec 09, 2037	U-3094			
	>A> 9079928	Jul 27, 2032	DP			
<b><u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u></b>						
N 212994 002	>A> 10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	>A> 10584113	Dec 09, 2037	DP			
	>A> 10759778	Dec 09, 2037	DP			
	>A> 10858341	Dec 09, 2037	U-3094			
	>A> 10954213	Dec 09, 2037	U-3094			
	>A> 9079928	Jul 27, 2032	DP			
<b><u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u></b>						
N 212994 003	>A> 10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	>A> 10584113	Dec 09, 2037	DP			
	>A> 10759778	Dec 09, 2037	DP			
	>A> 10858341	Dec 09, 2037	U-3094			
	>A> 10954213	Dec 09, 2037	U-3094			
	>A> 9079928	Jul 27, 2032	DP			
<b><u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u></b>						
A 212317 001					CGT	Sep 26, 2021
<b><u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u></b>						
A 212317 002					CGT	Sep 26, 2021
<b><u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u></b>						
A 212317 003					CGT	Sep 26, 2021
<b><u>DIMETHYL FUMARATE - TECFIDERA</u></b>						
N 204063 001	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	>A> 10994003	Mar 13, 2035	U-3148			
	>A> 11007166	Nov 16, 2035	U-1384			
	>A> 11007167	Nov 16, 2035	U-1384			
<b><u>DIMETHYL FUMARATE - TECFIDERA</u></b>						
N 204063 002	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	>A> 10994003	Mar 13, 2035	U-3148			
	>A> 11007166	Nov 16, 2035	U-1384			
	>A> 11007167	Nov 16, 2035	U-1384			
<b><u>DOCETAXEL - DOCETAXEL</u></b>						
N 205934 001	>A> 10842770	Aug 07, 2031	DP U-2998			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>DOCETAXEL - DOCETAXEL</b></u>						
N 205934 002 >A> 10842770		Aug 07, 2031		DP U-2998		
<u><b>DOCETAXEL - DOCETAXEL</b></u>						
N 205934 003 >A> 10842770		Aug 07, 2031		DP U-2998		
<u><b>DROSPIRENONE - SLYND</b></u>						
N 211367 001 10987364		Jun 28, 2031		DP		
<u><b>DROSPIRENONE; ESTETROL - NEXTSTELLIS</b></u>						
N 214154 001 7732430		Mar 02, 2025		DP U-3152	NCE	Apr 15, 2026
<u><b>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</b></u>						
N 212516 001 10959982		Apr 13, 2037		DP		
<u><b>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</b></u>						
N 212516 002 10959982		Apr 13, 2037		DP		
<u><b>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</b></u>						
N 212516 003 10959982		Apr 13, 2037		DP		
<u><b>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</b></u>						
N 212516 004 10959982		Apr 13, 2037		DP		
<u><b>EDARAVONE - RADICAVA</b></u>						
N 209176 002					ODE*	May 05, 2024
<u><b>EDOXABAN TOSYLATE - SAVAYSA</b></u>						
N 206316 001 7365205		Apr 18, 2027		DS		
<u><b>EDOXABAN TOSYLATE - SAVAYSA</b></u>						
N 206316 002 7365205		Apr 18, 2027		DS		
<u><b>EDOXABAN TOSYLATE - SAVAYSA</b></u>						
N 206316 003 7365205		Apr 18, 2027		DS		
<u><b>EFINACONAZOLE - JUBLIA</b></u>						
N 203567 001 10864274		Oct 02, 2034		U-2720		
	7214506	Feb 22, 2026		U-281		
<u><b>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</b></u>						
N 213388 001 10881659		Mar 14, 2034		U-2842		
<u><b>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</b></u>						
N 212273 001 10081621		Mar 25, 2031		DP U-2652	ODE-323	Dec 21, 2027
	10081621	Mar 25, 2031		DP U-3032		
	10239867	Apr 09, 2027		DS DP U-2653		
	10239867	Apr 09, 2027		DS DP U-3033		
	10758534	Oct 06, 2035		DS DP U-2645		
	10758534	Oct 06, 2035		DS DP U-3028		
	10793547	Dec 08, 2037		DS DP U-2645		
	10793547	Dec 08, 2037		DS DP U-3028		
	8324242	Aug 05, 2027		U-2645		
	8324242	Aug 05, 2027		U-3028		
	8354427	Jul 06, 2026		U-2646		
	8354427	Jul 06, 2026		U-3029		
	8415387	Nov 12, 2027		U-2645		
	8415387	Nov 12, 2027		U-3028		
	8598181	May 01, 2027		U-2645		
	8598181	May 01, 2027		U-3028		
	8629162	Jun 24, 2025		U-2648		
	8629162	Jun 24, 2025		U-3030		
	9670163	Dec 28, 2026		DP U-2650		
	9670163	Dec 28, 2026		DP U-3031		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</b>						
N 212273 001	9931334	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-3031			
	9974781	Apr 09, 2027	DP U-2645			
	9974781	Apr 09, 2027	DP U-3028			
<b>ELIGLUSTAT TARTRATE - CERDELGA</b>						
N 205494 001	10888544	Dec 13, 2038	U-3040			
	10888544	Dec 13, 2038	U-3041			
	10888547	Jan 31, 2031	U-3042			
	10888547	Jan 31, 2031	U-3043			
<b>ELUXADOLINE - VIBERZI</b>						
N 206940 001 >A> 11007179		Mar 14, 2033	DP			
<b>ELUXADOLINE - VIBERZI</b>						
N 206940 002 >A> 11007179		Mar 14, 2033	DP			
<b>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</b>						
A 209721 001				PC		Mar 09, 2021
<b>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</b>						
A 209721 002				PC		Mar 09, 2021
<b>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</b>						
A 209721 003				PC		Mar 09, 2021
<b>EPINEPHRINE - AUVI-Q</b>						
N 201739 001	10960155	Jun 25, 2026	DP			
<b>EPINEPHRINE - AUVI-Q</b>						
N 201739 002	10842938	Dec 21, 2037	DP U-2980			
	10960155	Jun 25, 2026	DP			
<b>EPINEPHRINE - AUVI-Q</b>						
N 201739 003	10842938	Dec 21, 2037	DP U-2980			
	10960155	Jun 25, 2026	DP			
<b>ERDAFITINIB - BALVERSA</b>						
N 212018 001	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<b>ERDAFITINIB - BALVERSA</b>						
N 212018 002	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<b>ERDAFITINIB - BALVERSA</b>						
N 212018 003	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<b>ESKETAMINE HYDROCHLORIDE - SPRAVATO</b>						
N 211243 001	10869844	Sep 10, 2035	U-3034			
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>ESLICARBAZEPINE ACETATE - APTIOM</u></b>						
N 022416 001	10912781	Oct 23, 2028	DP			
<b><u>ESLICARBAZEPINE ACETATE - APTIOM</u></b>						
N 022416 002	10912781	Oct 23, 2028	DP			
<b><u>ESLICARBAZEPINE ACETATE - APTIOM</u></b>						
N 022416 003	10912781	Oct 23, 2028	DP			
<b><u>ESLICARBAZEPINE ACETATE - APTIOM</u></b>						
N 022416 004	10912781	Oct 23, 2028	DP			
<b><u>ESTRADIOL - IMVEXXY</u></b>						
N 208564 001	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
<b><u>ESTRADIOL - IMVEXXY</u></b>						
N 208564 002	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
<b><u>ETEPLIRSEN - EXONDYS 51</u></b>						
N 206488 001	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<b><u>ETEPLIRSEN - EXONDYS 51</u></b>						
N 206488 002	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<b><u>ETHINYL ESTRADIOL; LEVONORGESTREL - TYBLUME</u></b>						
N 209405 001					NDF	Mar 30, 2023
<b><u>ETHINYL ESTRADIOL; NORELGESTROMIN - ETHINYL ESTRADIOL AND NORELGESTROMIN</u></b>						
A 213950 001					CGT	Aug 25, 2021
<b><u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MERZEE</u></b>						
A 212706 001					CGT	Jul 17, 2021
<b><u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u></b>						
N 209627 001	10918649	Jun 21, 2039	DP			
	10925882	Jun 21, 2039	DP			
	10940157	Jun 21, 2039	DP			
<b><u>EXENATIDE - BYDUREON BCISE</u></b>						
N 209210 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			PED	Aug 15, 2023
	6824822	Oct 09, 2022	DP			
	6824822*PED	Apr 09, 2023				
	7223440	Aug 31, 2021	DP			
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>EXENATIDE - BYDUREON BCISE</u></b>						
N 209210 001	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2597			
	8431685	Apr 13, 2025	DP U-2598			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2597			
	8461105	Apr 13, 2025	DP U-2598			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	U-2588			
	8501698*PED	Dec 20, 2027				
	8895033	Oct 04, 2030	DP U-2589			
	8895033	Oct 04, 2030	DP U-2590			
	8895033	Oct 04, 2030	DP U-2597			
	8895033	Oct 04, 2030	DP U-2600			
	8895033	Oct 04, 2030	DP U-2601			
	8895033	Oct 04, 2030	DP U-2602			
	8895033*PED	Apr 04, 2031				
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-2597			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2597			
	9238076	Apr 15, 2024	DP U-2599			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-2597			
	9884092*PED	Feb 18, 2027				
<b><u>EXENATIDE SYNTHETIC - BYDUREON</u></b>						
N 022200 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			PED	Aug 15, 2023
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7456254*PED	Dec 30, 2025				
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			PED	Aug 15, 2023
	6824822	Oct 09, 2022	DP			
	6824822*PED	Apr 09, 2023				
	7223440	Aug 31, 2021	DP			
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	7612176*PED	Oct 13, 2025				
	8216180	Jan 12, 2028	DP			
	8216180*PED	Jul 12, 2028				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8431685*PED	Oct 13, 2025				
	8439864	Mar 25, 2028	DP			
	8439864*PED	Sep 25, 2028				
	8461105	Apr 13, 2025	DP U-2588			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8690837	May 19, 2029	DP			
	8690837*PED	Nov 19, 2029				
	8721615	Jan 18, 2030	DP			
	8721615*PED	Jul 18, 2030				
	8758292	Nov 12, 2027	DP			
	8758292*PED	May 12, 2028				
	8827963	Feb 04, 2029	DP			
	8827963*PED	Aug 04, 2029				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851*PED	Feb 18, 2027				
	8998876	Jan 07, 2030	DP			
	8998876*PED	Jul 07, 2030				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076*PED	Oct 15, 2024				
	9320853	Mar 25, 2028	DP			
	9320853*PED	Sep 25, 2028				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092*PED	Feb 18, 2027				
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 001	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 002	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 003	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 004	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	10947183	Dec 20, 2036	DS DP			
	10950331	Sep 28, 2035	U-3098			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
>A>	8895612	Jan 08, 2027	U-1620			
>A>	8895612	Jan 08, 2027	U-3050			
>A>	8895612	Jan 08, 2027	U-3051			
>A>	8895612	Jan 08, 2027	U-3115			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>FERRIC CARBOXYMALTOSE - INJECTAFER</u></b>						
N 203565 001	>A> 8895612	Jan 08, 2027		U-3116		
<b><u>FERRIC CARBOXYMALTOSE - INJECTAFER</u></b>						
N 203565 002	7612109 7754702 7754702 7754702 >A> 8895612 >A> 8895612 >A> 8895612 >A> 8895612 >A> 8895612 9376505	Feb 05, 2024 Feb 15, 2028 Feb 15, 2028 Feb 15, 2028 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Oct 20, 2023	DS DP	U-2555 U-2556 U-2557 U-1620 U-3050 U-3051 U-3115 U-3116		
<b><u>FERRIC CARBOXYMALTOSE - INJECTAFER</u></b>						
N 203565 003	>A> 7612109 >A> 7754702 >A> 7754702 >A> 7754702 >A> 8895612 >A> 8895612 >A> 8895612 >A> 8895612 >A> 8895612 Oct 20, 2023	Feb 05, 2024 Feb 15, 2028 Feb 15, 2028 Feb 15, 2028 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Oct 20, 2023	DS DP	U-2555 U-2556 U-2557 U-1620 U-3050 U-3051 U-3115 U-3116		
<b><u>FERRIC OXYHYDROXIDE - VELPHORO</u></b>						
N 205109 001	>A> 10624855 >A> 10624855*PED >A> 10682376 >A> 10682376*PED >A> 10695367 >A> 10695367*PED >A> 10925896 >A> 10925896*PED >A> 10925897 >A> 10925897*PED >A> 10933090 >A> 10933090*PED >A> 11013761 >A> 11013761*PED >A> 11013762 >A> 11013762*PED >A> 9561251 >A> 9561251*PED	Nov 26, 2034 May 26, 2035 Nov 13, 2028 May 13, 2029 Nov 13, 2028 May 13, 2029 Jan 23, 2030 Jul 23, 2030	DP			
<b><u>FESOTERODINE FUMARATE - TOVIAZ</u></b>						
N 022030 001	>A> 8501723 >A> 8501723*PED	Jun 07, 2027 Dec 07, 2027		DP		
<b><u>FESOTERODINE FUMARATE - TOVIAZ</u></b>						
N 022030 002	>A> 8501723 >A> 8501723*PED	Jun 07, 2027 Dec 07, 2027		DP		
<b><u>FLUCICLOVINE F-18 - AXUMIN</u></b>						
N 208054 001	10933147 10953112 10967077	Dec 30, 2035 Nov 28, 2026 Dec 30, 2035		U-2450 U-1879 U-2450		
<b><u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALHALER</u></b>						
N 208798 004	10918816	Dec 14, 2035		DP		
<b><u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALHALER</u></b>						
N 208798 005	10918816	Dec 14, 2035		DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	10918816	Dec 14, 2035	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10918816	Dec 14, 2035	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10918816	Dec 14, 2035	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10918816	Dec 14, 2035	DP			
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001	7504095	Jan 31, 2025	DP U-3092	NCE ODE-342	Feb 26, 2026 Feb 26, 2028	
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212642 001				NCE W	Dec 01, 2025 Dec 01, 2025	
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212643 001				NCE W	Dec 01, 2025 Dec 01, 2025	
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	>A> 10028937 >A> 10028937 >A> 10028937*PED >A> 10039754 >A> 10039754 >A> 10039754*PED >A> 10286029 >A> 10286029*PED >A> 8648037 >A> 8648037 >A> 8648037*PED >A> 8937150 >A> 8937150*PED >A> 9321807 >A> 9321807*PED >A> 9586978 >A> 9586978 >A> 9586978*PED	Jun 10, 2030 Jun 10, 2030 Dec 10, 2030 Jun 10, 2030 Jun 10, 2030 Dec 10, 2030 Mar 14, 2034 Sep 14, 2034 Jan 19, 2032 Jan 19, 2032 Jul 19, 2032 May 18, 2032 	U-2141 U-2532 U-2141 U-2532 U-2532 U-2532 DS DP U-2141 DS DP U-2532 DS DP U-2141 DS DP U-2532 DS DP DS DS U-2141 U-2532	>A> D-175 >A> M-259 >A> NCE >A> NPP >A> ODE-232 >A> ODE-233 >A> PED >A> PED	Sep 26, 2022 Apr 10, 2023 Aug 03, 2022 Apr 30, 2022 Apr 30, 2026 Apr 30, 2026 Oct 30, 2022 Feb 03, 2023 Mar 26, 2023 Oct 10, 2023 Oct 30, 2026 Oct 30, 2026 Oct 30, 2026 Oct 30, 2026	
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001	10894133	Jan 03, 2038	DP			
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	10940110	Feb 26, 2029	DP U-1773			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	>A> 10968450 >A> 10995337	Jun 28, 2025 Jun 28, 2025	DS DP DP U-2675			
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566 001	>A> 10857159 >A> 10857159*PED	Nov 30, 2036 May 30, 2037	DP			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 001	9649280 9675559 9717740	May 12, 2034 Jan 10, 2033 Nov 19, 2032	DP U-3075 U-3075 U-3075			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 002	9649280	May 12, 2034	DP	U-3075		
	9675559	Jan 10, 2033		U-3075		
	9717740	Nov 19, 2032		U-3075		
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 003	9649280	May 12, 2034	DP	U-3075		
	9675559	Jan 10, 2033		U-3075		
	9717740	Nov 19, 2032		U-3075		
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 004	9649280	May 12, 2034	DP	U-3075		
	9675559	Jan 10, 2033		U-3075		
	9717740	Nov 19, 2032		U-3075		
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10961251	Jun 03, 2033	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10918635	Apr 30, 2030	U-1455			
	10918635	Apr 30, 2030	U-172			
<u>INFIGRATINIB PHOSPHATE - TRUSELTIO</u>						
N 214622 001	>A> 10278969	Dec 11, 2034	DP			
	>A> 8552002	Aug 25, 2029	DS	DP		
	>A> 9067896	Dec 20, 2026	DS			
<u>INFIGRATINIB PHOSPHATE - TRUSELTIO</u>						
N 214622 002	>A> 10278969	Dec 11, 2034	DP			
	>A> 8552002	Aug 25, 2029	DS	DP		
	>A> 9067896	Dec 20, 2026	DS			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	10980795	Jun 12, 2033	U-1848			
	10993914	Oct 15, 2036	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001					ODE-338	Dec 21, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003					ODE-338	Dec 21, 2027
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10058546	Jul 15, 2033	U-2399		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10058546	Jul 15, 2033	U-2399		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	>A> 10980788	Jun 07, 2039	U-3112			
	>A> 10980788	Jun 07, 2039	U-3113			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10799505	Aug 15, 2036	DS			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10882840	Jul 11, 2026	U-1524			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	>A> 10987244	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	>A> 10987244	Apr 01, 2031	DP			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	>A> 10987244	Apr 01, 2031	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>LINAGLIPITIN; METFORMIN HYDROCHLORIDE - JENTADUETO</b></u>						
N 201281 001	10973827	Apr 02, 2029	DP			
<u><b>LINAGLIPITIN; METFORMIN HYDROCHLORIDE - JENTADUETO</b></u>						
N 201281 002	10973827	Apr 02, 2029	DP			
<u><b>LINAGLIPITIN; METFORMIN HYDROCHLORIDE - JENTADUETO</b></u>						
N 201281 003	10973827	Apr 02, 2029	DP			
<u><b>LIRAGLUTIDE RECOMBINANT - SAXENDA</b></u>						
N 206321 001					NPP	Dec 04, 2023
<u><b>LISINOPRIL - OBRELIS</b></u>						
N 208401 001	10940177	Nov 06, 2035	DP			
<u><b>LONAFARNIB - ZOKINVY</b></u>						
N 213969 001	7838531 8828356	Jul 26, 2024 Oct 17, 2023	U-3070 U-3070		ODE-324	Nov 20, 2027
<u><b>LONAFARNIB - ZOKINVY</b></u>						
N 213969 002	7838531 8828356	Jul 26, 2024 Oct 17, 2023	U-3070 U-3070		ODE-324	Nov 20, 2027
<u><b>LORLATINIB - LORBRENA</b></u>						
N 210868 001	10420749 10420749	Jul 27, 2036 Jul 27, 2036	DS DP U-2633 DS DP U-3096		I-847 >A> ODE-349	Mar 03, 2024 Mar 03, 2028
<u><b>LORLATINIB - LORBRENA</b></u>						
N 210868 002	10420749 10420749	Jul 27, 2036 Jul 27, 2036	DS DP U-2633 DS DP U-3096		I-847 >A> ODE-349	Mar 03, 2024 Mar 03, 2028
<u><b>LOTEPREDNOL ETABONATE - LOTEPEPDNOL ETABONATE</b></u>						
A 212450 001					CGT	Nov 02, 2021
<u><b>LOTEPREDNOL ETABONATE - EYSUVIS</b></u>						
N 210933 001	10940108 10945948 >A> 10993908	May 03, 2033 May 03, 2033 May 03, 2033	U-2985 U-2985 U-3117			
<u><b>LUMASIRAN SODIUM - OXLUMO</b></u>						
N 214103 001					ODE-339	Nov 23, 2027
<u><b>LUMATEPERONE TOSYLATE - CAPLYTA</b></u>						
N 209500 001	10960009	Dec 03, 2034	U-814			
<u><b>MACITENTAN - OPSUMIT</b></u>						
N 204410 001	10946015	Nov 25, 2026	DP U-1445			
<u><b>MANNITOL - BRONCHITOL</b></u>						
N 202049 001					NP ODE-327	Oct 30, 2023 Oct 30, 2027
<u><b>MELOXICAM - ANJESO</b></u>						
N 210583 001	10881663	Mar 08, 2039	U-3038			
<u><b>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</b></u>						
N 214383 001	10285946 10322182 10543274 10869928 6992207	Apr 25, 2032 Apr 25, 2032 Apr 25, 2032 Apr 25, 2032 Jun 25, 2022	DP DP U-3093 DP DS DP U-3093		NCE ODE-348	Feb 26, 2026 Feb 26, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	10940128	Jun 14, 2030	DP	U-3086		
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	8680136	Aug 29, 2031	DS	DP	NCE GAIN	Aug 29, 2022 Aug 29, 2027
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	>A> 11020361	Dec 22, 2029		U-2843		
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844 001	10966990	Jun 20, 2038		DP		
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844 002	10966990	Jun 20, 2038		DP		
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10874655	May 30, 2038		U-2371		
	10874656	May 30, 2038		U-2371		
	10874657	May 30, 2038		U-2371		
	10925866	Apr 28, 2028		U-2371		
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	10946101	Oct 01, 2030		U-1631		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>MIRABEGRON - MYRBETRIO</u></b>						
N 202611 001	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030			I-855	Mar 25, 2024
	6346532	Mar 27, 2022	DS DP		PED	Sep 25, 2024
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
<b><u>MIRABEGRON - MYRBETRIO</u></b>						
N 202611 002	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030			I-855	Mar 25, 2024
	6346532	Mar 27, 2022	DS DP		PED	Sep 25, 2024
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
<b><u>MIRABEGRON - MYRBETRIO GRANULES</u></b>						
N 213801 001	10058536	Mar 31, 2036	DP U-3108		NP	Mar 25, 2024
	6346532	Mar 27, 2022	DS		PED	Sep 25, 2024
	7342117	Nov 04, 2023	DS			
	7982049	Nov 04, 2023	DP			
<b><u>MONOMETHYL FUMARATE - BAFIERTAM</u></b>						
N 210296 001	10918615	Aug 12, 2035	DP U-1384			
	10918616	Jun 03, 2035	U-1384			
	10918617	Aug 10, 2035	DP			
	10945985	Aug 14, 2035	DP			
<b><u>MORPHINE SULFATE - MORPHINE SULFATE</u></b>						
A 212451 001					CGT	Aug 10, 2021
<b><u>MORPHINE SULFATE - MORPHINE SULFATE</u></b>						
A 212451 002					CGT	Aug 10, 2021
<b><u>NALDEMEDINE TOSYLATE - SYMPROIC</u></b>						
N 208854 001	10952968	May 13, 2033	DS DP			
<b><u>NALOXONE HYDROCHLORIDE - EVZIO</u></b>						
N 205787 001	10960155	Jun 25, 2026	DP			
<b><u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u></b>						
N 209862 001	10960155	Jun 25, 2026	DP			
<b><u>NALOXONE HYDROCHLORIDE - KLOXXADO</u></b>						
N 212045 001	>A> 10722510	Aug 26, 2034	DP U-3110			
	>A> 10973814	Aug 26, 2034	DP U-3110			
<b><u>NERATINIB MALEATE - NERLYNX</u></b>						
N 208051 001	10035788	Oct 15, 2028	U-2043			
	10035788	Oct 15, 2028	U-3047			
	10035788	Oct 15, 2028	U-3097			
	7982043	Oct 08, 2025	U-2043			
	7982043	Oct 08, 2025	U-3047			
	7982043	Oct 08, 2025	U-3097			
	8518446	Nov 20, 2030	DP U-2043			
	8518446	Nov 20, 2030	DP U-3047			
	8518446	Nov 20, 2030	DP U-3097			
	8669273	Jul 18, 2031	U-3047			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>NERATINIB MALEATE - NERLYNX</u></b>						
N 208051 001	8790708	Nov 05, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-3047			
	8790708	Nov 05, 2030	DP U-3097			
	9139558	Oct 15, 2028	U-2043			
	9139558	Oct 15, 2028	U-3047			
	9139558	Oct 15, 2028	U-3097			
	9211291	Mar 24, 2030	U-2043			
	9211291	Mar 24, 2030	U-3097			
	9265784	Aug 04, 2029	U-3047			
	9630946	Oct 15, 2028	U-2043			
	9630946	Oct 15, 2028	U-3047			
	9630946	Oct 15, 2028	U-3097			
<b><u>NETARSUDIL MESYLATE - RHOPRESSA</u></b>						
N 208254 001	10882840	Jul 11, 2026		U-1524		
<b><u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u></b>						
N 205718 001	10961195	Sep 25, 2035	DS DP			
<b><u>NIFURTIMOX - LAMPIT</u></b>						
N 213464 001					ODE-319	Aug 06, 2027
<b><u>NIFURTIMOX - LAMPIT</u></b>						
N 213464 002					ODE-319	Aug 06, 2027
<b><u>NIRAPARIB TOSYLATE - ZEJULA</u></b>						
N 208447 001 >A> 8071623		Mar 27, 2031	DS DP			
<b><u>NITAZOXANIDE - NITAZOXANIDE</u></b>						
A 213820 001					CGT	Jun 05, 2021
<b><u>NITRIC OXIDE - GENOSYLL</u></b>						
N 202860 001	10124142	Aug 18, 2025	U-3037			
	10814092	Oct 17, 2025	U-3037			
	10926054	Aug 13, 2029	DP			
	7947227	Oct 17, 2026	U-3037			
	8057742	Jan 18, 2026	U-3037			
	8226916	Aug 18, 2025	U-3037			
	8607785	Jul 14, 2030	DP			
	8609028	Aug 18, 2025	U-3037			
	8821801	Aug 18, 2025	DP			
	8944049	Aug 13, 2029	DP			
	9522249	Aug 18, 2025	DP			
	9701538	Jan 28, 2029	DP			
	9956373	Aug 18, 2025	U-3037			
<b><u>OBETICOLIC ACID - OCALIVA</u></b>						
N 207999 001	RE48286	Nov 16, 2027	DS DP			
<b><u>OBETICOLIC ACID - OCALIVA</u></b>						
N 207999 002	RE48286	Nov 16, 2027	DS DP			
<b><u>OLAPARIB - LYNNPARZA</u></b>						
N 208558 001	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>OLAPARIB - LYNPARZA</u></b>						
N 208558 001	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
<b><u>OLAPARIB - LYNPARZA</u></b>						
N 208558 002	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
<b><u>OLICERIDINE - OLINVYK</u></b>						
N 210730 001					NCE	Oct 30, 2025
<b><u>OLICERIDINE - OLINVYK</u></b>						
N 210730 002					NCE	Oct 30, 2025
<b><u>OLICERIDINE - OLINVYK</u></b>						
N 210730 003					NCE	Oct 30, 2025
<b><u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u></b>						
N 214155 001	8420592	Aug 29, 2029	U-3101		>A> NP	Mar 12, 2024
	9649352	Jul 16, 2035	DS DP			
	9682061	Apr 26, 2030	U-3101			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777	I-853	Dec 18, 2023	
	10183020	Jan 02, 2035	DP U-2289	ODE-337	Dec 18, 2027	
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777	I-853	Dec 18, 2023	
	10183020	Jan 02, 2035	DP U-2289	ODE-337	Dec 18, 2027	
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	9566252	Nov 02, 2022	U-1370			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	10898573	Dec 16, 2039	DP			
	10912765	Aug 26, 2031	U-2849			
	10940138	Dec 16, 2039	U-2849			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 007	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Nov 09, 2023	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	RE47739	Mar 05, 2027	DS DP			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	>A> 10035822	Nov 15, 2033	DS			
	>A> 10125171	Aug 02, 2033	DS			
	>A> 10875893	Nov 15, 2033	DS	U-3124		
	>A> 7888323	Dec 04, 2027	DS			
	>A> 7989589	Dec 04, 2027	DS			
	>A> 9169307	Nov 18, 2027	DS	U-3123		
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	10391075	Feb 12, 2027	U-2622			
	10391075	Feb 12, 2027	U-3069			
	8778997	May 07, 2027	U-1627			
	8778997	May 07, 2027	U-2622			
	8778997	May 07, 2027	U-3069			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	>A> 6949571	Jun 08, 2022	DS DP U-106			
	>A> 6949571	Jun 08, 2022	DS DP U-2088			
	>A> 6949571	Jun 08, 2022	DS DP U-2089			
	>A> 6949571	Jun 08, 2022	DS DP U-2428			
	>A> 6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	>A> 6949571	Jun 08, 2022	DS DP U-106			
	>A> 6949571	Jun 08, 2022	DS DP U-2088			
	>A> 6949571	Jun 08, 2022	DS DP U-2089			
	>A> 6949571	Jun 08, 2022	DS DP U-2428			
	>A> 6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	>A> 6949571	Jun 08, 2022	DS DP U-106			
	>A> 6949571	Jun 08, 2022	DS DP U-2088			
	>A> 6949571	Jun 08, 2022	DS DP U-2089			
	>A> 6949571	Jun 08, 2022	DS DP U-2428			
	>A> 6949571	Jun 08, 2022	DS DP U-2429			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>PERAMPANEL - FYCOMPA</u></b>						
N 202834 004	>A> 6949571	Jun 08, 2022	DS DP U-106			
	>A> 6949571	Jun 08, 2022	DS DP U-2088			
	>A> 6949571	Jun 08, 2022	DS DP U-2089			
	>A> 6949571	Jun 08, 2022	DS DP U-2428			
	>A> 6949571	Jun 08, 2022	DS DP U-2429			
<b><u>PERAMPANEL - FYCOMPA</u></b>						
N 202834 005	>A> 6949571	Jun 08, 2022	DS DP U-106			
	>A> 6949571	Jun 08, 2022	DS DP U-2088			
	>A> 6949571	Jun 08, 2022	DS DP U-2089			
	>A> 6949571	Jun 08, 2022	DS DP U-2428			
	>A> 6949571	Jun 08, 2022	DS DP U-2429			
<b><u>PERAMPANEL - FYCOMPA</u></b>						
N 202834 006	>A> 6949571	Jun 08, 2022	DS DP U-106			
	>A> 6949571	Jun 08, 2022	DS DP U-2088			
	>A> 6949571	Jun 08, 2022	DS DP U-2089			
	>A> 6949571	Jun 08, 2022	DS DP U-2428			
	>A> 6949571	Jun 08, 2022	DS DP U-2429			
<b><u>PERAMPANEL - FYCOMPA</u></b>						
N 208277 001	>A> 6949571	Jun 08, 2022	DS DP U-106			
	>A> 6949571	Jun 08, 2022	DS DP U-2088			
	>A> 6949571	Jun 08, 2022	DS DP U-2089			
	>A> 6949571	Jun 08, 2022	DS DP U-2428			
	>A> 6949571	Jun 08, 2022	DS DP U-2429			
<b><u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u></b>						
N 211810 001	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038	U-2606			
<b><u>PIMAVANSERIN TARTRATE - NUPLAZID</u></b>						
N 207318 002	10953000	Mar 23, 2037	U-1974			
<b><u>PITOLISANT HYDROCHLORIDE - WAKIX</u></b>						
N 211150 001				ODE-331	Oct 13, 2027	
<b><u>PITOLISANT HYDROCHLORIDE - WAKIX</u></b>						
N 211150 002				ODE-331	Oct 13, 2027	
<b><u>POMALIDOMIDE - POMALYST</u></b>						
N 204026 001				M-14	Nov 20, 2023	
				PED	May 20, 2024	
<b><u>POMALIDOMIDE - POMALYST</u></b>						
N 204026 002				M-14	Nov 20, 2023	
				PED	May 20, 2024	
<b><u>POMALIDOMIDE - POMALYST</u></b>						
N 204026 003				M-14	Nov 20, 2023	
				PED	May 20, 2024	
<b><u>POMALIDOMIDE - POMALYST</u></b>						
N 204026 004				M-14	Nov 20, 2023	
				PED	May 20, 2024	
<b><u>PONATINIB HYDROCHLORIDE - ICUSIG</u></b>						
N 203469 001				I-849	Dec 18, 2023	
<b><u>PONATINIB HYDROCHLORIDE - ICUSIG</u></b>						
N 203469 002				I-849	Dec 18, 2023	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONESIMOD - PONVORY</u>						
N 213498 001	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 008	9062014 RE43728	May 06, 2032 Nov 16, 2024	DS DP U-2774 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	10220023 8273779 9000018 9062014 RE43728	Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024	U-3103 U-2774 U-3102 DS DP U-2774 DS DP		NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498 010	10220023 8273779 9000018 9062014 RE43728	Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024	U-3103 U-2774 U-3102 DS DP U-2774 DS DP		NCE	Mar 18, 2026
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001					ODE-340 ODE-341	Dec 01, 2027 Dec 01, 2027
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	10350170 10449191 10786501 7300935 8058280 8735401	Feb 25, 2036 Sep 29, 2037 Sep 29, 2037 Jan 28, 2024 Jan 28, 2024 Feb 04, 2024	DP U-3020 U-3020 DS DS DP U-3019		NCE	Dec 18, 2025
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001					>A> NCE	Oct 06, 2025
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	>A> 11008289	Jul 14, 2030	U-2440			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879 7125879 7125879 7125879	Apr 21, 2025 Apr 21, 2025 Apr 21, 2025 Apr 21, 2025	DS DP U-1153 DS DP U-1307 DS DP U-1740 DS DP U-3068			
<u>RIPRETTINIB - QINLOCK</u>						
N 213973 001	10966966	Aug 12, 2040	U-3153			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001					ODE-334	Aug 07, 2027
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	9517226 9937143	Aug 22, 2033 Aug 22, 2033	U-3084 U-3084		M-82	Feb 16, 2024
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	9517226 9937143	Aug 22, 2033 Aug 22, 2033	U-3084 U-3084		M-82	Feb 16, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>SACUBITRIL: VALSARTAN - ENTRESTO</u></b>						
N 207620 003	9517226 9937143	Aug 22, 2033 Aug 22, 2033	U-3084 U-3084		M-82	Feb 16, 2024
<b><u>SAFINAMIDE MESYLATE - XADAGO</u></b>						
N 207145 001	>A> 8283380	Mar 21, 2031	U-1993			
<b><u>SAFINAMIDE MESYLATE - XADAGO</u></b>						
N 207145 002	>A> 8283380	Mar 21, 2031	U-1993			
<b><u>SECNIDAZOLE - SOLOSEC</u></b>						
N 209363 001	>A> 11000507 >A> 11000508	Sep 04, 2035 Sep 04, 2035	DP U-2583 DP U-2583			
<b><u>SELENIOUS ACID - SELENIOUS ACID</u></b>						
N 209379 002				>A> NCE		Apr 30, 2024
<b><u>SELINEXOR - XPOVIO</u></b>						
N 212306 001	10519139 10519139 10519139 10544108 10544108 9079865 9079865 9079865	Aug 14, 2035 Aug 14, 2035 Aug 14, 2035 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032	DS DP U-2584 DS DP U-2855 DS DP U-3018 U-2584 U-3018 U-2584 U-2855 U-3018		>A> ODE-346	Dec 18, 2027
<b><u>SELINEXOR - XPOVIO</u></b>						
N 212306 002				>A> ODE-346		Dec 18, 2027
<b><u>SELINEXOR - XPOVIO</u></b>						
N 212306 003				>A> ODE-346		Dec 18, 2027
<b><u>SELINEXOR - XPOVIO</u></b>						
N 212306 004				>A> ODE-346		Dec 18, 2027
<b><u>SEMAGLUTIDE - RYBELSUS</u></b>						
N 213051 001	10933120 10960052	Mar 15, 2033 Dec 16, 2031	DP			
<b><u>SEMAGLUTIDE - RYBELSUS</u></b>						
N 213051 002	10933120 10960052	Mar 15, 2033 Dec 16, 2031	DP			
<b><u>SEMAGLUTIDE - RYBELSUS</u></b>						
N 213051 003	10933120 10960052	Mar 15, 2033 Dec 16, 2031	DP			
<b><u>SETMELANOTIDE ACETATE - IMCIVREE</u></b>						
N 213793 001				ODE-336		Nov 25, 2027
<b><u>SITAGLIPTIN PHOSPHATE - JANUVIA</u></b>						
N 021995 001				M-187 PED		Dec 04, 2023 Jun 04, 2024
<b><u>SITAGLIPTIN PHOSPHATE - JANUVIA</u></b>						
N 021995 002				M-187 PED		Dec 04, 2023 Jun 04, 2024
<b><u>SITAGLIPTIN PHOSPHATE - JANUVIA</u></b>						
N 021995 003				M-187 PED		Dec 04, 2023 Jun 04, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10864181	Mar 15, 2033		U-1532		
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001					ODE*	Aug 28, 2026
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 002					ODE*	Apr 07, 2024
					ODE*	Aug 28, 2026
					PED	Oct 07, 2024
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	>A> 10086011	Jan 30, 2034	U-1470		>A> D-177	Nov 15, 2022
	>A> 10086011*PED	Jul 30, 2034			>A> M-264	Jul 14, 2023
	>A> 8575135	Nov 16, 2032	DS DP U-1470		>A> NPP	Mar 19, 2023
	>A> 8575135*PED	May 16, 2033			>A> PED	May 15, 2023
	>A> 8735372	Mar 21, 2028	U-1470		>A> PED	Sep 19, 2023
	>A> 8735372*PED	Sep 21, 2028			>A> PED	Jan 14, 2024
	>A> 8921341	Nov 16, 2032	DS DP U-1470			
	>A> 8921341*PED	May 16, 2033				
	>A> 8940718	Nov 16, 2032	DS DP U-1470			
	>A> 8940718*PED	May 16, 2033				
	>A> 9757406	Jan 30, 2034	DP			
	>A> 9757406*PED	Jul 30, 2034				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 002	>A> 10086011	Jan 30, 2034	U-1470		>A> M-264	Jul 14, 2023
	>A> 10086011*PED	Jul 30, 2034			>A> NS	Mar 19, 2023
	>A> 7964580	Mar 26, 2029	DS DP U-1470		>A> PED	Sep 19, 2023
	>A> 7964580*PED	Sep 26, 2029			>A> PED	Jan 14, 2024
	>A> 8334270	Mar 21, 2028	DS DP U-1470			
	>A> 8334270*PED	Sep 21, 2028				
	>A> 8575135	Nov 16, 2032	DS DP U-1470			
	>A> 8575135*PED	May 16, 2033				
	>A> 8580765	Mar 21, 2028	DS DP U-1470			
	>A> 8580765*PED	Sep 21, 2028				
	>A> 8618076	Dec 11, 2030	DS DP U-1470			
	>A> 8618076*PED	Jun 11, 2031				
	>A> 8633309	Mar 26, 2029	DS DP U-1470			
	>A> 8633309*PED	Sep 26, 2029				
	>A> 8735372	Mar 21, 2028	U-1470			
	>A> 8735372*PED	Sep 21, 2028				
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8889159*PED	Sep 26, 2029				
	>A> 8921341	Nov 16, 2032	DS DP U-1470			
	>A> 8921341*PED	May 16, 2033				
	>A> 8940718	Nov 16, 2032	DS DP U-1470			
	>A> 8940718*PED	May 16, 2033				
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9085573*PED	Sep 21, 2028				
	>A> 9284342	Sep 13, 2030	DS DP U-1470			
	>A> 9284342*PED	Mar 13, 2031				
	>A> 9757406	Jan 30, 2034	DP			
	>A> 9757406*PED	Jul 30, 2034				
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	10912814	Jun 01, 2037	DP			
	>A> 8575135	Nov 05, 2033	DS DP U-2039			
	>A> 8575135	Nov 05, 2033	DS DP U-2040			
	>A> 8575135*PED	May 05, 2034				
	>A> 8735372	Mar 21, 2028	DS DP U-2039			
	>A> 8735372	Mar 21, 2028	DS DP U-2040			
	>A> 8735372*PED	Sep 21, 2028				
	>A> 8921341	Nov 16, 2032	DS DP U-2039			
	>A> 8921341	Nov 16, 2032	DS DP U-2040			
	>A> 8921341*PED	May 16, 2033				
	>A> 8940718	Nov 16, 2032	DS DP U-2039			
	>A> 8940718	Nov 16, 2032	DS DP U-2040			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</b></u>						
N 209195 001 >A> 8940718*PED		May 16, 2033				
	8957046	Mar 21, 2028		U-2039		
	8957046	Mar 21, 2028		U-2040		
<u><b>SOLIFENACIN SUCCINATE - VESICARE LS</b></u>						
N 209529 001	9918970	May 18, 2031	DP			
<u><b>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</b></u>						
N 211230 001	10912754	Jun 01, 2038		U-3082		
	10940133	Mar 19, 2040		U-3099		
	10959976	Jun 01, 2038		U-3151		
<u><b>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</b></u>						
N 211230 002	10912754	Jun 01, 2038		U-3082		
	10959976	Jun 01, 2038		U-3151		
<u><b>SOTALOL HYDROCHLORIDE - SOTYLIZE</b></u>						
N 205108 001 >A> 11013703		Apr 01, 2034	DP			
<u><b>SPINOSAD - NATROBA</b></u>						
N 022408 001				>A> I-858		Apr 28, 2024
<u><b>SPIRONOLACTONE - CAROSPIR</b></u>						
N 209478 001	10888570	Oct 28, 2036	DP			
<u><b>SUFENTANIL CITRATE - DSUVIA</b></u>						
N 209128 001	10896751	Mar 16, 2030	DP			
<u><b>TACROLIMUS - ASTAGRAF XL</b></u>						
N 204096 001				ODE*		May 24, 2025
<u><b>TACROLIMUS - ASTAGRAF XL</b></u>						
N 204096 002				ODE*		May 24, 2025
<u><b>TACROLIMUS - ASTAGRAF XL</b></u>						
N 204096 003				ODE*		May 24, 2025
<u><b>TAFENOQUINE SUCCINATE - ARAKODA</b></u>						
N 210607 001	10888558	Dec 02, 2035	U-2582			
<u><b>TAFLUPROST - ZIOPTAN</b></u>						
N 202514 001	10864159	May 28, 2029	DP U-778			
<u><b>TASIMELTEON - HETLIOZ</b></u>						
N 205677 001	10610511	Oct 10, 2034	U-2615	I-850	Dec 01, 2023	
	10610511	Oct 10, 2034	U-3007	ODE-330	Dec 01, 2027	
	10945988	Jan 25, 2033	U-2149			
	10980770	Jan 25, 2033	U-3106			
	10980770	Jan 25, 2033	U-3107			
<u><b>TASIMELTEON - HETLIOZ LQ</b></u>						
N 214517 001	10980770	Jan 25, 2033	U-3106	NP	Dec 01, 2023	
				ODE-329	Dec 01, 2027	
<u><b>TAVABOROLE - TAVABOROLE</b></u>						
A 211963 001				PC		Apr 17, 2021
<u><b>TEPOTINIB HYDROCHLORIDE - TEPMETKO</b></u>						
N 214096 001	8329692	Oct 30, 2029	DS DP	NCE	Feb 03, 2026	
	8580781	Mar 19, 2030	DS DP	ODE-325	Feb 03, 2028	
	8658643	Jul 04, 2028	U-3077			
	8921357	May 30, 2028	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>TEPOTINIB HYDROCHLORIDE - TEPMETKO</u></b>						
N 214096 001	8927540	Jul 21, 2028	U-3078			
	9062029	Jul 04, 2028	DP			
	9284300	Apr 29, 2028	DP			
	9403799	Jul 04, 2028	U-3077			
<b><u>TERIFLUONOMIDE - AUBAGIO</u></b>						
N 202992 001	6794410	Sep 12, 2026	U-1285		>A> M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			>A> PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034	U-1786			
	9186346*PED	Aug 04, 2034				
<b><u>TERIFLUONOMIDE - AUBAGIO</u></b>						
N 202992 002	6794410	Sep 12, 2026	U-1285		>A> M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			>A> PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034	U-1786			
	9186346*PED	Aug 04, 2034				
<b><u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u></b>						
N 209863 001	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<b><u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u></b>						
N 209863 002	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<b><u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u></b>						
N 209863 003	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<b><u>TICAGRELOR - BRILINTA</u></b>						
N 022433 001					I-851	May 28, 2023
<b><u>TICAGRELOR - BRILINTA</u></b>						
N 022433 002					I-851	May 28, 2023
<b><u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u></b>						
N 207981 001	10960004	Feb 03, 2037	U-2642			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<b><u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u></b>						
N 207981 002	10960004	Feb 03, 2037	U-2642			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<b><u>TIRBANIBULIN - KLISYRI</u></b>						
N 213189 001	10323001	Dec 28, 2027	DP		NCE	Dec 14, 2025
	10617693	Mar 12, 2038	U-3015			
	10669236	Sep 07, 2038	DS DP			
	7300931	Feb 06, 2026	DS DP			
	7851470	Feb 02, 2029	DS DP U-3015			
	8236799	Dec 28, 2025	DS DP			
	8980890	Dec 28, 2025	DS DP			
<b><u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u></b>						
N 212904 001	6821987	Apr 26, 2022	DS DP U-3100		NCE	Mar 10, 2026
	7166722	Nov 16, 2023	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>TIVOZANIB HYDROCHLORIDE - FOTIVDA</b>						
N 212904 001	6821987 7166722	Apr 26, 2022 Nov 16, 2023	DS DP U-3100 DS		NCE	Mar 10, 2026
<b>TIVOZANIB HYDROCHLORIDE - FOTIVDA</b>						
N 212904 002	6821987 7166722	Apr 26, 2022 Nov 16, 2023	DS DP U-3100 DS		NCE	Mar 10, 2026
<b>TOLVAPTAN - SAMSCA</b>						
N 022275 001	10905694	Apr 07, 2030	DP			
<b>TOLVAPTAN - SAMSCA</b>						
N 022275 002	10905694	Apr 07, 2030	DP			
<b>TOLVAPTAN - SAMSCA</b>						
N 022275 003	10905694	Apr 07, 2030	DP			
<b>TOLVAPTAN - JYNARQUE</b>						
N 204441 001	10905694	Apr 07, 2030	DP			
<b>TOLVAPTAN - JYNARQUE</b>						
N 204441 002	10905694	Apr 07, 2030	DP			
<b>TOLVAPTAN - JYNARQUE</b>						
N 204441 003	10905694	Apr 07, 2030	DP			
<b>TOLVAPTAN - JYNARQUE</b>						
N 204441 004	10905694	Apr 07, 2030	DP			
<b>TOLVAPTAN - JYNARQUE</b>						
N 204441 005	10905694	Apr 07, 2030	DP			
<b>TREPROSTINIL - TYVASO</b>						
N 022387 001					I-856	Mar 31, 2024
<b>TRILACICLIB DIHYDROCHLORIDE - COSELA</b>						
N 214200 001	10085992 10189849 10189850 10927120 10966984 10966984 8598186 8598197 9487530 9487530 9957276	Mar 14, 2034 Oct 25, 2031 Oct 25, 2031 Oct 25, 2031 Mar 14, 2034 Mar 14, 2034 Oct 25, 2031 Oct 25, 2031 Mar 14, 2034 Mar 14, 2034 Oct 25, 2031	U-3081 DS DP DP U-3079 U-3080 DS DP DS DP U-3079 U-3080 DS		NCE	Feb 12, 2026
<b>UMBRALISIB TOSYLATE - UKONIQ</b>						
N 213176 001	10072013 10072013 10414773 10414773 10570142 10570142 10947244 10947244 9150579 9669033 9669033 9969740 9969740	Jul 02, 2033 Jul 02, 2033 May 26, 2035 May 26, 2035 Jul 02, 2033 Jul 02, 2033 May 26, 2035 May 26, 2035 Jul 02, 2033 Jul 02, 2033 May 26, 2035 May 26, 2035	U-3063 U-3064 DS DP U-3063 DS DP U-3064 DS DP U-3063 DS DP U-3064 U-3063 U-3064 DS DP U-3063 U-3064 DS DP U-3063 DS DP U-3064		NCE ODE-343 ODE-344	Feb 05, 2026 Feb 05, 2028 Feb 05, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>UPADACITINIB - RINVOQ</u></b>						
N 211675 001	>A> 10981923 >A> 10981924	Oct 17, 2036 Oct 17, 2036	DS DP			
<b><u>VALBENAZINE TOSYLATE - INGREZZA</u></b>						
N 209241 001	10874648 10874648 10906902 10906903 10912771 10912771 10919892 10940141 10952997 >A> 10993941	Oct 10, 2037 Oct 10, 2037 Dec 22, 2036 Dec 22, 2036 Oct 10, 2037 Oct 10, 2037 Dec 22, 2036 Aug 10, 2040 Oct 10, 2037 Oct 10, 2037	U-1995 U-3046 DS DP DS DP U-1995 U-3076 DS DP U-1995 U-1995 U-1995			
N 209241 002	10874648 10874648 10906902 10906903 10912771 10912771 10919892 10940141 10952997 >A> 10993941	Oct 10, 2037 Oct 10, 2037 Dec 22, 2036 Dec 22, 2036 Oct 10, 2037 Oct 10, 2037 Dec 22, 2036 Aug 10, 2040 Oct 10, 2037 Oct 10, 2037	U-1995 U-3046 DS DP DS DP U-1995 U-3076 DS DP U-1995 U-1995 U-1995			
N 209241 003	>A> 10065952 >A> 10844058 >A> 10851103 >A> 10851104 >A> 10857137 >A> 10857148 >A> 10874648 >A> 10874648 >A> 10906902 >A> 10906903 >A> 10912771 >A> 10912771 >A> 10919892 >A> 10940141 >A> 10952997 >A> 10993941 >A> 8039627 >A> 8357697	Oct 28, 2036 Oct 28, 2036 Oct 28, 2036 Oct 28, 2036 Oct 10, 2037 Oct 10, 2037 Oct 10, 2037 Oct 10, 2037 Dec 22, 2036 Dec 22, 2036 Oct 10, 2037 Oct 10, 2037 Dec 22, 2036 Aug 10, 2040 Oct 10, 2037 Oct 10, 2037 Oct 06, 2029 Nov 08, 2027	DS DP U-1995 DS DP U-1995 DS DP U-1995 DS U-1995 U-1995 U-1995 U-1995 U-3046 DS DP DS DP U-1995 U-3076 DS DP U-1995 U-1995 U-1995 DS DP U-1995	>A> NCE	Apr 11, 2022	
N 021283 001						
N 021283 002						
N 021283 004						
<b><u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u></b>						
N 208910 001	10959946 10959947 10959947 10959948 10959948 10959949 10959949	Mar 13, 2035 Mar 13, 2035 Mar 13, 2035 Mar 13, 2035 Mar 13, 2035 Mar 13, 2035 Mar 13, 2035	DP DP U-3104 DP U-3105 DP U-3104 DP U-3105 DP U-3104 DP U-3105			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001 >A>	10993942	Sep 06, 2033	U-3114			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002 >A>	10993942	Sep 06, 2033	U-3114			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003 >A>	10993942	Sep 06, 2033	U-3114			
<u>VERICIGUAT - VERQUVO</u>						
N 214377 001	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VERQUVO</u>						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VERQUVO</u>						
N 214377 003	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	8247415	Dec 01, 2030	DS DP U-3045		NCE	Dec 23, 2025
	8653260	Apr 02, 2029	DS			
<u>VIGABATRIN - VIGABATRIN</u>						
A 211539 001					CGT	Jul 31, 2021
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001	10870676	Aug 31, 2031	DS DP U-3039		ODE-280	Aug 12, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001 >A> 9790183		Sep 02, 2025		U-3109		
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	10286036	Dec 07, 2037		U-3056	NCE	Jan 22, 2026
	7332472	Oct 17, 2022	DS DP	U-3056		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004					M-187	Jan 22, 2024
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001 >A> 10570139		Apr 22, 2034	DS DP	U-2145		
	10927117	Aug 15, 2037	DS DP			

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 41<sup>ST</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at  
[http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at  
[http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)